IMAX (IMAX) 10-Q 28 Oct 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2021shares
Document Information [Line Items]
Entity Registrant Name	IMAX Corporation
Entity Central Index Key	0000921582
Document Type	10-Q
Document Period End Date	Sep. 30, 2021
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock Shares Outstanding	59,081,999
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation, State or Country Code	Z4
Title of 12(b) Security	Common Shares, no par value
Trading Symbol	IMAX
Security Exchange Name	NYSE
Entity File Number	001-35066
Entity Tax Identification Number	98-0140269
Entity Address, Address Line One	2525 Speakman Drive
Entity Address, City or Town	Mississauga
Entity Address, State or Province	ON
Entity Address, Country	CA
Entity Address, Postal Zip Code	L5K 1B1
City Area Code	(905)
Local Phone Number	403-6500
Other Address [Member]
Document Information [Line Items]
Entity Address, Address Line One	902 Broadway, Floor 20
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Country	US
Entity Address, Postal Zip Code	10010
City Area Code	(212)
Local Phone Number	821-0100

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Assets
Cash and cash equivalents	$ 193,008	$ 317,379
Accounts receivable, net	82,728	56,300
Financing receivables, net	135,202	131,810
Variable consideration receivables, net	42,540	40,526
Inventories	38,245	39,580
Prepaid expenses	11,863	10,420
Film assets, net	5,347	5,777
Property, plant and equipment, net	260,852	277,397
Investment in equity securities	1,089	13,633
Other assets	18,514	21,673
Deferred income tax assets, net	18,652	17,983
Goodwill	39,027	39,027
Other intangible assets, net	24,094	26,245
Total assets	871,161	997,750
Liabilities
Accounts payable	15,584	20,837
Accrued and other liabilities	98,272	99,354
Revolving credit facility borrowings, net	9,486	305,676
Convertible notes, net	223,265
Deferred revenue	86,442	87,982
Deferred income tax liabilities	17,642	19,134
Total liabilities	450,691	532,983
Commitments and contingencies (see Note 8)
Non-controlling interests
Non-controlling interests	760	759
Shareholders' equity
Capital stock common shares - no par value. Authorized - unlimited number.59,082,275 issued and 59,081,999 outstanding (December 31, 2020 — 58,921,731 issued and 58,921,008 outstanding)	413,531	407,031
Less: Treasury stock, 276 shares at cost (December 31, 2020 — 723)	(4)	(11)
Other equity	161,524	180,330
Statutory surplus reserve	3,932
Accumulated deficit	(241,440)	(202,849)
Accumulated other comprehensive (loss) income	(637)	988
Total shareholders' equity attributable to common shareholders	336,906	385,489
Non-controlling interests	82,804	78,519
Total shareholders' equity	419,710	464,008
Total liabilities and shareholders' equity	$ 871,161	$ 997,750

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Shareholders' equity
Common stock, par value
Common stock, shares issued	59,082,275	58,921,731
Common stock, shares outstanding	59,081,999	58,921,008
Number of treasury shares held in trust for future settlement of share based awards	276	723

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues
Revenues, total		$ 56,602	$ 37,256	$ 146,311	$ 81,013
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total		29,115	33,427	75,940	79,786
Gross margin	[1]	27,487	3,829	70,371	1,227
Selling, general and administrative expenses		28,377	24,815	82,393	83,247
Research and development		2,025	1,130	5,696	4,562
Amortization of intangibles		1,255	1,349	3,586	4,014
Credit loss (reversal) expense, net		(3,317)	3,925	(4,884)	15,582
Asset impairments		0	0	0	1,151
Legal judgment and arbitration awards (see Note 8)		0	0	(1,770)	0
Loss from operations		(853)	(27,390)	(14,650)	(107,329)
Realized and unrealized investment gains (losses)		30	1,575	5,311	(939)
Retirement benefits non-service expense		(117)	(186)	(347)	(432)
Interest income		538	586	1,680	1,842
Interest expense		(1,540)	(2,391)	(5,534)	(4,620)
Loss before taxes		(1,942)	(27,806)	(13,540)	(111,478)
Income tax expense		(4,402)	(19,349)	(9,416)	(24,606)
Equity in losses of investees, net of tax		0	(1,329)	0	(1,858)
Net loss		(6,344)	(48,484)	(22,956)	(137,942)
Less: Net (income) loss attributable to non-controlling interests		(2,034)	1,275	(9,473)	15,412
Net loss attributable to common shareholders		$ (8,378)	$ (47,209)	$ (32,429)	$ (122,530)
Net loss per share attributable to common shareholders - basic and diluted:
Net loss per share — basic and diluted		$ (0.14)	$ (0.80)	$ (0.55)	$ (2.06)
Technology Sales [Member]
Revenues
Revenues, total		$ 13,160	$ 15,753	$ 34,508	$ 24,102
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total		6,230	9,222	17,779	15,637
Image Enhancement and Maintenance Services [Member]
Revenues
Revenues, total		30,588	14,589	76,914	39,109
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total		16,461	16,989	38,582	42,049
Technology Rentals [Member]
Revenues
Revenues, total		10,219	4,473	26,708	10,307
Costs and expenses applicable to revenues
Cost and expenses applicable to revenues, total		6,424	7,216	19,579	22,100
Finance Income [Member]
Revenues
Revenues, total		$ 2,635	$ 2,441	$ 8,181	$ 7,495
[1]	IMAX DMR gross margin includes marketing costs of $3.2 million and $5.8 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.4 million and $2.8 million, respectively). JRSA gross margin includes advertising, marketing and commission expense of $0.8 million and $1.9 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.7 million and $1.3 million, respectively). IMAX Systems gross margin includes marketing and commission costs of $0.3 million and $0.9 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.6 million and $1.0 million, respectively). Film Distribution segment gross margin includes marketing expense of $nil and less than $0.1 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.2 million and $0.4 million, respectively).

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (6,344)	$ (48,484)	$ (22,956)	$ (137,942)
Other comprehensive (loss) income, before tax
Unrealized net (loss) gain from cash flow hedging instruments	(759)	591	(159)	(935)
Realized net (gain) loss from cash flow hedging instruments	(312)	110	(1,367)	805
Reclassification of unrealized gain from ineffective cash flow hedging instruments	(25)		(318)
Foreign currency translation adjustments	(1,325)	2,387	(531)	1,772
Defined benefit and postretirement benefit plans	48	19	144	36
Total other comprehensive (loss) income, before tax	(2,373)	3,107	(2,231)	1,678
Income tax benefit (expense) related to other comprehensive (loss) income	276	(189)	446	64
Other comprehensive (loss) income, net of tax	(2,097)	2,918	(1,785)	1,742
Comprehensive loss	(8,441)	(45,566)	(24,741)	(136,200)
Comprehensive (income) loss attributable to non-controlling interests	(1,636)	553	(9,313)	14,876
Comprehensive loss attributable to common shareholders	$ (10,077)	$ (45,013)	$ (34,054)	$ (121,324)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating Activities
Net loss	$ (22,956)	$ (137,942)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	40,570	40,699
Amortization of deferred financing costs	1,749	595
Credit loss (reversal) expense, net	(4,884)	15,582
Write-downs	878	13,339
Deferred income tax (benefit) expense	(1,687)	23,142
Share-based and other non-cash compensation	18,558	16,345
Unrealized foreign currency exchange loss (gain)	555	(394)
Realized and unrealized investment (gains) losses	(5,311)	939
Equity in losses of investees	0	1,858
Changes in assets and liabilities:
Accounts receivable	(24,336)	30,350
Inventories	653	(10,278)
Film assets	(10,035)	(6,177)
Deferred revenue	(1,434)	5,233
Changes in other operating assets and liabilities	(11,902)	(24,109)
Net cash used in operating activities	(19,582)	(30,818)
Investing Activities
Purchase of property, plant and equipment	(2,353)	(658)
Investment in equipment for joint revenue sharing arrangements	(5,361)	(5,289)
Acquisition of other intangible assets	(3,399)	(1,661)
Proceeds from sale of equity investment	17,769
Net cash provided by (used in) investing activities	6,656	(7,608)
Financing Activities
Proceeds from issuance of convertible notes, net	223,675
Debt issuance costs related to convertible notes	(1,163)
Purchase of capped calls related to convertible notes	(19,067)
Revolving credit facility borrowings	3,600	280,244
Repayments of revolving credit facility borrowings	(300,243)
Credit facility amendment fees paid	(474)	(1,026)
Repurchase of common shares	(4,610)	(36,624)
Treasury stock purchased for future settlement of restricted share units		3,086
Taxes withheld and paid on employee stock awards vested	(3,045)	(251)
Common shares issued - stock options exercised	883
Dividends paid to non-controlling interests	(5,027)	(4,214)
Net cash (used in) provided by financing activities	(110,487)	233,509
Effects of exchange rate changes on cash	(958)	630
(Decrease) increase in cash and cash equivalents during period	(124,371)	195,713
Cash and cash equivalents, beginning of period	317,379	109,484
Cash and cash equivalents, end of period	193,008	305,197
IMAX China
Financing Activities
Repurchase of common shares	$ (5,016)	$ (1,534)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Capital Stock [Member]	Other Equity [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Non-controlling Interests [Member]	Statutory Surplus Reserve [Member]
Balance, beginning of period at Dec. 31, 2019		$ 419,348	$ 171,789	$ (40,253)	$ (3,190)
Movement of Shareholders' Equity
Change in shares held in treasury		3,767
Amortization of share-based payment expense - stock options			2,137
Amortization of share-based payment expense - restricted share units			11,099
Amortization of share-based payment expense - performance stock units			1,307
Restricted share units vested			(7,688)
Common shares repurchased and retired		(17,803)		(18,821)
Common shares repurchased, IMAX China			(1,534)
Net loss attributable to common shareholders	$ (122,530)			(122,530)
Other comprehensive income (loss), net of tax	1,742				1,206
Balance, end of period at Sep. 30, 2020		405,312	177,110	(181,604)	(1,984)
Balance, beginning of period at Dec. 31, 2019						$ 89,493
Movement of Shareholders' Equity
Net income (loss) attributable to non-controlling interests	(15,412)					(10,280)
Other comprehensive (loss) income, net of tax						536
Dividends paid to non-controlling shareholders						(4,214)
Balance, end of period at Sep. 30, 2020						75,535
Balance, beginning of period at Jun. 30, 2020		405,254	172,690	(134,395)	(4,180)
Movement of Shareholders' Equity
Change in shares held in treasury		58
Amortization of share-based payment expense - stock options			1,034
Amortization of share-based payment expense - restricted share units			3,337
Amortization of share-based payment expense - performance stock units			514
Restricted share units vested			(463)
Common shares repurchased, IMAX China			(2)
Net loss attributable to common shareholders	(47,209)			(47,209)
Other comprehensive income (loss), net of tax	2,918				2,196
Balance, end of period at Sep. 30, 2020		405,312	177,110	(181,604)	(1,984)
Balance, beginning of period at Jun. 30, 2020						74,723
Movement of Shareholders' Equity
Net income (loss) attributable to non-controlling interests	(1,275)					2,186
Other comprehensive (loss) income, net of tax						722
Dividends paid to non-controlling shareholders						(2,096)
Balance, end of period at Sep. 30, 2020						75,535
Movement of Shareholders' Equity
Total shareholders' equity	474,369
Total shareholders' equity	464,008
Balance, beginning of period at Dec. 31, 2020	385,489	407,020	180,330	(202,849)	988
Movement of Shareholders' Equity
Change in shares held in treasury		7
Employee stock options exercised		883
Amortization of share-based payment expense - stock options			951
Amortization of share-based payment expense - restricted share units			13,327
Amortization of share-based payment expense - performance stock units			3,519
Restricted share units vested			(12,249)
Purchase of capped calls related to convertible notes			(19,067)
Grant date fair value of stock options exercised		272	(271)
Common shares repurchased and retired		(2,380)		(2,230)
Common shares repurchased, IMAX China			(5,016)
Net loss attributable to common shareholders	(32,429)			(32,429)
Other comprehensive income (loss), net of tax	(1,785)				(1,625)
Establishment of statutory surplus reserve, IMAX China							$ 3,932
Statutory surplus reserve deducted from retained earnings, IMAX China				(3,932)
Restricted share units vested, net of shares withheld for employee tax obligations		7,725
Balance, end of period at Sep. 30, 2021	336,906	413,527	161,524	(241,440)	(637)		3,932
Balance, beginning of period at Dec. 31, 2020	78,519					78,519
Movement of Shareholders' Equity
Net income (loss) attributable to non-controlling interests	9,473					9,472
Other comprehensive (loss) income, net of tax						(160)
Establishment of statutory surplus reserve						1,699
Statutory surplus reserve deducted from retained earnings						(1,699)
Dividends paid to non-controlling shareholders						(5,027)
Balance, end of period at Sep. 30, 2021	82,804					82,804
Balance, beginning of period at Jun. 30, 2021		415,849	160,658	(226,900)	1,062
Movement of Shareholders' Equity
Change in shares held in treasury		4
Amortization of share-based payment expense - stock options			294
Amortization of share-based payment expense - restricted share units			4,331
Amortization of share-based payment expense - performance stock units			1,315
Restricted share units vested			(58)
Common shares repurchased and retired		(2,380)		(2,230)
Common shares repurchased, IMAX China			(5,016)
Net loss attributable to common shareholders	(8,378)			(8,378)
Other comprehensive income (loss), net of tax	(2,097)				(1,699)
Establishment of statutory surplus reserve, IMAX China							3,932
Statutory surplus reserve deducted from retained earnings, IMAX China				(3,932)
Restricted share units vested, net of shares withheld for employee tax obligations		54
Balance, end of period at Sep. 30, 2021	336,906	$ 413,527	$ 161,524	$ (241,440)	$ (637)		$ 3,932
Balance, beginning of period at Jun. 30, 2021						84,090
Movement of Shareholders' Equity
Net income (loss) attributable to non-controlling interests	2,034					2,040
Other comprehensive (loss) income, net of tax						(398)
Establishment of statutory surplus reserve						1,699
Statutory surplus reserve deducted from retained earnings						(1,699)
Dividends paid to non-controlling shareholders						(2,928)
Balance, end of period at Sep. 30, 2021	82,804					$ 82,804
Movement of Shareholders' Equity
Total shareholders' equity	$ 419,710

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Basis of Presentation	1. Basis of Presentation Accounting Principles IMAX Corporation, together with its consolidated subsidiaries (the “Company”), prepares its financial statements in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. In the Company’s opinion, the unaudited Condensed Consolidated Financial Statements reflect all adjustments of a normal recurring nature that are necessary for a fair statement of the results for the interim periods presented. The interim results presented in the Company’s Condensed Consolidated Statements of Operations are not necessarily indicative of results for a full year, particularly in this interim period due to the impacts of the COVID-19 global pandemic (see Note 2). These Condensed Consolidated Financial Statements Condensed Consolidated Financial Statements Principles of Consolidation These Condensed Consolidated Financial Statements include the accounts of the Company together with its consolidated subsidiaries, except for subsidiaries which have been identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. All intercompany accounts and transactions have been eliminated. The Company has evaluated its various variable interests to determine whether they are VIEs as required by U.S. GAAP. The Company has interests in ten film production companies, which have been identified as VIEs. The Company is the primary beneficiary of and consolidates five of these entities as it has the power to direct the activities that most significantly impact the economic performance of the VIE, and it has the obligation to absorb losses or the right to receive benefits from the respective VIE that could potentially be significant. The majority of the assets relating to these production companies are held by the IMAX Original Film Fund (the “Original Film Fund”) as described in Note 17(b). The Company does not consolidate the other five film production companies because it does not have the power to direct their activities and it does not have the obligation to absorb the majority of the expected losses or the right to receive expected residual returns. The Company uses the equity method of accounting for these entities, which are not material to the Company’s Condensed Consolidated Financial Statements. Total assets and liabilities of the Company’s consolidated VIEs are as follows: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Total assets $ 1,575 $ 1,543 Total liabilities $ 259 $ 230 In October 2021, the Company and Maximus Technologies Limited dissolved its previously announced joint venture, IMAX AI, and the intellectual property assets contributed to the joint venture were returned to each party. Estimates and Assumptions In preparing the Company’s Condensed Consolidated Financial Statements, management makes judgments in applying various accounting policies. The areas of policy judgment are consistent with those reported in Note 3(b) in the 2020 Form 10-K. In addition, management makes assumptions about the Company’s future operating results and cash flows in deriving critical accounting estimates used in preparing the Condensed Consolidated Financial Statements. The significant estimates made by management include, but are not limited to: (i) the allocation of the transaction price in an IMAX Theater System arrangement to distinct performance obligations; (ii) estimates of variable consideration ; (iii) expected credit losses on accounts receivable, financing receivables and variable consideration receivables; (iv) provisions for the write-down of excess and obsolete inventory; (v) the fair values of the reporting units used in assessing the recoverability of goodwill; (vi) the cash flow estimates used in testing the recoverability of long-lived assets such as the theater system equipment supporting joint revenue sharing arrangements; (vii) the economic lives of the theater system equipment supporting joint revenue sharing arrangements; (viii) the useful lives of intangible assets; (ix) the ultimate revenue forecasts used to test the recoverability of film assets; (x) the discount rates used to determine the present value of lease liabilities; (xi) pension plan assumptions; (xii) estimates related to the fair value and projected vesting of share-based payment awards; (xiii) the valuation of deferred income tax assets; and (xiv) reserves related to uncertain tax positions. The Company’s operations have been significantly impacted by the COVID-19 global pandemic, as described in Note 2. T he impact of the COVID-19 global pandemic on the Company’s business and financial results will continue to depend on numerous evolving factors that cannot be accurately predicted and that will vary by jurisdiction and market, including the duration and scope of the pandemic, the emergence of variants of the virus, the progress made on administering vaccines, the continuing impact of the pandemic on global economic conditions and ongoing government responses to the pandemic, which could lead to further theater closures, theater capacity restrictions and/or delays in the release of films. However, management is encouraged by the broad reopening of the IMAX theater network, the continued progress towards the resumption of normal theater operations, and recent box office results. Accordingly, during the three and nine months ended September 30, 2021, the Company reversed $3.3 million and $4.9 million, respectively, of its allowance for current expected credit losses, reflecting the improving outlook for theater operators as the theatrical exhibition industry continues to recover from the COVID-19 global pandemic. Despite the improving environment, there continues to be a degree of risk and uncertainty relating to future credit losses on receivables, inventory write downs, impairments of film assets, impairments of long-lived assets (including the theater system equipment supporting the Company’s joint revenue sharing arrangements), impairments of goodwill, a further valuation allowance against deferred tax assets, and the reversal of variable consideration receivables that are based on estimates of future box office performance. In the current environment, assumptions about box office results, IMAX Theater System installations, and customer creditworthiness have greater variability than normal, which could in the future significantly management’s estimates and judgments relating to the recoverability of the Company’s financial and non-financial assets.

Impact of COVID-19 Pandemic

Impact of COVID-19 Pandemic	9 Months Ended
	Sep. 30, 2021
Impact Of Coronavirus Nineteen Pandemic [Abstract]
Impact of COVID-19 Pandemic	2. Impact of COVID-19 Pandemic The impact of the COVID-19 pandemic is complex and continuously evolving, resulting in significant disruption to the Company’s business and the global economy. At various points during the pandemic, authorities around the world imposed measures intended to control the spread of COVID-19, including stay-at-home orders and restrictions on large public gatherings, which caused movie theaters in countries around the world to temporarily close, including the IMAX theaters in those countries. As a result of the theater closures, movie studios postponed the theatrical release of most films originally scheduled for release in 2020 and early 2021, including many scheduled to be shown in IMAX theaters, while several other films were released directly or concurrently to streaming platforms. More recently, stay-at-home orders and capacity restrictions have been lifted in almost all key markets and, beginning in the third quarter of 2020, movie theaters throughout the IMAX network gradually reopened. As of September 30, 2021, 93% of the theaters in the global IMAX commercial multiplex network were open at various capacities, spanning 70 countries. This included 100% of Domestic theaters (i.e., in the United States and Canada), 93% of the theaters in Greater China and 87% of the theaters in Rest of World markets. The impact of the COVID-19 global pandemic has resulted in significantly lower levels of revenues, earnings and operating cash flows for the Company during 2020 and, to a lesser extent, during the nine months ended September 30, 2021, when compared to periods prior to the onset of the pandemic, as gross box office (“GBO”) results from the Company’s theater customers declined, the installation of certain theater systems was delayed, and maintenance services were generally suspended for theaters that were closed. In response to uncertainties associated with the pandemic, the Company took significant steps to preserve cash by eliminating non-essential costs, temporarily furloughing certain employees, reducing the working hours of other employees and reducing all non-essential capital expenditures to minimum levels. The Company also implemented an active cash management process, which, among other things, required senior management approval of all outgoing payments. For the three and nine months ended September 30, 2021, GBO receipts generated by IMAX DMR films totaled $141.9 million and $360.7 million, respectively, surpassing the totals for the same periods in 2020 by $71.7 million (102%) and $192.6 million (115%), respectively. Moreover, GBO receipts for September 2021 approximated the levels achieved prior to the onset of the COVID-19 global pandemic. Management is encouraged by these box office results, the return of the prevalence of exclusive theatrical windows beginning with the release of Shang-Chi and the Legend of the Ten Rings

Recently Issued Accounting Stan

Recently Issued Accounting Standards	9 Months Ended
	Sep. 30, 2021
Accounting Changes And Error Corrections [Abstract]
Recently Issued Accounting Standards	3. Recently Issued Accounting Standards In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). The purpose of ASU 2020-04 is to provide optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments are effective for all entities from the beginning of an interim period that includes the issuance date of the ASU. An entity may elect to apply the amendments prospectively through December 31, 2022. The only contract held by the Company that references the London Interbank Offered Rate ( LIBOR) is the Credit Agreement (as defined in Note 7), which utilizes USD LIBOR to determine the interest rate applicable to borrowings. The Credit Agreement matures on June 28, 2023, prior to the date that USD LIBOR rates will cease publication on June 30, 2023. Accordingly, the Company does not expect ASU 2020-04 to have a material effect on its Condensed Consolidated Financial Statements. In July 2021, the FASB issued ASU No. 2021-05, “Leases (Topic 842): Lessors - Certain Leases with Variable Lease Payments” (“ASU 2021-05”), which requires sales-type or direct financing leases that have variable payments (that do not depend on a rate or an index) and result in a day-one loss to be classified as operating leases. When a lease is classified as operating, the lessor does not recognize a net investment in the lease, does not derecognize the underlying asset, and, therefore, does not recognize a selling profit or loss. The amendments are effective for annual periods beginning after December 15, 2021 including interim periods within those periods. Early adoption is permitted. The Company has not yet adopted ASU 2021-05, but has determined that the impact of adopting this guidance will not have a material impact on its Condensed Consolidated Financial Statements. The Company considers the applicability and impact of all recently issued FASB ASUs. ASUs that are not noted above were assessed and determined to be not applicable or not significant to the Company’s Condensed Consolidated Financial Statements for the period ended September 30, 2021.

Current Expected Credit Losses

Current Expected Credit Losses	9 Months Ended
	Sep. 30, 2021
Credit Loss [Abstract]
Current Expected Credit Losses	4. Current Expected Credit Losses The Company’s accounts receivable, financing receivables and variable consideration receivables are measured on the amortized cost basis and presented at the net amount expected to be collected Accounts Receivable Accounts receivable principally includes amounts currently due to the Company under theater sale and sales-type lease arrangements, contingent fees owed by theater operators as a result of box office performance and fees for theater maintenance services. Accounts receivable also includes amounts due to the Company from movie studios and other content creators for digitally remastering films into IMAX formats, as well as for film distribution and post-production services. In order to mitigate the credit risk associated with accounts receivable, management performs an initial credit evaluation prior to entering into an arrangement with a customer and then regularly monitors the credit quality of each customer through an analysis of collections history and aging. This monitoring process includes meetings on at least a monthly basis to identify credit concerns and potential changes in credit quality classification. A customer may improve their credit quality classification once a substantial payment is made on an overdue balance or when the customer has agreed to a payment plan and payments have commenced in accordance with that plan. Changes in credit quality classification are dependent upon management approval. The Company’s internal credit quality classifications for theater operators are as follows: • Good Standing — The theater operator continues to be in good standing as payments and reporting are up to date. • Credit Watch — The theater operator has demonstrated a delay in payments, but continues to be in active communication with the Company. Theater operators placed on Credit Watch are subject to enhanced monitoring. In addition, depending on the size of the outstanding balance, length of time in arrears and other factors, future transactions may need to be approved by management. These receivables are in better condition than those in the Pre-Approved Transactions Only category, but are not in as good condition as the receivables in the Good Standing category. • Pre-Approved Transactions Only — The theater operator has demonstrated a delay in payments with little or no communication with the Company. All services and shipments to the theater operator must be reviewed and approved by management. These receivables are in better condition than those in the All Transactions Suspended category, but are not in as good condition as the receivables in the Credit Watch category. In certain situations, depending on the individual facts and circumstances related to each customer, finance income recognition may be suspended for the net investment in lease and financed sale receivable balances for customers in the Pre-Approved Transactions Only category. See below for a discussion of the Company’s net investment in leases and financed sale receivables. • All Transactions Suspended — The theater operator is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater operator is classified within the All Transactions Suspended category, the theater is placed on nonaccrual status and all revenue recognitions related to the theater are stopped. The ability of the Company to collect its accounts receivable balances is heavily dependent on the viability and solvency of individual theater operators which is significantly influenced by consumer behavior and general economic conditions. Theater operators, or other customers, may experience financial difficulties, such as those caused by the COVID-19 global pandemic, that could result in their being unable to fulfill their payment obligations to the Company. The Company develops its estimate of credit losses by class of receivable and customer type through a calculation that utilizes historical loss rates which are then adjusted for specific receivables that are judged to have a higher-than-normal risk profile after taking into account management’s internal credit quality classifications, as well as macro-economic and industry risk factors. The write-off of any billed receivable balance requires the approval of management. The following tables summarize the activity in the Allowance for Credit Losses related to Accounts Receivable for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 (In thousands of U.S. Dollars) Theater Operators Studios Other Total Theater Operators Studios Other Total Beginning balance $ 8,597 $ 2,517 $ 1,192 $ 12,306 $ 8,368 $ 4,481 $ 1,446 $ 14,295 Current period reversal, net (489 ) (251 ) (24 ) (764 ) (111 ) (1,928 ) (269 ) (2,308 ) Write-offs (43 ) (270 ) — (313 ) (278 ) (522 ) — (800 ) Foreign exchange (89 ) 2 — (87 ) (3 ) (33 ) (9 ) (45 ) Ending balance $ 7,976 $ 1,998 $ 1,168 $ 11,142 $ 7,976 $ 1,998 $ 1,168 $ 11,142 Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 (In thousands of U.S. Dollars) Theater Operators Studios Other Total Theater Operators Studios Other Total Beginning balance $ 6,317 $ 5,455 $ 838 $ 12,610 $ 3,302 $ 893 $ 942 $ 5,137 Current period provision (reversal), net 1,623 (262 ) 468 1,829 4,718 4,424 364 9,506 Write-offs (614 ) — — (614 ) (614 ) — — (614 ) Foreign exchange 133 184 (9 ) 308 53 60 (9 ) 104 Ending balance $ 7,459 $ 5,377 $ 1,297 $ 14,133 $ 7,459 $ 5,377 $ 1,297 $ 14,133 For the three and nine months ended September 30, 2021, the Company’s allowance for current expected credit losses related to Accounts Receivable decreased by $1.2 million and $3.2 million, respectively. These decreases are principally due to the reversal of previously recorded credit loss expense as a result of an improving outlook for theater operators following the reopening of theaters and the resumption of normal film release schedules as the theatrical exhibition industry continues to recover from the COVID-19 global pandemic, as well as better than anticipated collection experience with respect to foreign studio receivable balances. For the three and nine months ended September 30, 2020, the Company’s allowance for current expected credit losses related to Accounts Receivable increased by $1.5 million and $9.0 million, respectively, principally reflecting a reduction in the credit quality of and heightened collection risk associated with theater and foreign movie studio accounts receivable primarily due to the COVID-19 global pandemic. Management believes that the September 30, 2021 allowance for current expected credit losses related to Accounts Receivable adequately addresses the risk of not collecting these receivables in full. Management’s judgments regarding expected credit losses are based on the facts available to management and involve estimates about the future. Due to the unprecedented nature of the COVID-19 pandemic, its effect on the Company’s customers and their ability to meet their financial obligations to the Company is difficult to predict. As a result, the Company’s judgments and associated estimates of credit losses may ultimately prove, with the benefit of hindsight, to be incorrect (see Note 2). Financing Receivables Financing receivables are due from theater operators and consist of the Company’s net investment in sales-type leases and receivables associated with financed sales of IMAX Theater Systems. Similar to accounts receivable, management performs an initial credit evaluation prior to entering into an arrangement with a customer and then regularly monitors the credit quality of each customer through an analysis of collections history and aging. This monitoring process includes meetings on at least a monthly basis to identify credit concerns and potential changes in credit quality classification. A customer may improve their credit quality classification once a substantial payment is made on an overdue balance or when the customer has agreed to a payment plan and payments have commenced in accordance with that plan. Changes in credit quality classification are dependent upon management approval. The internal credit quality classifications utilized by the Company for accounts receivable, as described above, are also used for financing receivables. The ability of the Company to collect its financing receivable balances is heavily dependent on the viability and solvency of individual theater operators which is significantly influenced by consumer behavior and general economic conditions. Theater operators may experience financial difficulties, such as those caused by the COVID-19 global pandemic, that could result in their being unable to fulfill their payment obligations to the Company. The Company develops its estimate of credit losses by class of receivable and customer type through a calculation that utilizes historic al loss rates which are then adjusted for specific receivables that are judged to have a higher - than - normal risk profile after taking into account management’s internal credit quality classifications, as well as macro-economic and industry risk factors. As of September 30, 2021 and December 31, 2020, financing receivables consist of the following: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Net investment in leases Gross minimum payments due under sales-type leases $ 23,284 $ 20,830 Unearned finance income (788 ) (859 ) Present value of minimum payments due under sales-type leases 22,496 19,971 Allowance for credit losses (494 ) (557 ) Net investment in leases 22,002 19,414 Financed sales receivables Gross minimum payments due under financed sales 150,964 150,917 Unearned finance income (32,199 ) (31,247 ) Present value of minimum payments due under financed sales 118,765 119,670 Allowance for credit losses (5,565 ) (7,274 ) Net financed sales receivables 113,200 112,396 Total financing receivables $ 135,202 $ 131,810 Net financed sales receivables due within one year $ 32,154 $ 34,937 Net financed sales receivables due after one year 81,046 77,459 Total financed sales receivables $ 113,200 $ 112,396 As of September 30, 2021 and December 31, 2020, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s sales-type lease arrangements and financed sale receivables, as applicable, are as follows: September 30, December 31, 2021 2020 Weighted-average remaining lease term (in years) Sales-type lease arrangements 9.0 8.3 Weighted-average interest rate Sales-type lease arrangements 6.55 % 6.56 % Financed sales receivables 8.75 % 8.92 % The tables below provide information on the Company’s net investment in leases by credit quality indicator as of September 30, 2021 and December 31, 2020. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of September 30, 2021 2021 2020 2019 2018 2017 Prior Total Net investment in leases: Credit quality classification: In good standing $ 959 $ 2,747 $ 2,245 $ — $ — $ 1,150 $ 7,101 Credit Watch 3,374 1,251 5,650 2,533 881 863 14,552 Pre-approved transactions — — — — — — — Transactions suspended — — — — — 843 843 Total net investment in leases $ 4,333 $ 3,998 $ 7,895 $ 2,533 $ 881 $ 2,856 $ 22,496 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2020 2020 2019 2018 2017 2016 Prior Total Net investment in leases: Credit quality classification: In good standing $ 2,143 $ 1,190 $ 2,730 $ — $ — $ 1,826 $ 7,889 Credit Watch 2,005 7,278 — 988 — 1,047 11,318 Pre-approved transactions — — — — — — — Transactions suspended — — — — — 764 764 Total net investment in leases $ 4,148 $ 8,468 $ 2,730 $ 988 $ — $ 3,637 $ 19,971 The tables below provide information on the Company’s financed sale receivables by credit quality indicator as of September 30, 2021 and December 31, 2020. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of September 30, 2021 2021 2020 2019 2018 2017 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 6,311 $ 4,414 $ 5,733 $ 3,831 $ 5,890 $ 17,830 $ 44,009 Credit Watch 1,911 4,108 6,046 9,847 7,733 35,739 65,384 Pre-approved transactions — — — 309 1,420 2,285 4,014 Transactions suspended — — — — 1,315 4,043 5,358 Total financed sales receivables $ 8,222 $ 8,522 $ 11,779 $ 13,987 $ 16,358 $ 59,897 $ 118,765 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2020 2020 2019 2018 2017 2016 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 6,830 $ 5,480 $ 3,547 $ 3,740 $ 5,072 $ 12,660 $ 37,329 Credit Watch 1,986 6,501 11,356 12,520 11,446 34,351 78,160 Pre-approved transactions — — — — 613 755 1,368 Transactions suspended — — — 987 728 1,098 2,813 Total financed sales receivables $ 8,816 $ 11,981 $ 14,903 $ 17,247 $ 17,859 $ 48,864 $ 119,670 The following tables provide an aging analysis for the Company’s net investment in leases and financed sale receivables as of September 30, 2021 and December 31, 2020: As of September 30, 2021 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 221 $ 149 $ 876 $ 1,246 $ 21,250 $ 22,496 $ (494 ) $ 22,002 Financed sales receivables 1,989 1,748 10,207 13,944 104,821 118,765 (5,565 ) 113,200 Total $ 2,210 $ 1,897 $ 11,083 $ 15,190 $ 126,071 $ 141,261 $ (6,059 ) $ 135,202 As of December 31, 2020 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 298 $ 180 $ 689 $ 1,167 $ 18,804 $ 19,971 $ (557 ) $ 19,414 Financed sales receivables 3,307 1,943 10,699 15,949 103,721 119,670 (7,274 ) 112,396 Total $ 3,605 $ 2,123 $ 11,388 $ 17,116 $ 122,525 $ 139,641 $ (7,831 ) $ 131,810 The Company considers Financing Receivables with an aging between 60-89 days as indications of theaters with potential collection concerns. At this point, the Company will begin to focus its review on these Financing Receivables and increase its discussions internally and with the theater regarding payment status. Once a theater’s aging exceeds 90 days, the Company’s policy is to perform an enhanced review to assess collectibility of the theater’s past due accounts. The over 90 days past due category may be an indicator of potential impairment as up to 90 days outstanding is considered to be a reasonable time to resolve any issues. Given the potential impacts of the COVID-19 global pandemic on the Company’s customers, management has enhanced its monitoring procedures with respect to overdue receivables. The following table provides information about the Company’s net investment in leases and financed sale receivables with billed amounts past due for which it continues to accrue finance income as of September 30, 2021 and December 31, 2020. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. As of September 30, 2021 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Allowance for Credit Losses Net Net investment in leases $ 180 $ 144 $ 458 $ 782 $ 13,770 $ (248 ) $ 14,304 Financed sales receivables 1,152 1,083 8,286 10,521 51,756 (2,870 ) 59,407 Total $ 1,332 $ 1,227 $ 8,744 $ 11,303 $ 65,526 $ (3,118 ) $ 73,711 As of December 31, 2020 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Allowance for Credit Losses Net Net investment in leases $ 231 $ 162 $ 359 $ 752 $ 13,912 $ (310 ) $ 14,354 Financed sales receivables 2,026 1,551 10,249 13,826 62,602 (4,434 ) 71,994 Total $ 2,257 $ 1,713 $ 10,608 $ 14,578 $ 76,514 $ (4,744 ) $ 86,348 The following table provides information about the Company’s net investment in leases and financed sale receivables that are on nonaccrual status as of September 30, 2021 and December 31, 2020: As of September 30, 2021 As of December 31, 2020 (In thousands of U.S. Dollars) Recorded Receivable Allowance for Credit Losses Net Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 843 $ (16 ) $ 827 $ 764 $ (18 ) $ 746 Net financed sales receivables 6,158 (1,276 ) 4,882 2,813 (1,482 ) 1,331 Total $ 7,001 $ (1,292 ) $ 5,709 $ 3,577 $ (1,500 ) $ 2,077 A theater operator that is classified within the “All Transactions Suspended” category is placed on nonaccrual status and all revenue recognitions related to the theater are stopped. In certain cases, a theater operator classified within the “Pre-Approved Transactions” category may also be placed on nonaccrual status. While the recognition of Finance Income is suspended, payments received by a customer are applied against the outstanding balance owed. If payments are sufficient to cover any unreserved receivables, a recovery of provision taken on the billed amount, if applicable, is recorded to the extent of the residual cash received. Once the collectibility issues are resolved and the customer has returned to being in good standing, the Company will resume recognition of Finance Income. For the three and nine months ended September 30, 2021, the Company recognized less than $0.1 million and $0.1 million, respectively, (2020 — $nil and $0.1 million, respectively) in Finance Income related to the net investment in leases with billed amounts past due. For the three and nine months ended September 30, 2021, the Company recognized $1.3 million and $3.6 million, respectively, (2020 — $1.4 million and $4.2 million, respectively) in Finance Income related to the financed sale receivables with billed amounts past due. The following tables summarize the activity in the allowance for credit losses related to the Company’s net investment in leases and financed sale receivables for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Net Investment Financed Net Investment Financed (In thousands of U.S. Dollars) in Leases Sales Receivables in Leases Sales Receivables Beginning balance $ 579 $ 7,113 $ 557 $ 7,274 Current period reversal, net (84 ) (1,536 ) (64 ) (1,741 ) Foreign exchange (1 ) (12 ) 1 32 Ending balance $ 494 $ 5,565 $ 494 $ 5,565 Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Net Investment Net Financed Net Investment Net Financed (In thousands of U.S. Dollars) in Leases Sales Receivables in Leases Sales Receivables Beginning balance $ 459 $ 3,709 $ 155 $ 915 Current period provision 105 1,201 409 4,014 Write-offs (69 ) (330 ) (69 ) (330 ) Foreign exchange 9 63 9 44 Ending balance $ 504 $ 4,643 $ 504 $ 4,643 For the three and nine months ended September 30, 2021, the Company’s allowance for current expected credit losses related to its net investment in leases and financed sale receivables decreased by $1.6 million and $1.8 million, respectively. These decreases are principally due to the reversal of previously recorded credit loss expense as a result of an improving outlook for theater operators following the reopening of theaters and the resumption of normal film release schedules as the theatrical exhibition industry continues to recover from the COVID-19 global pandemic. For the three and nine months ended September 30, 2020 , the Company ’s allowance for current expected credit losses related to its investment in leases and financed sale receivables increased by $ 1.0 million and $ 4.1 million, respectively , principally reflecting a reduction in the credit quality of and heightened collection risk associated with these r eceivable s primarily due to the COVID-19 global pandemic . Management believes that the September 30, 2021 allowance for current expected credit losses related to Financing Receivables adequately addresses the risk of not collecting these receivables in full. Management’s judgments regarding expected credit losses are based on the facts available to management and involve estimates about the future. Due to the unprecedented nature of the COVID-19 pandemic, its effect on the Company’s customers and their ability to meet their financial obligations to the Company is difficult to predict. As a result, the Company’s judgments and associated estimates of credit losses may ultimately prove, with the benefit of hindsight, to be incorrect (see Note 2). Variable Consideration Receivables In sale arrangements, variable consideration may become due to the Company from theater operators if certain annual minimum box office receipt thresholds are exceeded. Such variable consideration is recorded as revenue in the period when the sale is recognized and adjusted in future periods based on actual results and changes in estimates. Variable consideration is only recognized to the extent the Company believes there is not a risk of significant revenue reversal. The ability of the Company to collect its variable consideration receivables is heavily dependent on the viability and solvency of individual theater operators which is significantly influenced by consumer behavior and general economic conditions. Theater operators may experience financial difficulties, such as those caused by the COVID-19 global pandemic, that could result in their being unable to fulfill their payment obligations to the Company. The Company develops its estimate of credit losses by class of receivable and customer type through a calculation utilizing historical loss rates for financed sale receivables which are then adjusted for specific receivables that are judged to have a higher-than-normal risk profile after taking into account management’s internal credit quality classifications, as well as macro-economic and industry risk factors. The following table summarizes the activity in the Allowance for Credit Losses related to Variable Consideration Receivables for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands of U.S. Dollars) Theater Operators Theater Operators Theater Operators Theater Operators Beginning balance $ 2,028 $ 863 $ 1,887 $ — Current period (reversal) provision, net (933 ) 790 (771 ) 1,653 Foreign Exchange (1 ) 6 (22 ) 6 Ending balance $ 1,094 $ 1,659 $ 1,094 $ 1,659 For the three and nine months ended September 30, 2021, the Company’s allowance for current expected credit losses related to Variable Consideration Receivables For the three and nine months ended September 30, 2020, the Company’s allowance for current expected credit losses related to Variable Consideration Receivables increased by Management believes that the September 30, 2021 allowance for current expected credit losses related to Variable Consideration Receivables adequately addresses the risk of not collecting these receivables in full. Management’s judgments regarding expected credit losses are based on the facts available to management and involve estimates about the future. Due to the unprecedented nature of the COVID-19 pandemic, its effect on the Company’s customers and their ability to meet their financial obligations to the Company is difficult to predict. As a result, the Company’s judgments and associated estimates of credit losses may ultimately prove, with the benefit of hindsight, to be incorrect (see Note 2).

Lease Arrangements

Lease Arrangements	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Lease Arrangements	5. Lease Arrangements (a) IMAX Corporation as a Lessee The Company’s operating lease arrangements principally involve office and warehouse space. Office equipment is generally purchased outright. Leases with an initial term of less than 12 months are not recorded on the Condensed Consolidated Balance Sheets and the related lease expense is recognized on a straight-line basis over the lease term. Most of the Company’s leases include one or more options to renew, with renewal terms that can extend the lease term from one to five years or more. The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs and its level of investment in leasehold improvements, among other factors. The incremental borrowing rate used in the calculation of the Company’s lease liability is based on the location of each leased property. None of the Company’s leases include options to purchase the leased property. The depreciable lives of right-of-use assets and related leasehold improvements are limited by the expected lease term. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed. For the three and nine months ended September 30, 2021 and 2020, the components of lease expense recorded within Selling, General and Administrative expenses are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 2021 2020 Operating lease cost (1) $ 163 $ 133 $ 546 $ 392 Amortization of lease assets 684 706 2,098 2,155 Interest on lease liabilities 242 258 715 765 Total lease cost $ 1,089 $ 1,097 $ 3,359 $ 3,312 (1) Includes short-term leases and variable lease costs, which are not significant for the three and nine months ended September 30, 2021 and 2020. For the nine months ended September 30, 2021 and 2020, supplemental cash and non-cash information related to leases is as follows: Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 Cash paid for amounts included in the measurement of lease liabilities $ 2,907 $ 2,721 Right-of-use assets obtained in exchange for lease obligations $ 1,047 $ 297 As of September 30, 2021 and December 31, 2020, supplemental balance sheet information related to leases is as follows: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Assets Balance Sheet Classification Right-of-Use Assets Property, plant and equipment $ 12,833 $ 13,911 Liabilities Balance Sheet Classification Operating Leases Accrued and other liabilities $ 15,388 $ 16,634 As of September 30, 2021 and December 31, 2020, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s operating leases are as follows: September 30, December 31, 2021 2020 Weighted-average remaining lease term (years) 7.0 7.6 Weighted-average discount rate 5.96 % 5.91 % As of September 30, 2021, the maturities of the Company’s operating lease liabilities are as follows: (In thousands of U.S. Dollars) 2021 (three months remaining) $ 924 2022 3,360 2023 2,454 2024 2,230 2025 2,078 Thereafter 8,026 Total lease payments $ 19,072 Less: interest expense (3,684 ) Present value of operating lease liabilities $ 15,388 (b) IMAX Corporation as a Lessor The Company provides IMAX Theater Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX Theater System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system. The customer’s rights under the Company’s sales-type lease arrangements are described in Note 3(n) in the Company’s 2020 Form 10-K. Under the Company’s sales-type lease arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s lease portfolio terms are typically non-cancellable for 10 to 20 years with renewal provisions from inception. The Company’s sales-type lease arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty generally after the first year of the lease until the end of the lease term. The customer is responsible for obtaining insurance coverage for the IMAX Theater System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX Theater System is returned to the Company. The Company also provides IMAX Theater Systems to customers through joint revenue sharing arrangements. Under the traditional form of these arrangements, in exchange for providing the IMAX Theater System under a long-term lease, the Company earns rent based on a percentage of contingent box office receipts and, in some cases, concession revenues, rather than requiring the customer to pay a fixed upfront fee or annual minimum payments. Under certain other joint revenue sharing arrangements, known as hybrid arrangements, the customer is responsible for making fixed upfront payments prior to the delivery and installation of the IMAX Theater System. Under joint revenue sharing arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to the IMAX Theater System under a joint revenue sharing arrangement generally does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the IMAX Theater System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX Theater System is returned to the Company. (See Note 4 for information related to the net investment in leases related to the Company’s sales-type lease arrangements.)

Inventories

Inventories	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventories	6. Inventories As of September 30, 2021 and December 31, 2020, Inventories consist of the following: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Raw materials $ 27,172 $ 30,096 Work-in-process 1,964 3,014 Finished goods 9,109 6,470 $ 38,245 $ 39,580 At September 30, 2021, Inventories include finished goods of $2.2 million (December 31, 2020 — $2.1 million) for which title had passed to the customer, but the criteria for revenue recognition were not met as of the balance sheet date. During the three and nine months ended September 30, 2021, the Company recognized write-downs of $0.3 million and $0.5 million, respectively, (2020 — $0.6 million and $0.7 million, respectively) for excess and damaged inventory.

Debt

Debt	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Debt	7. Debt (a) Revolving Credit Facility Borrowings As of September 30, 2021 and December 31, 2020, Revolving Credit Facility Borrowings consist of the following: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Credit Facility borrowings $ — $ 300,000 Working Capital Facility borrowings 10,974 7,643 Unamortized debt issuance costs (1,488 ) (1,967 ) Revolving Credit Facility Borrowings, net $ 9,486 $ 305,676 Credit Agreement The Company has a credit agreement, the Fifth Amended and Restated Credit Agreement, with Wells Fargo Bank, National Association (“Wells Fargo”), as agent, and a syndicate of lenders party thereto (the “Credit Agreement”). The Company’s obligations under the Credit Agreement are guaranteed by certain of its subsidiaries (the “Guarantors”) and are secured by first-priority security interests in substantially all the assets of the Company and the Guarantors. The facility provided by the Credit Agreement (the “Credit Facility”) matures on June 28, 2023. The Credit Agreement has a revolving borrowing capacity of $300.0 million, and contains an uncommitted accordion feature allowing the Company to further expand its borrowing capacity to $440.0 million or greater, subject to certain conditions, depending on the mix of revolving and term loans comprising the incremental facility. In the first quarter of 2020, in response to uncertainties associated with the outbreak of the COVID-19 global pandemic and its impact on the Company’s business, the Company drew down $280.0 million in available borrowing capacity under the Credit Facility, resulting in total outstanding borrowings of $300.0 million, which remained outstanding as of December 31, 2020. During the first half of 2021, the Company completely repaid the $300.0 million of Credit Facility borrowings, using cash on hand following the issuance of the Convertible Notes (as discussed below). Accordingly, as of September 30, 2021, there were no outstanding borrowings under the Credit Facility. As of September 30, 2021 and December 31, 2020, the Company did not have any letters of credit or advance payment guarantees outstanding under the Credit Facility. The Credit Agreement contains a covenant that requires the Company to maintain a Senior Secured Net Leverage Ratio (as defined in the Credit Agreement), as of the last day of any Fiscal Quarter (as defined in the Credit Agreement) of no greater than 3.25:1.00. In addition, the Credit Agreement contains customary affirmative and negative covenants, including covenants that limit indebtedness, liens, capital expenditures, asset sales, investments and restricted payments, in each case subject to negotiated exceptions and baskets. The Credit Agreement also contains customary representations, warranties, and event of default provisions. On March 15, 2021, the Company entered into the Second Amendment to the Credit Agreement (as previously amended by the First Amendment to the Credit Agreement, dated as of June 10, 2020) (collectively, the “First and Secondment Amendments”). On July 28, 2021, the Company entered into the Third Amendment to the Credit Agreement (as previously amended by the First and Second Amendments) (collectively, the “Amendments”). The Amendments, among other things, (i) suspend the Senior Secured Net Leverage Ratio covenant through the first quarter of 2022, (ii) re-establish the Senior Secured Net Leverage Ratio covenant thereafter, provided that for subsequent quarters that such covenant is tested, as applicable, the Company will be permitted to use its quarterly EBITDA (as defined in the Credit Agreement) from the third and fourth quarters of 2019 in lieu of EBITDA for the corresponding quarters of 2021, (iii) add a $75.0 million minimum liquidity covenant measured at the end of each calendar month, (iv) restrict the Company’s ability to make certain restricted payments, dispositions and investments, create or assume liens and incur debt that would otherwise have been permitted by the Credit Agreement, (v) permit the issuance of the Convertible Notes (as discussed below) and related transactions, including the capped call transactions, or other unsecured debt, in an amount not to exceed $290.0 million, (vi) allow $ 30.0 Borrowings under the Credit Facility bear interest, at the Company’s option, at (i) LIBOR plus a margin ranging from 1.00% to 1.75% per annum; or (ii) the U.S. base rate plus a margin ranging from 0.25% to 1.00% per annum, in each case depending on the Company’s Total Leverage Ratio (as defined in the Credit Agreement); provided, however, that from the effective date of the First Amendment to the Credit Agreement until the Company delivers a compliance certificate under the Credit Facility following the end of the Designated Period, the applicable margin for LIBOR borrowings will be 2.50% per annum and the applicable margin for U.S. base rate borrowings will be 1.75% per annum. The effective interest rate for the three and nine months ended September 30, 2021 was nil and 2.64%, respectively (2020 — 2.70% and 2.24%, respectively). In addition, the Credit Facility has standby fees ranging from 0.25% to 0.38% per annum, based on the Company’s Total Leverage Ratio with respect to the unused portion of the Credit Facility; provided, however, that from the effective date of the First Amendment to the Credit Agreement until the Company delivers a compliance certificate under the Credit Facility following the end of the Designated Period, the standby fee will be 0.50% per annum. The Company incurred fees of approximately $1.6 million in connection with the Amendments, which are being amortized on a straight-line basis to Interest Expense over the relevant amendment periods. Working Capital Facility On July 1, 2021, IMAX (Shanghai) Multimedia Technology Co., Ltd. (“IMAX Shanghai”), one of the Company’s majority-owned subsidiaries in China, renewed its unsecured revolving facility for up to 200.0 million Chinese Renminbi (“RMB”) (approximately $30.8 million) to fund ongoing working capital requirements (the “Working Capital Facility”). The Working Capital Facility expires in July 2022. As of September 30, 2021, outstanding Working Capital Facility borrowings were RMB 71.2 million ($11.0 million) and outstanding letters of guarantee were RMB 0.3 million (less than $0.1 million). As of December 31, 2020, outstanding Working Capital Facility borrowings were RMB 49.9 million ($7.6 million) and no letters of guarantee were issued. As of September 30, 2021, the amount available for future borrowings under the Working Capital Facility was RMB 118.8 million ($18.3 million) and the amount available for letters of guarantee was RMB 9.7 million ($1.5 million). The amount available for future borrowings under the Working Capital Facility is not subject to a standby fee. The effective interest rate for borrowings under the Working Capital Facility for the three and nine months ended September 30, 2021 was 4.29% and 4.32%, respectively (2020 ― 4.35%, respectively). Wells Fargo Foreign Exchange Facility Within the Credit Facility, the Company is able to enter into foreign currency forward contracts and/or other swap arrangements. As of September 30, 2021, the net unrealized loss on the Company’s outstanding foreign currency forward contracts was $(0.3) million, representing the amount by which the notional value of these forward contracts exceeded their fair value (December 31, 2020 — $2.0 million). As of September 30, 2021, the notional value of the Company’s outstanding foreign currency forward contracts was $25.8 million (December 31, 2020 — $31.9 million). NBC Facility On October 28, 2019, the Company entered into a $5.0 million facility with the National Bank of Canada (the “NBC Facility”) fully insured by Export Development Canada for use solely in conjunction with the issuance of performance guarantees and letters of credit. The NBC Facility is renewed on an annual basis. It was renewed on October 15, 2021 for a one-year term on the same terms and conditions. The Company did not have any letters of credit or advance payment guarantees outstanding as of September 30, 2021 and December 31, 2020 under the NBC Facility. (b) Convertible Notes As of September 30, 2021 and December 31, 2020, Convertible Notes (as defined below) consist of the following: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Convertible Notes $ 230,000 $ — Unamortized discounts and debt issuance costs (6,735 ) — $ 223,265 $ — On March 19, 2021, the Company issued $230.0 million of 0.500% Convertible Senior Notes due 2026 (the “Convertible Notes”) in a private placement conducted pursuant to Rule 144A under the Securities Act of 1933, as amended The net proceeds from the issuance of the Convertible Notes were $223.7 million, after deducting the initial purchasers’ discounts and commissions. In addition, the Company paid $1.2 million of debt issuance costs associated with the Convertible Notes. The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 0.500% per annum on the principal thereof, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021. The Convertible Notes will mature on April 1, 2026, unless they are redeemed or repurchased by the Company or converted on an earlier date. Holders of the Convertible Notes have the right to convert their Convertible Notes in certain circumstances and during specified periods. Before January 1, 2026, holders of the Convertible Notes have the right to convert their Convertible Notes only upon the occurrence of certain events. From and after January 1, 2026, holders of the Convertible Notes may convert their Convertible Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as applicable, cash or a combination of cash (in an amount no less than the principal amount of the Convertible Notes being converted) and common shares, at its election, based on the applicable conversion rates. The initial conversion rate is 34.7766 common shares per $1,000 principal amount of Convertible Notes, which represents an initial conversion price of approximately $28.75 per common share, and is subject to adjustment upon the occurrence of certain events. The Convertible Notes are redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after April 6, 2024 and on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest, if any, In addition, calling any Convertible Notes for redemption will constitute a “make-whole fundamental change” with respect to such notes, in which case the conversion rate applicable to the conversion of such notes will be increased in certain circumstances if such notes are converted after they are called for redemption. In addition, upon the occurrence of a “fundamental change” (as defined below ), holders may require the Company to repurchase their Convertible Notes at a cash repurchase price equal to the principal amount of the Convertible Notes to be repurchased, plus accrued and unpaid interest, if any. Subject to the terms and conditions of the indenture governing the Convertible Notes, a “fundamental change” means, among other things, an event resulting in (i) a change of control, (ii) a transfer of all or substantially all of the assets of the Company, (iii) a merger, (iv) liquidation or dissolution of the Company, or (v) delisting of the Company’s common shares from a national securities exchange. On January 1, 2021, the Company elected to early adopt ASU No. 2020-06, “Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for convertible debt that may be settled in cash. As a result, the Company recorded the Convertible Notes entirely as a liability in the Condensed Consolidated Balance Sheet s , net of initial purchasers’ discounts and commissions and other debt issuance costs , with interest expense reflecting the cash coupon plus the amortization of the discounts and capitalized costs. Additionally, ASU 2020-06 modifies the treatment of convertible debt securities that may be settled in cash or shares by requiring the use of the “if-converted” method. Under the “if-converted” method, because the principal amount of the Convertible N otes is settled in cash and the conversion spread is settleable in the Company’s common shares, diluted earnings per share is calculated by including the net number of incremental shares that would be issued upon conversion of the Convertible Notes , using the average market price during the period. Accordingly, the application of the “if-converted” method may reduce the Company’s reported diluted earnings per share. In connection with the pricing of the Convertible Notes, the Company entered into privately negotiated capped call transactions (the “Capped Call Transactions”) with certain financial institutions. The Capped Call Transactions are expected to reduce potential dilution resulting from the common shares the Company is required to issue and/or to offset any potential cash payments the Company is required to make in excess of the principal amount of the Convertible Notes in the event that the market price per share of the Company’s common shares is greater than the strike price of the Capped Call Transactions, with such reduction and/or offset subject to a cap. The Capped Call Transactions have an initial cap price of $37.2750 per share of the Company’s common shares, which represents a premium of 75% over the last reported sale price of the common shares on March 16, 2021, and is subject to certain adjustments under the terms of the Capped Call Transactions. Collectively, the Capped Call Transactions cover, subject to anti-dilution adjustments substantially similar to those applicable to the Convertible Notes, the number of the Company’s common shares underlying the Convertible Notes. The cost of the Capped Call Transactions was approximately $19.1 million. The Capped Call Transactions are separate transactions, and are not part of the terms of the Convertible Notes and will not affect any holder’s rights under the Convertible Notes. Holders of the Convertible Notes will not have any rights with respect to the Capped Call Transactions. The Capped Call Transactions meet all of the applicable criteria for equity classification in accordance with ASC 815-10-15-74(a), “Derivatives and Hedging—Embedded Derivatives—Certain Contracts Involving an Entity’s Own Equity,” and, as a result, the related $19.1 million cost was recorded as a reduction to Other Equity within Shareholders’ Equity on the Company’s Condensed Consolidated Statements of Shareholder’s Equity and Condensed Consolidated Balance Sheets.

Commitments, Contingencies and

Commitments, Contingencies and Guarantees	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments, Contingencies and Guarantees	8. Commitments, Contingencies and Guarantees (a) Commitments In the ordinary course of business, the Company enters into contractual agreements with third parties that include non-cancellable payment obligations, for which it is liable in future periods. These arrangements can include terms binding the Company to minimum payments and/or penalties if it terminates the agreement for any reason other than an event of default as described by the agreement. (b) Contingencies and guarantees The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. Management is required to assess the likelihood of any adverse judgments or outcomes related to these legal contingencies, as well as potential ranges of probable or reasonably possible losses. The Company records a provision for a liability when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The determination of the amount of any liability recorded or disclosed is reviewed at least quarterly based on a careful analysis of each individual exposure with, in some cases, the assistance of outside legal counsel, taking into account the impact of negotiations, settlements, rulings, and other pertinent information related to the case. The amount of liabilities recorded or disclosed for these contingencies may change in the future due to changes in management’s judgments resulting from new developments or changes in settlement strategy. Any resulting adjustment to the liabilities recorded by the Company could have a material adverse effect on its results of operations, cash flows, and financial position in the period or periods in which such changes in judgment occur. The Company believes it has adequate provisions for any such matters. The Company expenses legal costs relating to its lawsuits, claims and proceedings as incurred. (i) In January 2004, the Company and IMAX Theatre Services Ltd., a subsidiary of the Company, commenced an arbitration seeking damages before the International Court of Arbitration of the International Chamber of Commerce (the “ICC”) with respect to the breach by Electronic Media Limited (“EML”) of its December 2000 agreement with the Company. In June 2004, the Company commenced a related arbitration before the ICC against EML’s affiliate, E-City Entertainment (I) PVT Limited (“E-City”). On March 27, 2008, the arbitration panel issued a final award in favor of the Company in the amount of $11.3 million, consisting of past and future rents owed to the Company, plus interest and costs, as well as an additional $2,512 each day in interest from October 1, 2007 until the date the award is paid. In July 2008, E-City commenced a proceeding in Mumbai, India seeking an order that the ICC award may not be recognized in India and on June 10, 2013, the Bombay High Court ruled that it had jurisdiction over the proceeding filed by E-City. The Company appealed that ruling to the Supreme Court of India, and on March 10, 2017, the Supreme Court set aside the Bombay High Court’s judgment and dismissed E-City’s petition. On March 29, 2017, the Company filed an Execution Application in the Bombay High Court seeking to enforce the ICC award against E-City and several related parties, which award the Company calculates to be $24.2 million, inclusive of interest, as of September 30, 2021. That matter is currently pending. The Company has also taken steps to enforce the ICC final award outside of India. In December 2011, the Ontario Superior Court of Justice issued an order recognizing the final award and requiring E-City to pay the Company $30,000 to cover the costs of the application, and in May 2012, the New York Supreme Court recognized the Canadian judgment and entered it as a New York judgment. The Company intends to continue pursuing its rights and seeking to enforce the award, although no assurances can be given with respect to the ultimate outcome. (ii) On November 11, 2013, Giencourt Investments, S.A. (“Giencourt”) initiated arbitration before the International Centre for Dispute Resolution in Miami, Florida, based on alleged breaches by the Company of its theater agreement and related license agreement with Giencourt. On February 7, 2017, the panel issued a Partial Final Award and on July 21, 2017, the panel issued a Final Award (collectively, the “Award”), which held that the parties had reached a binding settlement, and therefore the panel did not reach a decision regarding the merits of the dispute. On December 3, 2020, the District Judge entered a final judgment (the “Final Judgment”) against the Company in the total amount of $11.3 million as damages under the Award. As of December 31, 2020, the Company’s Consolidated Balance Sheets includes a liability within Accrued and Other Liabilities of $11.3 million related to the Final Judgment, consisting of $7.2 million related to amounts previously collected from or owed to Giencourt principally in respect of theater systems that were not delivered and $4.1 million recorded within Legal Judgment and Arbitration Awards in the Company’s Consolidated Statements of Operations during the year ended December 31, 2020 in respect of the remaining amounts owed under the Final Judgment. On June 23, 2021, the Company entered into a final settlement agreement with Giencourt to fully resolve all disputes between the parties in the United States and Ontario (the “Settlement Agreement”). In the second quarter of 2021, the Company paid Giencourt $9.5 million as required by the terms of the Settlement Agreement. As a result of the Settlement Agreement, the Final Judgment has been vacated, all litigation between the parties in all jurisdictions has been dismissed and full and final releases have been exchanged by the parties. Accordingly, upon entry in the Settlement Agreement on June 23, 2021, the remaining $1.8 million liability recorded within Accrued and Other Liabilities was reversed and a corresponding $1.8 million benefit was recorded in the Company’s Condensed Consolidated Statements of Operations within Legal Judgment and Arbitration Awards. (iii) In addition to the matters described above, the Company is currently involved in other legal proceedings or governmental inquiries which, in the opinion of the Company’s management, will not materially affect the Company’s financial position or future operating results, although no assurance can be given with respect to the ultimate outcome of any such proceedings. (iv) In the normal course of business, the Company enters into agreements that may contain features that meet the definition of a guarantee. A guarantee is a contract (including an indemnity) that contingently requires the Company to make payments (either in cash, financial instruments, other assets, shares of its stock or provision of services) to a third party based on (a) changes in an underlying interest rate, foreign exchange rate, equity or commodity instrument, index or other variable, that is related to an asset, a liability or an equity security of the counterparty, (b) failure of another party to perform under an obligating agreement or (c) failure of another third party to pay its indebtedness when due. (c) Financial Guarantees Certain subsidiaries of the Company have provided significant financial guarantees to third parties under the Credit Agreement. (d) Product Warranties The Company’s accrual for product warranties, which is recorded within Accrued and Other Liabilities in the Condensed Consolidated Balance Sheets, was $nil and less than $0.1 million as of September 30, 2021 and December 31, 2020 (e) Director/Officer Indemnifications The Company’s by-laws contain an indemnification of its directors/officers, former directors/officers and persons who have acted at its request to be a director/officer of an entity in which the Company is a shareholder or creditor, to indemnify them, to the extent permitted by the Canada Business Corporations Act (f) Other Indemnification Agreements In the normal course of the Company’s operations, the Company provides indemnifications to counterparties in transactions such as: IMAX Theater Systems lease and sale agreements and the supervision of installation or servicing of IMAX Theater Systems; film production, exhibition and distribution agreements; real property lease agreements; and employment agreements. These indemnification agreements require the Company to compensate the counterparties for costs incurred as a result of litigation claims that may be suffered by the counterparty as a consequence of the transaction or the Company’s breach or non-performance under these agreements. While the terms of these indemnification agreements vary based upon the contract, they normally extend for the life of the agreements. A small number of agreements do not provide for any limit on the maximum potential amount of indemnification; however, virtually all of the IMAX Theater System lease and sale agreements limit such maximum potential liability to the purchase price of the system. The fact that the maximum potential amount of indemnification required by the Company is not specified in some cases prevents the Company from making a reasonable estimate of the maximum potential amount it could be required to pay to counterparties. Historically, the Company has not made any significant payments under such indemnifications and no amounts have been accrued in the Condensed Consolidated Financial Statements with respect to the contingent aspect of these indemnities.

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Operations Supplemental Information	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Condensed Consolidated Statements of Operations Supplemental Information	9. Condensed Consolidated Statements of Operations Supplemental Information (a) Selling Expenses Sales commissions and other selling expenses paid prior to the recognition of the related revenue are deferred and recognized in the Condensed Consolidated Statements of Operations upon the recognition of the related theater system revenue. For the three and nine months ended September 30, 2021, the sales commission costs recognized within Costs and Expenses Applicable to Revenues – Technology Sales are $0.2 million and $0.6 million, respectively (2020 — $0.3 million and $0.4 million, respectively). Direct Sales commissions related to joint revenue sharing arrangements accounted for operating leases Film exploitation costs, including advertising and marketing expense, totaled $3.2 million and $5.9 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.5 million and $3.1 million, respectively), and are expensed as incurred within Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services. (b) Foreign Exchange Included in Selling, General and Administrative Expenses for the three and nine months ended September 30, 2021 respectively gain (c) Collaborative Arrangements Joint Revenue Sharing Arrangements The Company provides IMAX Theater Systems to customers through joint revenue sharing arrangements. Under the traditional form of these arrangements, in exchange for providing the IMAX Theater System under a long-term lease, the Company earns rent based on a percentage of contingent box office receipts and, in some cases, concession revenues, rather than requiring the customer to pay a fixed upfront fee or annual minimum payments. Under certain other joint revenue sharing arrangements, known as hybrid arrangements, the customer is responsible for making fixed upfront payments prior to the delivery and installation of the IMAX Theater System. Under joint revenue sharing arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to the IMAX Theater System under a joint revenue sharing arrangement generally does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the IMAX Theater System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX Theater System is returned to the Company. As of September 30, 2021, the Company has signed traditional and hybrid joint revenue sharing agreements with 42 exhibitors (2020 — 41) — 1,233) — 881) Revenue attributable to transactions arising between the Company and its customers under joint revenue sharing arrangements are recorded within Revenues — Technology Sales and Revenues — Technology Rentals. For the three and nine months ended September 30, 2021, such revenues totaled $10.9 million and $29.9 million, respectively (2020 — $4.5 million and $11.5 million, respectively). (See Note 13(a) for a disaggregated presentation of the Company’s revenues.) IMAX DMR In an IMAX DMR arrangement, the Company receives a percentage of the box office receipts from a third party who owns the copyright to a film in exchange for converting the film into IMAX DMR format and distributing it through the IMAX network For the three and nine months ended September 30, 2021, the majority of IMAX DMR revenue was earned from the exhibition of 24 films (21 new and 3 carryovers) and 53 films (47 new and 6 carryovers), respectively, and the re-release of classic titles throughout the IMAX theater network, as compared to six new films and 20 films (16 new and 4 carryovers), respectively, and the re-release of classic titles in the three and nine months ended September 30, 2020. The accounting policy for the Company’s IMAX DMR arrangements is disclosed in Note 3(n) of the Company’s 2020 Form 10-K. Revenue attributable to transactions arising between the Company and its customers under IMAX DMR arrangements are included in Revenues – Image Enhancement and Maintenance Services. For the three and nine months ended September 30, 2021, such revenues totaled $15.7 million and $39.4 million, respectively (2020 — $6.9 million and $18.1 million, respectively). (See Note 13(a) for a disaggregated presentation of the Company’s revenues.) Co-Produced Film Arrangements In certain film arrangements, the Company co-produces a film with a third party whereby the third party retains the copyright and rights to the film. In some cases, the Company obtains exclusive theatrical distribution rights to the film. Under these arrangements, both parties contribute funding to the Company’s partly-owned subsidiary for the production and distribution of the film and for associated exploitation costs. As of September 30, 2021, the Company has one co-produced film arrangement, which represents the VIE total assets balance of $1.6 million and liabilities balance of $0.3 million and three other co-produced film arrangements, the terms of which are similar. The accounting policies relating to co-produced film arrangements are disclosed in Notes 3(a) and 3(n) of the Company’s 2020 Form 10-K. For the three and nine months ended September 30, 2021, an expense of $0.2 million and $0.3 million, respectively (2020 — $0.5 million and $1.9 million, respectively) attributable to transactions between the Company and other parties involved in the production of the films have been included in Costs and Expenses Applicable to Revenues – Image Enhancement and Maintenance Services.

Condensed Consolidated Statem_6

Condensed Consolidated Statements of Cash Flows Supplemental Information	9 Months Ended
	Sep. 30, 2021
Supplemental Cash Flow Elements [Abstract]
Condensed Consolidated Statements of Cash Flows Supplemental Information	10. Condensed Consolidated Statements of Cash Flows – Supplemental Information (a) Changes in other operating assets and liabilities Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 (Increase) decrease in: Financing receivables $ (1,693 ) $ (3,212 ) Prepaid expenses (2,767 ) (1,332 ) Variable consideration receivables (1,243 ) (1,007 ) Other assets 664 (3,712 ) Decrease in: Accounts payable (5,135 ) (8,320 ) Accrued and other liabilities (1) (1,728 ) (6,526 ) $ (11,902 ) $ (24,109 ) (1) Includes a $9.5 million payment made in the second quarter of 2021 in connection with the settlement of the Giencourt matter, as discussed in Note 8(b)(ii). (b) Depreciation and amortization Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 Film assets $ 10,661 $ 6,159 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements 16,784 19,247 Other property, plant and equipment 7,176 8,478 Other intangible assets (1) 4,509 4,882 Other assets (2) 1,440 1,933 $ 40,570 $ 40,699 (1) Includes the amortization of licenses and intellectual property recorded in Research and Development on the Condensed Consolidated Statement of Operations of $1.0 million in the nine months ended September 30, 2021 ( 2020 $1.0 million). (2) Includes the amortization of lessee incentives provided by the Company to its customers under joint revenue sharing arrangements. (c) Write-downs Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 Inventories (1) $ 468 $ 729 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements (2) 328 1,050 Other property, plant and equipment — 66 Other intangible assets 63 132 Film assets (3) 19 10,211 Other assets (4) — 1,151 $ 878 $ 13,339 (1) In the nine months ended September 30, 2021, the Company recorded write-downs of $0.5 million (2020 — $0.7 million) in Costs and Expenses Applicable to Technology Sales related to excess and damaged inventory. (2) In the nine months ended September 30, 2021, the Company recorded charges of $0.3 million (2020 — $1.1 million) in Costs and Expenses Applicable to Technology Rentals mostly related to the write-down of leased xenon-based digital systems which were taken out of service in connection with customer upgrades to laser-based digital systems. (3) In the nine months ended September 30, 2020, the Company recorded impairment losses of $10.2 million in Costs and Expenses Applicable to Image Enhancement and Maintenance Services principally to write-down the carrying value of certain documentary and alternative film content due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments. To a much lesser extent, the impairment losses also relate to the write-down of DMR related film assets. ( 4 ) In the nine months ended September 30, 2020, the Company recorded a write-down of $1.2 million in Asset Impairments related to content-related assets which became impaired in the period. (d) Significant non-cash investing activities Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 Net (decrease) increase in accruals related to: Investment in equipment supporting joint revenue sharing arrangements $ 217 $ (1,897 ) Acquisition of other intangible assets (863 ) 69 Purchases of property, plant and equipment (8 ) 158 $ (654 ) $ (1,670 )

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes (a) Income Tax Expense For the three months ended September 30, 2021, the Company recorded income tax expense of $4.4 million (2020 — income tax expense of $19.3 million). For the , t Three Months Ended Three Months Ended September 30, 2021 September 30, 2020 (In thousands of U.S. Dollars, except rates) Amount Rate Amount Rate Income tax benefit at combined statutory rates $ 509 26.2% $ 7,279 26.2% Adjustments resulting from: Unrealized investment gains not taxable — — 420 1.5% Increase of valuation allowance (4,270 ) (219.8%) (23,707 ) (85.3%) Changes to tax reserves (215 ) (11.1%) (181 ) (0.7%) Withholding taxes resulting from management's decision to no longer indefinitely reinvest the historical earnings of certain foreign subsidiaries — — (186 ) (0.7%) Reduction in tax benefits resulting from the vesting of share-based compensation (4 ) (0.2%) (38 ) (0.1%) Other non-deductible/non-taxable items (422 ) (21.7%) (2,936 ) (10.5%) Income tax expense $ (4,402 ) (226.6%) $ (19,349 ) (69.6%) For the three months ended September 30, 2021, the Company recorded an additional $4.3 million valuation allowance against deferred tax assets in jurisdictions where management could not reliably forecast that future tax liabilities would arise, principally due to the uncertainties around the long-term impact of the COVID-19 global pandemic. Accordingly, the tax benefit associated with the current period losses in these jurisdictions is not ultimately reflected in the Company’s Condensed Consolidated Statements of Operations. For the nine months ended September 30, 2021, the Company recorded income tax expense of $9.4 million (2020 — $24.6 million). For the nine months ended September 30, 2021, the Company’s effective tax rate of (69.5)% varies from the Canadian statutory tax rate of 26.2% that was in effect during the period as follows: Nine Months Ended Nine Months Ended September 30, 2021 September 30, 2020 (In thousands of U.S. Dollars, except rates) Amount Rate Amount Rate Income tax benefit at combined statutory rates $ 3,548 26.2% $ 29,201 26.2% Adjustments resulting from: Realized and unrealized investment gains (losses) not taxable 1,367 10.1% (239 ) (0.2%) Increase of valuation allowance (14,248 ) (105.2%) (23,706 ) (21.3%) Changes to tax reserves 1,234 9.1% (4,978 ) (4.5%) Withholding taxes resulting from management's decision to no longer indefinitely reinvest the historical earnings of certain foreign subsidiaries (547 ) (4.0%) (18,661 ) (16.7%) Increase in tax benefits resulting from the vesting of share-based compensation 709 5.2% 33 — Other non-deductible/non-taxable items (1,479 ) (10.9%) (6,256 ) (5.6%) Income tax expense $ (9,416 ) (69.5%) $ (24,606 ) (22.1%) As of September 30, 2021, the Company’s Condensed Consolidated Balance Sheets include net deferred income tax assets of $18.7 million, net of a valuation allowance of $45.5 million (December 31, 2020 — $18.0 million, net of a valuation allowance of $28.8 million). The $16.7 million valuation allowance change recorded during the nine months ended September 30, 2021 is reflected within Income Tax Expense in the Company’s Condensed Consolidated Statements of Operations ($14.2 million) and within Shareholder’s Equity on the Company’s Condensed Consolidated Balance Sheets ($2.5 million). The valuation allowance is expected to reverse at the point in time when management determines it is more likely than not that the Company will incur sufficient tax liabilities to allow it to utilize the deferred tax assets against which the valuation allowance is recorded. Despite the valuation allowance recorded against its deferred tax assets, the Company remains entitled to benefit from tax attributes which currently have a valuation allowance applied to them. During the three and nine months ended September 30, 2021, $20.4 million of historical earnings from a subsidiary in China were repatriated and, as a result $2.0 million of foreign withholding taxes were paid in the period (2020 — $nil). (b) Income Tax Effect on Other Comprehensive (Loss) Income For the three and nine months ended September 30, 2021 and 2020, the income tax expense related to the following items in Other Comprehensive (Loss) Income are: Three Months Ended Nine Months Ended September 30, September 30, (In thousands of U.S. Dollars) 2021 2020 2021 2020 Unrealized change in cash flow hedging instruments $ 199 $ (160 ) $ 42 $ 235 Realized change in cash flow hedging instruments 82 (29 ) 358 (211 ) Reclassification of unrealized change in ineffective cash flow hedging instruments 7 — 83 — Defined benefit and postretirement benefit plans (12 ) — (37 ) 40 $ 276 $ (189 ) $ 446 $ 64

Capital Stock and Reserves

Capital Stock and Reserves	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Capital Stock And Reserves	12. Capital Stock And Reserves (a) Share-Based Compensation For the three and nine months ended September 30, 2021, share-based compensation expense totaled $6.1 million and $18.2 million, respectively (2020 — $5.3 million and $16.0 million, respectively) and is reflected in the following accounts in the Condensed Consolidated Statements of Operations: Three Months Ended Nine Months Ended September 30, September 30, (In Thousands of U.S. Dollars) 2021 2020 2021 2020 Cost and expenses applicable to revenues $ 314 $ 130 $ 920 $ 530 Selling, general and administrative expenses 5,706 5,151 17,046 15,325 Research and development 89 29 245 114 $ 6,109 $ 5,310 $ 18,211 $ 15,969 For the three and nine months ended September 30, 2020, there was a lower level of share-based compensation expenses allocated to Costs and Expense Applicable to Revenues or Research and Development due to the lower level of production during the COVID-19 global pandemic. The following table summarizes the Company’s share-based compensation expense by each award type: Three Months Ended Nine Months Ended September 30, September 30, (In Thousands of U.S. Dollars) 2021 2020 2021 2020 Stock Options $ 253 $ 433 $ 808 $ 1,449 Restricted Share Units 3,900 3,430 11,524 10,866 Performance Stock Units 1,183 483 3,169 1,229 IMAX China Stock Options 41 600 143 701 IMAX China Long Term Incentive Plan Restricted Share Units 600 332 2,217 1,645 IMAX China Long Term Incentive Plan Performance Stock Units 132 32 350 79 $ 6,109 $ 5,310 $ 18,211 $ 15,969 Included in the above table is an expense of $nil $nil Stock Option Summary The following table summarizes the activity under the Company’s Stock Option Plan (“SOP”) and the IMAX Corporation Second Amended and Restated Long-Term Incentive Plan (as may be amended, “IMAX LTIP”) for the nine months ended September 30, 2021 and 2020: Number of Shares Weighted Average Exercise Price Per Share 2021 2020 2021 2020 Stock options outstanding, beginning of period 4,892,962 5,732,209 $ 26.81 $ 26.82 Granted — — — — Exercised (41,613 ) — 21.23 — Forfeited (86,587 ) (23,633 ) 22.51 22.35 Expired (903,038 ) (772,665 ) 28.31 27.03 Cancelled (123,220 ) (18,483 ) 26.68 27.97 Stock options outstanding, end of period 3,738,504 4,917,428 26.61 26.80 Stock options exercisable, end of period 3,487,857 4,315,484 26.93 27.32 Stock options are no longer granted under the Company’s previously approved SOP. Restricted Share Units (“RSU”) Summary The following table summarizes the activity in respect of RSUs issued under the IMAX LTIP for the nine months ended September 30, 2021 and 2020: Number of Awards Weighted Average Grant Date Fair Value Per Share 2021 2020 2021 2020 RSUs outstanding, beginning of period 1,564,838 1,065,347 $ 18.33 $ 23.17 Granted 831,123 1,050,385 21.03 15.35 Vested and settled (571,616 ) (386,451 ) 19.11 21.59 Forfeited (231,380 ) (54,933 ) 19.50 19.70 RSUs outstanding, end of period 1,592,965 1,674,348 19.29 18.75 Performance Stock Units Summary The Company grants awards for two types of performance stock units (“PSUs”), one which vests based on a combination of employee service and the achievement of certain EBITDA-based targets and one which vests based on a combination of employee service and the achievement of total shareholder return (“TSR”) targets. The achievement of the EBITDA and TSR targets in these PSUs is determined over a three-year performance period. The grant date fair value of PSUs with EBITDA-based targets is equal to the closing price of the Company’s common shares on the date of grant or the average closing price of the Company’s common shares for five days prior to the date of grant. The grant date fair value of PSUs with TSR targets is determined on the grant date using a Monte Carlo simulation, which is a valuation model that takes into account the likelihood of achieving the TSR targets embedded in the award (“Monte Carlo Model”). The compensation expense attributable to each type of PSU is recognized on a straight-line basis over the requisite service period. The fair value determined by the Monte Carlo Model is affected by the Company’s share price, as well as assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, market conditions as of the grant date, the Company’s expected share price volatility over the term of the awards, and other relevant data. The compensation expense is fixed on the date of grant based on the fair value of the PSUs granted. The amount and timing of compensation expense recognized for PSUs with EBITDA-based targets is dependent upon management's assessment of the likelihood of achieving these targets. If, as a result of management’s assessment, it is projected that a greater number of PSUs will vest than previously anticipated, a life-to-date adjustment to increase compensation expense is recorded in the period that such determination is made. Conversely, if, as a result of management’s assessment, it is projected that a lower number of PSUs will vest than previously anticipated, a life-to-date adjustment to decrease compensation expense is recorded in the period that such determination is made. The expense recognized in the nine months ended September 30, 2021 includes adjustments reflecting management’s estimate of the number of PSUs with EBITDA-based targets expected to vest. The following table summarizes the activity in respect of PSUs issued under the IMAX LTIP for the nine months ended September 30, 2021 and 2020: Number of Awards Weighted Average Grant Date Fair Value Per Share 2021 2020 2021 2020 PSUs outstanding, beginning of period 361,844 — $ 15.68 $ — Granted 309,574 370,265 20.77 15.66 Forfeited (54,634 ) (2,526 ) 16.08 14.84 PSUs outstanding, end of period 616,784 367,739 18.20 15.67 As of September 30, 2021, the maximum number of shares of common stock that may be issued with respect to PSUs outstanding is 1,079,372, assuming full achievement of the EBITDA and TSR targets. (b) Issuer Purchases of Equity Securities In April 2021, the Company’s Board of Directors approved a 12-month extension to its share repurchase program through June 30, 2022. The extension authorized the Company to repurchase up to approximately $89.4 million worth of common shares, the remaining amount available of the original $200.0 million initially authorized under the share repurchase program when it commenced on July 1, 2017. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time. During the three and nine months ended September 30, 2021, the Company repurchased 316,812 common shares, respectively (2020 — nil and 2,484,123 common shares, respectively), at an average price of $14.53 per share, respectively (2020 — $nil and $14.72 per share, respectively), excluding commissions. During the three and nine months ended September 30, 2021, there were no common shares purchased in the administration of employee share-based compensation plans (2020 — nil and 200,000 common shares at an average price of $nil and $15.43 per share, respectively). As of September 30, 2021, the IMAX LTIP trustee held 276 shares purchased for less than $0.1 million (December 31, 2020 — 723 shares for less than $0.1 million), in the open market to be issued upon the settlement of RSUs and certain stock options. The shares held with the trustee are recorded at cost and are reported as a reduction against Capital Stock on the Company’s Condensed Consolidated Balance Sheets. In 2021, IMAX China announced that its shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase of shares of IMAX China not to exceed 10% of the total number of issued shares as of May 6, 2021 (34,835,824 shares). This program will be valid until the 2022 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time. During the three and nine months ended September 30, 2021, IMAX China repurchased 3,569,000 common shares, respectively, at an average price of HKD 10.90 per share, respectively (U.S. $1.40 per share, respectively). During three and nine months ended September 30, 2020, IMAX China repurchased nil and 906,400 common shares, respectively, at an average price of HKD nil and HKD 13.13 per share, respectively (U.S. $nil and $1.69 per share, respectively). (c) Basic and Diluted Weighted Average Shares Outstanding The following table reconciles the denominator of the basic and diluted weighted average share computations: Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (In thousands) Issued and outstanding, beginning of period 59,396 58,857 58,921 61,176 Weighted average number of shares (repurchased) issued, net (152 ) 2 286 (1,816 ) Weighted average number of shares outstanding - basic 59,244 58,859 59,207 59,360 Weighted average effect of potential common shares, if dilutive — — — — Weighted average number of shares outstanding - diluted 59,244 58,859 59,207 59,360 For the three and nine months ended September 30, 2021, the calculation of diluted weighted average shares outstanding excludes 6,115,389 shares (2020 — 6,959,515 shares) that are issuable upon the vesting or exercise of share-based compensation including: (i) 1,592,965 RSUs (2020 — 1,674,348 RSUs), (ii) 783,920 PSUs (2020 — 367,739 PSUs) and (iii) 3,738,504 stock options (2020 — 4,917,428 stock options), as the effect would be anti-dilutive. The calculation of diluted weighted average shares outstanding for the three and nine months ended September 30, 2021 also excludes any shares potentially issuable upon the conversion of the Convertible Notes as the average market price of the Company’s common shares during the period of time they were outstanding was less than the conversion price of the Convertible Notes. (See Note 7(b).) (d) Statutory Surplus Reserve Pursuant to the corporate law of the People’s Republic of China (the “PRC”), entities registered in the PRC are required to maintain certain statutory reserves, which are appropriated from after-tax profits (after offsetting accumulated losses from prior years), as reported in their respective statutory financial statements, before the declaration or payment of dividends to equity holders. All statutory reserves are created for specific purposes. The Company’s PRC subsidiaries are required to appropriate 10% of statutory net profits to statutory surplus reserves, upon distribution of their after-tax profits. The Company’s PRC subsidiaries may discontinue the contribution when the aggregate sum of the statutory surplus reserve is more than 50% of its registered capital. The statutory surplus reserve is non-distributable other than during liquidation and During the three months ended September 30, 2021, one of the Company’s PRC subsidiaries declared and paid dividend s of RMB 131.6 million ($ 20.4 million) . In the third quarter of 2021, upon passage of the requisite resolution of the Board of Directors, a statutory surplus reserve of RMB 36.4 million ($ 5.6 million) was recorded within Shareholders’ Equity as an appropriation of the retained earnings of the Company’s PRC subsidiaries, of which $ 3.9 million is attributable to the Company’s common shareholder s and $ 1.7 million is attributable to non-controlling shareholders . The statutory surplus reserve of RMB 36.4 million ($5.6 million) has reached 50 % of its PRC subsidiaries’ registered capital.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	9 Months Ended
	Sep. 30, 2021
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	13. Revenue from Contracts with Customers (a) Disaggregated Information About Revenue The following tables summarize the Company’s revenues by type and reportable segment for the three and nine months ended September 30, 2021: Three Months Ended September 30, 2021 Revenue from Contracts with Customers Revenue from (In thousands of U.S. Dollars) Fixed Consideration Variable Consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems (1) $ 9,701 $ 802 $ 98 $ — $ 10,601 Joint Revenue Sharing Arrangements, fixed fees — — 1,036 — 1,036 Other Theater Business 363 — — — 363 Other sales (2) 1,154 6 — — 1,160 Sub-total 11,218 808 1,134 — 13,160 Image enhancement and maintenance services IMAX DMR — 15,701 — — 15,701 IMAX Maintenance 13,055 — — — 13,055 Film Post-Production 899 — — — 899 Film Distribution 203 496 — — 699 Other — 234 — — 234 Sub-total 14,157 16,431 — — 30,588 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 9,887 — 9,887 Other — — 332 — 332 Sub-total — — 10,219 — 10,219 Finance income IMAX Systems — — — 2,635 2,635 Total $ 25,375 $ 17,239 $ 11,353 $ 2,635 $ 56,602 Nine Months Ended September 30, 2021 Revenue from Contracts with Customers Revenue from (In thousands of U.S. Dollars) Fixed consideration Variable consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems (1) $ 20,143 $ 2,573 $ 4,220 $ — $ 26,936 Joint Revenue Sharing Arrangements, fixed fees — — 3,776 — 3,776 Other Theater Business 1,275 — — — 1,275 Other sales (2) 2,474 47 — — 2,521 Sub-total 23,892 2,620 7,996 — 34,508 Image enhancement and maintenance services IMAX DMR — 39,438 — — 39,438 IMAX Maintenance 33,196 — — — 33,196 Film Post-Production 2,886 — — — 2,886 Film Distribution 204 911 — — 1,115 Other — 279 — — 279 Sub-total 36,286 40,628 — — 76,914 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 26,108 — 26,108 Other — — 600 — 600 Sub-total — — 26,708 — 26,708 Finance income IMAX Systems — — — 8,181 8,181 Total $ 60,178 $ 43,248 $ 34,704 $ 8,181 $ 146,311 (1) Includes r evenues earned from sales or sales-type lease arrangements involving new and upgraded IMAX Theater Systems, as well as the impact on revenue of renewals and amendments to existing theater system arrangements. (2) Other sales include revenues associated with New Business Initiatives. The following tables summarize the Company’s revenues by type and reportable segment for the three and nine months ended September 30, 2020: Three Months Ended September 30, 2020 Revenue from Contracts with Customers Revenue from (In thousands of U.S. Dollars) Fixed Consideration Variable Consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems (1)(2) $ 12,356 $ 1,481 $ 1,159 $ — $ 14,996 Joint Revenue Sharing Arrangements, fixed fees — — 57 — 57 Other Theater Business 307 — — — 307 Other sales (3) 378 15 — — 393 Sub-total 13,041 1,496 1,216 — 15,753 Image enhancement and maintenance services IMAX DMR — 6,886 — — 6,886 IMAX Maintenance 5,855 — — — 5,855 Film Post-Production 739 — — — 739 Film Distribution 750 376 — — 1,126 Other — (17 ) — — (17 ) Sub-total 7,344 7,245 — — 14,589 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 4,473 — 4,473 Sub-total — — 4,473 — 4,473 Finance income IMAX Systems — — — 2,441 2,441 Total $ 20,385 $ 8,741 $ 5,689 $ 2,441 $ 37,256 Nine Months Ended September 30, 2020 Revenue from Contracts with Customers Revenue from (In thousands of U.S. Dollars) Fixed consideration Variable consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems (1)(2) $ 14,711 $ 3,143 $ 2,325 $ — $ 20,179 Joint Revenue Sharing Arrangements, fixed fees — — 1,196 — 1,196 Other Theater Business 1,261 — — — 1,261 Other sales (3) 1,361 105 — — 1,466 Sub-total 17,333 3,248 3,521 — 24,102 Image enhancement and maintenance services IMAX DMR — 18,061 — — 18,061 IMAX Maintenance 13,225 — — — 13,225 Film Post-production 3,088 — — — 3,088 Film Distribution 3,000 1,453 — — 4,453 Other 282 — — 282 Sub-total 19,313 19,796 — — 39,109 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 10,307 — 10,307 Sub-total — — 10,307 — 10,307 Finance income IMAX Systems — — — 7,495 7,495 Total $ 36,646 $ 23,044 $ 13,828 $ 7,495 $ 81,013 (1) Includes r evenues earned from sales or sales-type lease arrangements involving new and upgraded IMAX Theater Systems, as well as the impact on revenue of renewals and amendments to existing theater system arrangements. (2) Prior period comparatives have been revised to appropriately classify $1.1 million and $2.3 million, respectively, of fixed consideration under revenue from contracts with customers to revenue from lease arrangements for the three and nine months ended September 30, 2020. (3) Other sales include revenues associated with New Business Initiatives. (b) Deferred Revenue IMAX Theater System sale and lease arrangements include a requirement for the Company to provide maintenance services over the life of the arrangement, subject to a consumer price index adjustment each year. In circumstances where customers prepay the entire term’s maintenance fee, additional payments are due to the Company for the years after its extended warranty and maintenance obligations expire. Payments upon renewal each year are either prepaid or made in arrears and can vary in frequency from monthly to annually. At September 30, 2021, $20.3 million of consideration has been deferred in relation to outstanding maintenance services to be provided on existing maintenance contracts (December 31, 2020 — $21.6 million). Maintenance revenue is recognized evenly over the contract term which coincides with the period over which maintenance services are provided. In the event of customer default, any payments made by the customer may be retained by the Company. In instances where the Company receives consideration prior to satisfying its performance obligations, the recognition of revenue is deferred. The majority of the deferred revenue balance relates to payments received by the Company for IMAX Theater Systems where control of the system has not transferred to the customer. The deferred revenue balance related to an individual theater increases as progress payments are made and is then derecognized when control of the system is transferred to the customer. Recognition dates are variable and depend on numerous factors, including some outside of the Company’s control. (See Note 2 for information on the current impacts of and uncertainties relating to the COVID-19 global pandemic which are impacting the Company’s revenues

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Reporting	14. Segment Reporting The Company’s Chief Executive Officer (“CEO”) is its Chief Operating Decision Maker (“CODM”), as such term is defined under U.S. GAAP. The CODM, along with other members of management, assess segment performance based on segment revenues and gross margins. Selling, general and administrative expenses, research and development costs, the amortization of intangible assets, provision for (reversal of) current expected credit losses, certain write-downs, interest income, interest expense and income tax (expense) benefit are not allocated to the Company’s segments. The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements; (iii) IMAX Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) New Business Initiatives; (vii) Film Distribution; and (viii) Film Post-Production. The Company organizes its reportable segments into the following four categories, identified by the nature of the product sold or service provided: (i) IMAX Technology Network, which earns revenue based on contingent box office receipts and includes the IMAX DMR segment and contingent rent from the Joint Revenue Sharing Arrangement (“JRSA”) segment; (ii) IMAX Technology Sales and Maintenance, which includes results from the IMAX Systems, IMAX Maintenance and Other Theater Business segments, as well as fixed revenues from the JRSA segment; (iii) New Business Initiatives, which is a segment that includes activities related to the exploration of new lines of business and new initiatives outside of the Company’s core business; and (iv) Film Distribution and Post-Production, which includes activities related to the licensing of film content, and the distribution of films primarily for the Company’s institutional theater partners (through the Film Distribution segment) and the provision of film post-production and quality control services (through the Film Post-Production segment). The Company is presenting information at a disaggregated level to provide more relevant information to readers. Transactions between the IMAX DMR segment and the Film Post-Production segment are valued at exchange value. Inter-segment profits are eliminated upon consolidation, as well as for the disclosures below. The following table presents the Company’s revenue and gross margin (margin loss) by category and reportable segment for the three months ended September 30, 2021 and 2020: Revenue (1) Gross Margin (Margin Loss) (4) (In thousands of U.S. Dollars) 2021 2020 2021 2020 IMAX Technology Network IMAX DMR $ 15,701 $ 6,886 $ 7,293 $ 3,079 Joint Revenue Sharing Arrangements, contingent rent 9,887 4,473 3,626 (2,491 ) 25,588 11,359 10,919 588 IMAX Technology Sales and Maintenance IMAX Systems (2) 13,236 17,437 8,086 8,671 Joint Revenue Sharing Arrangements, fixed fees 1,036 57 280 (117 ) IMAX Maintenance 13,055 5,855 6,462 794 Other Theater Business (3) 363 307 64 31 27,690 23,656 14,892 9,379 New Business Initiatives 1,238 378 1,189 372 Film Distribution and Post-Production Film Distribution (5) 699 1,126 (4 ) (5,597 ) Post-Production 899 739 420 (464 ) 1,598 1,865 416 (6,061 ) Sub-total 56,114 37,258 27,416 4,278 Other 488 (2 ) 71 (449 ) Total $ 56,602 $ 37,256 $ 27,487 $ 3,829 The following table presents the Company’s revenue and gross margin (margin loss) by category and reportable segment for the nine months ended September 30, 2021 and 2020: Revenue (1) Gross Margin (Margin Loss) (4) (In thousands of U.S. Dollars) 2021 2020 2021 2020 IMAX Technology Network IMAX DMR $ 39,438 $ 18,061 $ 22,405 $ 7,492 Joint Revenue Sharing Arrangements, contingent rent 26,108 10,307 7,299 (10,610 ) 65,546 28,368 29,704 (3,118 ) IMAX Technology Sales and Maintenance IMAX Systems (2) 35,117 27,674 21,646 14,497 Joint Revenue Sharing Arrangements, fixed fees 3,776 1,196 783 110 IMAX Maintenance 33,196 13,225 15,360 (355 ) Other Theater Business (3) 1,283 1,261 269 77 73,372 43,356 38,058 14,329 New Business Initiatives 2,554 1,488 2,281 1,245 Film Distribution and Post-Production Film Distribution (5) 1,115 4,453 (319 ) (9,296 ) Post-Production 2,886 3,088 1,316 (96 ) 4,001 7,541 997 (9,392 ) Sub-total 145,473 80,753 71,040 3,064 Other 838 260 (669 ) (1,837 ) Total $ 146,311 $ 81,013 $ 70,371 $ 1,227 (1) The Company’s largest customer represents 18.2% and 22.2%, respectively, of total Revenues for the three and nine months ended September 30, 2021 (2020 — 11.0% and 11.3%, respectively). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of September 30, 2021 and December 31, 2020. ( 2 ) The revenue from this segment includes the initial upfront payments and the present value of fixed minimum payments from sales and sales-type lease arrangements of IMAX Theater Systems, as well as the present value of estimated variable consideration from sales of IMAX Theater Systems. To a lesser extent, the revenue from this segment also includes finance income associated with these revenue streams. ( 3 ) The revenue from this segment principally includes after-market sales of IMAX projection system parts and 3D glasses. ( 4 ) IMAX DMR gross margin includes marketing costs of $3.2 million and $5.8 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.4 million and $2.8 million, respectively). JRSA gross margin includes advertising, marketing and commission expense of $0.8 million and $1.9 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.7 million and $1.3 million, respectively). IMAX Systems gross margin includes marketing and commission costs of $0.3 million and $0.9 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.6 million and $1.0 million, respectively). Film Distribution segment gross margin includes marketing expense of $nil and less than $0.1 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.2 million and $0.4 million, respectively). ( 5 ) During the three and nine months ended September 30, 2020, Film Distribution segment results include impairment losses of $5.4 million and $9.9 million, respectively, to write-down the carrying value of certain documentary and alternative content film assets . No such charges were incurred in the . Geographic Information Revenue by geographic area is based on the location of the customer. Revenue related to IMAX DMR is presented based upon the geographic location of the theaters that exhibit the remastered films. IMAX DMR revenue is generated through contractual relationships with studios and other third parties and these may not be in the same geographical location as the theater. Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Revenue Greater China $ 22,203 $ 19,346 $ 75,634 $ 26,008 United States 16,469 4,335 34,275 21,112 Western Europe 7,634 5,085 11,160 10,273 Asia (excluding Greater China) 4,925 4,935 12,837 12,663 Russia & the CIS 1,353 738 4,577 2,962 Latin America 1,181 1,616 1,579 3,251 Canada 1,083 384 620 1,327 Rest of the World 1,754 817 5,629 3,417 Total $ 56,602 $ 37,256 $ 146,311 $ 81,013 No single country in the Rest of the World, Western Europe, Latin America and Asia (excluding Greater China) comprises more than 10% of the Company’s total revenue in the three and nine months ended September 30, 2021.

Employees Pension and Postretir

Employees Pension and Postretirement Benefits	9 Months Ended
	Sep. 30, 2021
Compensation And Retirement Disclosure [Abstract]
Employees Pension and Postretirement Benefits	15. Employee's Pension and Postretirement Benefits (a) Defined Benefit Plan The Company has an unfunded defined benefit pension plan, the Supplemental Executive Retirement Plan (the “SERP”), covering its CEO, Richard L. Gelfond. Under the terms of the SERP, if Mr. Gelfond’s employment is terminated other than for cause (as defined in his employment agreement), he is entitled to receive SERP benefits in the form of a lump sum payment. SERP benefit payments to Mr. Gelfond are subject to a deferral for six months after the termination of his employment, at which time Mr. Gelfond will be entitled to receive interest on the deferred amount credited at the applicable federal rate for short-term obligations. Pursuant to an amendment to his employment agreement dated November 1, 2019, the term of Mr. Gelfond’s employment was extended through December 31, 2022, although Mr. Gelfond has not informed the Company that he intends to retire at that time. Under the terms of this amendment to his employment agreement, the total benefit payable to Mr. Gelfond under the SERP was fixed at $20.3 million. As of September 30, 2021 and December 31, 2020, the Company’s projected benefit obligation and unfunded status related to the SERP are as follows: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Projected benefit obligation: Obligation, beginning of period $ 20,116 $ 18,840 Interest cost 54 379 Actuarial gain — 897 Obligation, end of period and unfunded status (1) $ 20,170 $ 20,116 (1) The accumulated benefit obligation for the SERP was $20.2 million at September 30, 2021 (December 31, 2020 — $20.1 million). For the three and nine months ended September 30, 2021, the Company recorded interest costs of less than $0.1 million and $0.1 million, respectively (2020 — $0.1 million and $0.3 million, respectively) related to the SERP. The Company expects to recognize additional interest costs of less than $0.1 million related to the SERP during the remainder of 2021. No contributions are expected to be made to the SERP in 2021. (b) Defined Contribution Pension Plan The Company also maintains defined contribution plans for its employees, including its executive officers. The Company makes contributions to these plans on behalf of employees in an amount up to 5% of their base salary subject to certain prescribed maximums. During the three and nine months ended September 30, 2021, the Company contributed and recorded expense of $0.3 million and $0.8 million, respectively respectively respectively respectively (c) Postretirement Benefits – Executives The Company has an unfunded postretirement plan for Mr. Gelfond and Bradley J. Wechsler, former Chairman of the Company’s Board of Directors. The plan provides that the Company will maintain health benefits for Messrs. Gelfond and Wechsler until they become eligible for Medicare and, thereafter, the Company will provide Medicare supplemental coverage as selected by Messrs. Gelfond and Wechsler. As of September 30, 2021, the Company’s postretirement benefits obligation under this plan is $0.7 million (December 31, 2020 — $0.7 million). For the three and nine months ended September 30, 2021, the Company has recorded an expense of less than $0.1 million (2020 — less than $0.1 million) related to this plan. Mr. Wechsler retired from the Company’s Board of Directors on June 9, 2021. The Company will maintain Mr. Wechsler’s current health benefits through December 31, 2021, and thereafter will provide him with Medicare supplemental coverage. (d) Postretirement Benefits – Canadian Employees The Company has an unfunded postretirement plan for its Canadian employees meeting specific eligibility requirements. The Company will provide eligible participants, upon retirement, with health and welfare benefits. As of September 30, 2021, the Company’s postretirement benefits obligation under this plan is $1.8 million (December 31, 2020 — $1.9 million). For the three and nine months ended September 30, 2021, the Company has recorded expense of less than $0.1 million (2020 — less than $0.1 million and $0.1 million, respectively) related to this plan. (e) Deferred Compensation Benefit Plan The Company maintained a nonqualified deferred compensation benefit plan (the “Retirement Plan”) covering the former CEO of IMAX Entertainment and Senior Executive Vice President of the Company. Under the terms of the Retirement Plan, the benefits were due to vest in full if the executive incurred a separation from service from the Company (as defined therein). In the fourth quarter of 2018, the executive incurred a separation from service from the Company, and as such, the Retirement Plan benefits became fully vested as of December 31, 2018 and the accelerated costs were recognized and reflected in Executive Transition Costs in the Consolidated Statements of Operations. As of September 30, 2021, the benefit obligation related to the Retirement Plan was $3.8 million (December 31, 2020 — $3.7 million) and is recorded on the Company’s Condensed Consolidated Balance Sheets within Accrued and Other Liabilities. As the Retirement Plan is fully vested, the benefit obligation is measured at the present value of the benefits expected to be paid in the future with the accretion of interest recognized in the Condensed Consolidated Statements of Operations within Retirement Benefits Non-service Expenses. The Retirement Plan is funded by an investment in company-owned life insurance (“COLI”), which is recorded at its fair value on the Company’s Condensed Consolidated Balance Sheets within Prepaid Expenses. As of September 30, 2021, fair value of the COLI asset was $3.2 million (December 31, 2020 — $3.2 million). Gains and losses resulting from changes in the cash surrender value of the COLI asset are recognized in the Condensed Consolidated Statements of Operations within Realized and Unrealized Investment Gains (Losses).

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2021
Investments All Other Investments [Abstract]
Financial Instruments	16. Financial Instruments (a) Financial Instruments The Company maintains cash with various major financial institutions. The Company’s cash is invested with highly rated financial institutions. The Company’s $193.0 million balance of cash and cash equivalents as of September 30, 2021 includes $101.0 million in cash held outside of Canada (December 31, 2020 — $89.9 million), of which $70.3 million was held in the PRC (December 31, 2020 — $77.2 million). (b) Fair Value Measurements The carrying values of the Company’s Cash and Cash Equivalents, Accounts Receivable, Accounts Payable and Accrued Liabilities due within one year approximate their fair values due to the short-term maturity of these instruments. Including these instruments, the Company’s financial instruments consist of the following: As of September 30, 2021 As of December 31, 2020 (In thousands of U.S. Dollars) Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Level 1 Cash and cash equivalents (1) $ 193,008 $ 193,008 $ 317,379 $ 317,379 Equity securities (2) 1,089 1,089 13,633 13,633 Level 2 Net financed sales receivables (3) $ 113,200 $ 113,210 $ 112,396 $ 112,603 Net investment in sales-type leases (3) 22,002 21,850 19,414 19,373 Equity securities (1) 1,000 1,000 1,000 1,000 COLI (4) 3,244 3,244 3,155 3,155 Foreign exchange contracts — (3) (209 ) (209 ) 1,635 1,635 Foreign exchange contracts — (3) (61 ) (61 ) 344 344 Working Capital Facility borrowings (1) (10,974 ) (10,974 ) (7,643 ) (7,643 ) Credit Facility borrowings (1) — — (300,000 ) (300,000 ) Convertible Notes (5) (230,000 ) (224,574 ) — — (1) Recorded at cost, which approximates fair value. (2) Fair value is determined using quoted prices in active markets. ( 3 ) Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms. (4) Measured at cash surrender value, which approximates fair value. (5) Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data. The Company did not have any material amounts of Level 3 assets or liabilities as of September 30, 2021 and December 31, 2020. (c) Foreign Exchange Risk Management The Company is exposed to market risk from changes in foreign currency rates. A majority of the Company’s revenues is denominated in U.S. Dollars while a substantial portion of its costs and expenses is denominated in Canadian Dollars. A portion of the net U.S. Dollar cash flows of the Company is periodically converted to Canadian Dollars to fund Canadian Dollar expenses through the spot market. In China and Japan, the Company has ongoing operating expenses related to its operations in RMB and Japanese Yen, respectively. Net cash flows are converted to and from U.S. Dollars through the spot market. The Company also has cash receipts under leases denominated in RMB, Japanese Yen, Canadian Dollars and Euros which are converted to U.S. Dollars through the spot market. In addition, because IMAX films generate box office in 85 different countries, unfavourable exchange rates between applicable local currencies and the U.S. Dollar affect the Company’s reported gross box-office receipts and revenues, further impacting the Company’s results of operations. The Company’s policy is to not use any financial instruments for trading or other speculative purposes. The Company has entered into a series of foreign currency forward contracts to manage the risks associated with the volatility of foreign currencies. Certain of these foreign currency forward contracts met the criteria required for hedge accounting under the Derivatives and Hedging Topic of the FASB ASC at inception, and continue to meet hedge effectiveness tests at September 30, 2021 (the “Foreign Currency Hedges”), with settlement dates throughout 2022. Foreign currency derivatives are recognized and measured in the Condensed Consolidated Balance Sheets at fair value. Changes in the fair value (i.e., gains or losses) are recognized in the Condensed Consolidated Statements of Operations except for derivatives designated and qualifying as foreign currency cash flow hedging instruments. The Company currently has cash flow hedging instruments associated with Selling, General and Administrative Expenses. For foreign currency cash flow hedging instruments related to Selling, General and Administrative Expenses, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in Other Comprehensive (Loss) Income and reclassified to the Condensed Consolidated Statements of Operations when the forecasted transaction occurs. For foreign currency cash flow hedging instruments related to Inventories, the effective portion of the gain or loss in a hedge of a forecasted transaction is reported in Other Comprehensive (Loss) Income and reclassified to Inventories in the Condensed Consolidated Balance Sheets when the forecasted transaction occurs. The following tabular disclosures reflect the impact that derivative instruments and hedging activities have on the Company’s Condensed Consolidated Financial Statements: Notional value of foreign exchange contracts September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards $ 24,642 $ 26,358 Derivatives not designated as hedging instruments: Foreign exchange contracts — Forwards 1,123 5,552 $ 25,765 $ 31,910 Fair value of derivatives in foreign exchange contracts September 30, December 31, (In thousands of U.S. Dollars) Balance Sheet Location 2021 2020 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 128 $ 1,635 Accrued and other liabilities (337 ) — Derivatives not designated as hedging instruments: Foreign exchange contracts — Forwards Other assets — 344 Accrued and other liabilities (61 ) — $ (270 ) $ 1,979 Derivatives in foreign currency hedging relationships are as follows Three Months Ended September 30, Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 2021 2020 Foreign exchange contracts Derivative (Loss) Gain — Forwards Recognized in OCI (Effective Portion) $ (759 ) $ 591 $ (159 ) $ (935 ) Location of Derivative Gain (Loss) Reclassified from AOCI Three Months Ended September 30, Nine months ended September 30, (In thousands of U.S. Dollars) (Effective Portion) 2021 2020 2021 2020 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ 312 $ (110 ) $ 1,367 (779 ) Inventory — — $ — (26 ) $ 312 $ (110 ) $ 1,367 $ (805 ) Three Months Ended September 30, Nine months ended September 30, (In thousands of U.S. Dollars) 2021 2020 2021 2020 Foreign exchange contracts Derivative Loss Recognized In — Forwards and Out of OCI (Effective Portion) $ — $ — $ — $ (55 ) The Company's estimated net amount of the existing loss as of September 30, 2021 is $0.2 million, which is expected to be reclassified to earnings within the next twelve months. Non-designated derivatives in foreign currency relationships are as follows Three Months Ended September 30, Nine months ended September 30, (In thousands of U.S. Dollars) 2021 2020 2021 2020 Foreign exchange contracts Derivative Gain Reclassified — Forwards From AOCI (Ineffective Portion) $ (25 ) $ — $ (318 ) $ — Three Months Ended September 30, Nine months ended September 30, (In thousands of U.S. Dollars) Location of Derivative (Loss) Gain 2021 2020 2021 2020 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ (122 ) $ 75 $ 269 $ 102 $ (122 ) $ 75 $ 269 $ 102 (d) Investments in Equity Securities As of September 30, 2021, the Condensed Consolidated Balance Sheets includes $1.1 million (December 31, 2020 — $13.6 million) of investments in equity securities. On January 17, 2019, IMAX China (Hong Kong), Limited, a wholly-owned subsidiary of IMAX China, as an investor entered into a cornerstone investment agreement with Maoyan Entertainment (“Maoyan”) (as the issuer) and Morgan Stanley Asia Limited (as a sponsor, underwriter and the underwriters’ representative). Pursuant to this agreement, IMAX China (Hong Kong), Limited agreed to invest $15.2 million to subscribe for a certain number of shares of Maoyan at the final offer price pursuant to the global offering of the share capital of Maoyan, and this investment would be subject to a lock-up period of six months following the date of the global offering. On February 4, 2019, Maoyan completed its global offering, upon which, IMAX China (Hong Kong), Limited became a less than 1% shareholder in Maoyan. In February 2021, IMAX China (Hong Kong), Limited sold all of its 7,949,000 shares of Maoyan for gross proceeds of $17.8 million, which represents a $2.6 million gain relative to the Company’s acquisition cost and a $5.2 million gain compared to the fair value of the investment as of December 31, 2020. Prior to this sale, the Company accounted for its investment in Maoyan at fair value with any changes in fair value recorded to the Condensed Consolidated Statements of Operations. For the three and nine months ended September 30, 2020, the fair value of the Company’s investment in Maoyan experienced an unrealized gain of $1.6 million and loss of $(0.9) million, respectively. The Company has an investment of $1.1 million (December 31, 2020 — $1.1 million) in the shares of an exchange traded fund. This investment is classified as an equity investment. As of September 30, 2021, the Company held investments in the preferred shares of enterprises which meet the criteria for classification as an equity security under FASB ASC 321, carried at historical cost, net of impairment charges. The carrying value of these equity security investments was $1.0 million at September 30, 2021 (December 31, 2020 — $1.0 million) and is recorded in Other Assets.

Non-Controlling Interests

Non-Controlling Interests	9 Months Ended
	Sep. 30, 2021
Temporary Equity Disclosure [Abstract]
Non-Controlling Interests	17. Non-Controlling Interests (a) IMAX China Non-Controlling Interest The Company indirectly owns 69.83% of IMAX China Holding, Inc. (“IMAX China”), whose shares trade on the Hong Kong Stock Exchange. IMAX China remains a consolidated subsidiary of the Company. As of September 30, 2021, the balance of the Company’s non-controlling interest in IMAX China is $82.8 million. For the three and nine months ended September 30, 2021, the net income attributable to the non-controlling interest in IMAX China is $2.0 million and $9.5 million, respectively (2020 — net income of $2.2 million and net loss of $(10.3) million, respectively). (b) Other Non-Controlling Interest The Company’s Original Film Fund was established in 2014 to co-finance a portfolio of 10 original large-format films. The initial investment in the Original Film Fund was committed by a third party in the amount of $25.0 million, with the possibility of contributing additional funds. The Company has contributed $9.0 million to the Original Film Fund since 2014 and has reached its maximum contribution. As of September 30, 2021, the Original Film Fund has invested $22.3 million toward the development of original films. The related production, financing and distribution agreement includes put and call rights relating to change of control of the rights, title and interest in the co-financed pictures. (c) Non-Controlling Interest in Temporary Equity The following table summarizes the movement of the non-controlling interest in temporary equity related to the Original Film Fund for the nine months ended September 30, 2021: Balance as of December 31, 2020 $ 759 Net income 1 Balance as of September 30, 2021 $ 760

Basis of Presentation (Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Accounting Principles	Accounting Principles IMAX Corporation, together with its consolidated subsidiaries (the “Company”), prepares its financial statements in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. In the Company’s opinion, the unaudited Condensed Consolidated Financial Statements reflect all adjustments of a normal recurring nature that are necessary for a fair statement of the results for the interim periods presented. The interim results presented in the Company’s Condensed Consolidated Statements of Operations are not necessarily indicative of results for a full year, particularly in this interim period due to the impacts of the COVID-19 global pandemic (see Note 2). These Condensed Consolidated Financial Statements Condensed Consolidated Financial Statements
Principles of Consolidation	Principles of Consolidation These Condensed Consolidated Financial Statements include the accounts of the Company together with its consolidated subsidiaries, except for subsidiaries which have been identified as variable interest entities (“VIEs”) where the Company is not the primary beneficiary. All intercompany accounts and transactions have been eliminated. The Company has evaluated its various variable interests to determine whether they are VIEs as required by U.S. GAAP. The Company has interests in ten film production companies, which have been identified as VIEs. The Company is the primary beneficiary of and consolidates five of these entities as it has the power to direct the activities that most significantly impact the economic performance of the VIE, and it has the obligation to absorb losses or the right to receive benefits from the respective VIE that could potentially be significant. The majority of the assets relating to these production companies are held by the IMAX Original Film Fund (the “Original Film Fund”) as described in Note 17(b). The Company does not consolidate the other five film production companies because it does not have the power to direct their activities and it does not have the obligation to absorb the majority of the expected losses or the right to receive expected residual returns. The Company uses the equity method of accounting for these entities, which are not material to the Company’s Condensed Consolidated Financial Statements.
Estimates and Assumptions	Estimates and Assumptions In preparing the Company’s Condensed Consolidated Financial Statements, management makes judgments in applying various accounting policies. The areas of policy judgment are consistent with those reported in Note 3(b) in the 2020 Form 10-K. In addition, management makes assumptions about the Company’s future operating results and cash flows in deriving critical accounting estimates used in preparing the Condensed Consolidated Financial Statements. The significant estimates made by management include, but are not limited to: (i) the allocation of the transaction price in an IMAX Theater System arrangement to distinct performance obligations; (ii) estimates of variable consideration ; (iii) expected credit losses on accounts receivable, financing receivables and variable consideration receivables; (iv) provisions for the write-down of excess and obsolete inventory; (v) the fair values of the reporting units used in assessing the recoverability of goodwill; (vi) the cash flow estimates used in testing the recoverability of long-lived assets such as the theater system equipment supporting joint revenue sharing arrangements; (vii) the economic lives of the theater system equipment supporting joint revenue sharing arrangements; (viii) the useful lives of intangible assets; (ix) the ultimate revenue forecasts used to test the recoverability of film assets; (x) the discount rates used to determine the present value of lease liabilities; (xi) pension plan assumptions; (xii) estimates related to the fair value and projected vesting of share-based payment awards; (xiii) the valuation of deferred income tax assets; and (xiv) reserves related to uncertain tax positions. The Company’s operations have been significantly impacted by the COVID-19 global pandemic, as described in Note 2. T he impact of the COVID-19 global pandemic on the Company’s business and financial results will continue to depend on numerous evolving factors that cannot be accurately predicted and that will vary by jurisdiction and market, including the duration and scope of the pandemic, the emergence of variants of the virus, the progress made on administering vaccines, the continuing impact of the pandemic on global economic conditions and ongoing government responses to the pandemic, which could lead to further theater closures, theater capacity restrictions and/or delays in the release of films. However, management is encouraged by the broad reopening of the IMAX theater network, the continued progress towards the resumption of normal theater operations, and recent box office results. Accordingly, during the three and nine months ended September 30, 2021, the Company reversed $3.3 million and $4.9 million, respectively, of its allowance for current expected credit losses, reflecting the improving outlook for theater operators as the theatrical exhibition industry continues to recover from the COVID-19 global pandemic. Despite the improving environment, there continues to be a degree of risk and uncertainty relating to future credit losses on receivables, inventory write downs, impairments of film assets, impairments of long-lived assets (including the theater system equipment supporting the Company’s joint revenue sharing arrangements), impairments of goodwill, a further valuation allowance against deferred tax assets, and the reversal of variable consideration receivables that are based on estimates of future box office performance. In the current environment, assumptions about box office results, IMAX Theater System installations, and customer creditworthiness have greater variability than normal, which could in the future significantly management’s estimates and judgments relating to the recoverability of the Company’s financial and non-financial assets.
Credit Risk	The Company’s internal credit quality classifications for theater operators are as follows: • Good Standing — The theater operator continues to be in good standing as payments and reporting are up to date. • Credit Watch — The theater operator has demonstrated a delay in payments, but continues to be in active communication with the Company. Theater operators placed on Credit Watch are subject to enhanced monitoring. In addition, depending on the size of the outstanding balance, length of time in arrears and other factors, future transactions may need to be approved by management. These receivables are in better condition than those in the Pre-Approved Transactions Only category, but are not in as good condition as the receivables in the Good Standing category. • Pre-Approved Transactions Only — The theater operator has demonstrated a delay in payments with little or no communication with the Company. All services and shipments to the theater operator must be reviewed and approved by management. These receivables are in better condition than those in the All Transactions Suspended category, but are not in as good condition as the receivables in the Credit Watch category. In certain situations, depending on the individual facts and circumstances related to each customer, finance income recognition may be suspended for the net investment in lease and financed sale receivable balances for customers in the Pre-Approved Transactions Only category. See below for a discussion of the Company’s net investment in leases and financed sale receivables. • All Transactions Suspended — The theater operator is severely delinquent, non-responsive or not negotiating in good faith with the Company. Once a theater operator is classified within the All Transactions Suspended category, the theater is placed on nonaccrual status and all revenue recognitions related to the theater are stopped.
Financing Receivable, Allowance for Credit Losses	The Company considers Financing Receivables with an aging between 60-89 days as indications of theaters with potential collection concerns. At this point, the Company will begin to focus its review on these Financing Receivables and increase its discussions internally and with the theater regarding payment status. Once a theater’s aging exceeds 90 days, the Company’s policy is to perform an enhanced review to assess collectibility of the theater’s past due accounts. The over 90 days past due category may be an indicator of potential impairment as up to 90 days outstanding is considered to be a reasonable time to resolve any issues. Given the potential impacts of the COVID-19 global pandemic on the Company’s customers, management has enhanced its monitoring procedures with respect to overdue receivables.
Lessee Leases	IMAX Corporation as a Lessee The Company’s operating lease arrangements principally involve office and warehouse space. Office equipment is generally purchased outright. Leases with an initial term of less than 12 months are not recorded on the Condensed Consolidated Balance Sheets and the related lease expense is recognized on a straight-line basis over the lease term. Most of the Company’s leases include one or more options to renew, with renewal terms that can extend the lease term from one to five years or more. The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs and its level of investment in leasehold improvements, among other factors. The incremental borrowing rate used in the calculation of the Company’s lease liability is based on the location of each leased property. None of the Company’s leases include options to purchase the leased property. The depreciable lives of right-of-use assets and related leasehold improvements are limited by the expected lease term. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed.
Lessor Leases	(b) IMAX Corporation as a Lessor The Company provides IMAX Theater Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX Theater System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system. The customer’s rights under the Company’s sales-type lease arrangements are described in Note 3(n) in the Company’s 2020 Form 10-K. Under the Company’s sales-type lease arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s lease portfolio terms are typically non-cancellable for 10 to 20 years with renewal provisions from inception. The Company’s sales-type lease arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty generally after the first year of the lease until the end of the lease term. The customer is responsible for obtaining insurance coverage for the IMAX Theater System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX Theater System is returned to the Company. The Company also provides IMAX Theater Systems to customers through joint revenue sharing arrangements. Under the traditional form of these arrangements, in exchange for providing the IMAX Theater System under a long-term lease, the Company earns rent based on a percentage of contingent box office receipts and, in some cases, concession revenues, rather than requiring the customer to pay a fixed upfront fee or annual minimum payments. Under certain other joint revenue sharing arrangements, known as hybrid arrangements, the customer is responsible for making fixed upfront payments prior to the delivery and installation of the IMAX Theater System. Under joint revenue sharing arrangements, the customer has the ability and the right to operate the hardware components or direct others to operate them in a manner determined by the customer. The Company’s joint revenue sharing arrangements are typically non-cancellable for 10 years or longer with renewal provisions. Title to the IMAX Theater System under a joint revenue sharing arrangement generally does not transfer to the customer. The Company’s joint revenue sharing arrangements do not contain a guarantee of residual value at the end of the lease term. The customer is required to pay for executory costs such as insurance and taxes and is required to pay the Company for maintenance and an extended warranty throughout the term. The customer is responsible for obtaining insurance coverage for the IMAX Theater System commencing on the date specified in the arrangement’s shipping terms and ending on the date the IMAX Theater System is returned to the Company. (See Note 4 for information related to the net investment in leases related to the Company’s sales-type lease arrangements.)
Commitments and Contingencies	The Company is involved in lawsuits, claims, and proceedings, including those identified below, which arise in the ordinary course of business. Management is required to assess the likelihood of any adverse judgments or outcomes related to these legal contingencies, as well as potential ranges of probable or reasonably possible losses. The Company records a provision for a liability when it is probable that a loss has been incurred and the amount of the loss can be reasonably estimated. The determination of the amount of any liability recorded or disclosed is reviewed at least quarterly based on a careful analysis of each individual exposure with, in some cases, the assistance of outside legal counsel, taking into account the impact of negotiations, settlements, rulings, and other pertinent information related to the case. The amount of liabilities recorded or disclosed for these contingencies may change in the future due to changes in management’s judgments resulting from new developments or changes in settlement strategy. Any resulting adjustment to the liabilities recorded by the Company could have a material adverse effect on its results of operations, cash flows, and financial position in the period or periods in which such changes in judgment occur. The Company believes it has adequate provisions for any such matters. The Company expenses legal costs relating to its lawsuits, claims and proceedings as incurred.
Segment Reporting	The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements; (iii) IMAX Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) New Business Initiatives; (vii) Film Distribution; and (viii) Film Post-Production. The Company organizes its reportable segments into the following four categories, identified by the nature of the product sold or service provided: (i) IMAX Technology Network, which earns revenue based on contingent box office receipts and includes the IMAX DMR segment and contingent rent from the Joint Revenue Sharing Arrangement (“JRSA”) segment; (ii) IMAX Technology Sales and Maintenance, which includes results from the IMAX Systems, IMAX Maintenance and Other Theater Business segments, as well as fixed revenues from the JRSA segment; (iii) New Business Initiatives, which is a segment that includes activities related to the exploration of new lines of business and new initiatives outside of the Company’s core business; and (iv) Film Distribution and Post-Production, which includes activities related to the licensing of film content, and the distribution of films primarily for the Company’s institutional theater partners (through the Film Distribution segment) and the provision of film post-production and quality control services (through the Film Post-Production segment).
Fair Value of Financial Instruments	The carrying values of the Company’s Cash and Cash Equivalents, Accounts Receivable, Accounts Payable and Accrued Liabilities due within one year approximate their fair values due to the short-term maturity of these instruments. Including these instruments, the Company’s financial instruments consist of the following: As of September 30, 2021 As of December 31, 2020 (In thousands of U.S. Dollars) Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Level 1 Cash and cash equivalents (1) $ 193,008 $ 193,008 $ 317,379 $ 317,379 Equity securities (2) 1,089 1,089 13,633 13,633 Level 2 Net financed sales receivables (3) $ 113,200 $ 113,210 $ 112,396 $ 112,603 Net investment in sales-type leases (3) 22,002 21,850 19,414 19,373 Equity securities (1) 1,000 1,000 1,000 1,000 COLI (4) 3,244 3,244 3,155 3,155 Foreign exchange contracts — (3) (209 ) (209 ) 1,635 1,635 Foreign exchange contracts — (3) (61 ) (61 ) 344 344 Working Capital Facility borrowings (1) (10,974 ) (10,974 ) (7,643 ) (7,643 ) Credit Facility borrowings (1) — — (300,000 ) (300,000 ) Convertible Notes (5) (230,000 ) (224,574 ) — — (1) Recorded at cost, which approximates fair value. (2) Fair value is determined using quoted prices in active markets. ( 3 ) Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms. (4) Measured at cash surrender value, which approximates fair value. (5) Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data. The Company did not have any material amounts of Level 3 assets or liabilities as of September 30, 2021 and December 31, 2020.

Basis of Presentation (Tables)

Basis of Presentation (Tables)	9 Months Ended
	Sep. 30, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]
VIEs Total Assets and Liabilities	Total assets and liabilities of the Company’s consolidated VIEs are as follows: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Total assets $ 1,575 $ 1,543 Total liabilities $ 259 $ 230

Current Expected Credit Losses

Current Expected Credit Losses (Tables)	9 Months Ended
	Sep. 30, 2021
Credit Loss [Abstract]
Summary of Allowance For Credit Losses Related to Accounts Receivable	The following tables summarize the activity in the Allowance for Credit Losses related to Accounts Receivable for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 (In thousands of U.S. Dollars) Theater Operators Studios Other Total Theater Operators Studios Other Total Beginning balance $ 8,597 $ 2,517 $ 1,192 $ 12,306 $ 8,368 $ 4,481 $ 1,446 $ 14,295 Current period reversal, net (489 ) (251 ) (24 ) (764 ) (111 ) (1,928 ) (269 ) (2,308 ) Write-offs (43 ) (270 ) — (313 ) (278 ) (522 ) — (800 ) Foreign exchange (89 ) 2 — (87 ) (3 ) (33 ) (9 ) (45 ) Ending balance $ 7,976 $ 1,998 $ 1,168 $ 11,142 $ 7,976 $ 1,998 $ 1,168 $ 11,142 Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 (In thousands of U.S. Dollars) Theater Operators Studios Other Total Theater Operators Studios Other Total Beginning balance $ 6,317 $ 5,455 $ 838 $ 12,610 $ 3,302 $ 893 $ 942 $ 5,137 Current period provision (reversal), net 1,623 (262 ) 468 1,829 4,718 4,424 364 9,506 Write-offs (614 ) — — (614 ) (614 ) — — (614 ) Foreign exchange 133 184 (9 ) 308 53 60 (9 ) 104 Ending balance $ 7,459 $ 5,377 $ 1,297 $ 14,133 $ 7,459 $ 5,377 $ 1,297 $ 14,133
Schedule of Financing Receivables	As of September 30, 2021 and December 31, 2020, financing receivables consist of the following: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Net investment in leases Gross minimum payments due under sales-type leases $ 23,284 $ 20,830 Unearned finance income (788 ) (859 ) Present value of minimum payments due under sales-type leases 22,496 19,971 Allowance for credit losses (494 ) (557 ) Net investment in leases 22,002 19,414 Financed sales receivables Gross minimum payments due under financed sales 150,964 150,917 Unearned finance income (32,199 ) (31,247 ) Present value of minimum payments due under financed sales 118,765 119,670 Allowance for credit losses (5,565 ) (7,274 ) Net financed sales receivables 113,200 112,396 Total financing receivables $ 135,202 $ 131,810 Net financed sales receivables due within one year $ 32,154 $ 34,937 Net financed sales receivables due after one year 81,046 77,459 Total financed sales receivables $ 113,200 $ 112,396
Schedule of Weighted-average Remaining Lease Term and Weighted-average Interest Rate	As of September 30, 2021 and December 31, 2020, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s sales-type lease arrangements and financed sale receivables, as applicable, are as follows: September 30, December 31, 2021 2020 Weighted-average remaining lease term (in years) Sales-type lease arrangements 9.0 8.3 Weighted-average interest rate Sales-type lease arrangements 6.55 % 6.56 % Financed sales receivables 8.75 % 8.92 %
Schedule of Net Investment In Leases by Credit Quality Indicator	The tables below provide information on the Company’s net investment in leases by credit quality indicator as of September 30, 2021 and December 31, 2020. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of September 30, 2021 2021 2020 2019 2018 2017 Prior Total Net investment in leases: Credit quality classification: In good standing $ 959 $ 2,747 $ 2,245 $ — $ — $ 1,150 $ 7,101 Credit Watch 3,374 1,251 5,650 2,533 881 863 14,552 Pre-approved transactions — — — — — — — Transactions suspended — — — — — 843 843 Total net investment in leases $ 4,333 $ 3,998 $ 7,895 $ 2,533 $ 881 $ 2,856 $ 22,496 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2020 2020 2019 2018 2017 2016 Prior Total Net investment in leases: Credit quality classification: In good standing $ 2,143 $ 1,190 $ 2,730 $ — $ — $ 1,826 $ 7,889 Credit Watch 2,005 7,278 — 988 — 1,047 11,318 Pre-approved transactions — — — — — — — Transactions suspended — — — — — 764 764 Total net investment in leases $ 4,148 $ 8,468 $ 2,730 $ 988 $ — $ 3,637 $ 19,971
Schedule of Financed Sale Receivables by Credit Quality Indicator	The tables below provide information on the Company’s financed sale receivables by credit quality indicator as of September 30, 2021 and December 31, 2020. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. (In thousands of U.S. Dollars) By Origination Year As of September 30, 2021 2021 2020 2019 2018 2017 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 6,311 $ 4,414 $ 5,733 $ 3,831 $ 5,890 $ 17,830 $ 44,009 Credit Watch 1,911 4,108 6,046 9,847 7,733 35,739 65,384 Pre-approved transactions — — — 309 1,420 2,285 4,014 Transactions suspended — — — — 1,315 4,043 5,358 Total financed sales receivables $ 8,222 $ 8,522 $ 11,779 $ 13,987 $ 16,358 $ 59,897 $ 118,765 (In thousands of U.S. Dollars) By Origination Year As of December 31, 2020 2020 2019 2018 2017 2016 Prior Total Financed sales receivables: Credit quality classification: In good standing $ 6,830 $ 5,480 $ 3,547 $ 3,740 $ 5,072 $ 12,660 $ 37,329 Credit Watch 1,986 6,501 11,356 12,520 11,446 34,351 78,160 Pre-approved transactions — — — — 613 755 1,368 Transactions suspended — — — 987 728 1,098 2,813 Total financed sales receivables $ 8,816 $ 11,981 $ 14,903 $ 17,247 $ 17,859 $ 48,864 $ 119,670
Schedule of Aging Analysis for Net Investment in Leases and Financed Sale Receivables	The following tables provide an aging analysis for the Company’s net investment in leases and financed sale receivables as of September 30, 2021 and December 31, 2020: As of September 30, 2021 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 221 $ 149 $ 876 $ 1,246 $ 21,250 $ 22,496 $ (494 ) $ 22,002 Financed sales receivables 1,989 1,748 10,207 13,944 104,821 118,765 (5,565 ) 113,200 Total $ 2,210 $ 1,897 $ 11,083 $ 15,190 $ 126,071 $ 141,261 $ (6,059 ) $ 135,202 As of December 31, 2020 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 298 $ 180 $ 689 $ 1,167 $ 18,804 $ 19,971 $ (557 ) $ 19,414 Financed sales receivables 3,307 1,943 10,699 15,949 103,721 119,670 (7,274 ) 112,396 Total $ 3,605 $ 2,123 $ 11,388 $ 17,116 $ 122,525 $ 139,641 $ (7,831 ) $ 131,810
Schedule of Net Investment in Leases and Financed Sale Receivables with Billed Amounts Past Due Continues to Accrue Finance Income	The following table provides information about the Company’s net investment in leases and financed sale receivables with billed amounts past due for which it continues to accrue finance income as of September 30, 2021 and December 31, 2020. The amounts disclosed for each credit quality classification are determined on a customer-by-customer basis and include both billed and unbilled amounts. As of September 30, 2021 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Allowance for Credit Losses Net Net investment in leases $ 180 $ 144 $ 458 $ 782 $ 13,770 $ (248 ) $ 14,304 Financed sales receivables 1,152 1,083 8,286 10,521 51,756 (2,870 ) 59,407 Total $ 1,332 $ 1,227 $ 8,744 $ 11,303 $ 65,526 $ (3,118 ) $ 73,711 As of December 31, 2020 (In thousands of U.S. Dollars) Accrued and Current 30-89 Days 90+ Days Billed Unbilled Allowance for Credit Losses Net Net investment in leases $ 231 $ 162 $ 359 $ 752 $ 13,912 $ (310 ) $ 14,354 Financed sales receivables 2,026 1,551 10,249 13,826 62,602 (4,434 ) 71,994 Total $ 2,257 $ 1,713 $ 10,608 $ 14,578 $ 76,514 $ (4,744 ) $ 86,348
Schedule of Net Investment in Leases and Financed Sale Receivables on Nonaccrual Status	The following table provides information about the Company’s net investment in leases and financed sale receivables that are on nonaccrual status as of September 30, 2021 and December 31, 2020: As of September 30, 2021 As of December 31, 2020 (In thousands of U.S. Dollars) Recorded Receivable Allowance for Credit Losses Net Recorded Receivable Allowance for Credit Losses Net Net investment in leases $ 843 $ (16 ) $ 827 $ 764 $ (18 ) $ 746 Net financed sales receivables 6,158 (1,276 ) 4,882 2,813 (1,482 ) 1,331 Total $ 7,001 $ (1,292 ) $ 5,709 $ 3,577 $ (1,500 ) $ 2,077
Summary of Allowance for Credit Losses Related to Net Investment in Leases and Financed Sale Receivables	The following tables summarize the activity in the allowance for credit losses related to the Company’s net investment in leases and financed sale receivables for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, 2021 Nine Months Ended September 30, 2021 Net Investment Financed Net Investment Financed (In thousands of U.S. Dollars) in Leases Sales Receivables in Leases Sales Receivables Beginning balance $ 579 $ 7,113 $ 557 $ 7,274 Current period reversal, net (84 ) (1,536 ) (64 ) (1,741 ) Foreign exchange (1 ) (12 ) 1 32 Ending balance $ 494 $ 5,565 $ 494 $ 5,565 Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Net Investment Net Financed Net Investment Net Financed (In thousands of U.S. Dollars) in Leases Sales Receivables in Leases Sales Receivables Beginning balance $ 459 $ 3,709 $ 155 $ 915 Current period provision 105 1,201 409 4,014 Write-offs (69 ) (330 ) (69 ) (330 ) Foreign exchange 9 63 9 44 Ending balance $ 504 $ 4,643 $ 504 $ 4,643
Summary of Allowance For Credit Losses Related to Variable Consideration Receivables	The following table summarizes the activity in the Allowance for Credit Losses related to Variable Consideration Receivables for the three and nine months ended September 30, 2021 and 2020: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 (In thousands of U.S. Dollars) Theater Operators Theater Operators Theater Operators Theater Operators Beginning balance $ 2,028 $ 863 $ 1,887 $ — Current period (reversal) provision, net (933 ) 790 (771 ) 1,653 Foreign Exchange (1 ) 6 (22 ) 6 Ending balance $ 1,094 $ 1,659 $ 1,094 $ 1,659

Lease Arrangements (Tables)

Lease Arrangements (Tables)	9 Months Ended
	Sep. 30, 2021
Leases [Abstract]
Components of Lease Expense	For the three and nine months ended September 30, 2021 and 2020, the components of lease expense recorded within Selling, General and Administrative expenses are as follows: Three Months Ended September 30, Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 2021 2020 Operating lease cost (1) $ 163 $ 133 $ 546 $ 392 Amortization of lease assets 684 706 2,098 2,155 Interest on lease liabilities 242 258 715 765 Total lease cost $ 1,089 $ 1,097 $ 3,359 $ 3,312 (1) Includes short-term leases and variable lease costs, which are not significant for the three and nine months ended September 30, 2021 and 2020.
Supplemental Cash and Non-Cash Flow Information Related to Leases	For the nine months ended September 30, 2021 and 2020, supplemental cash and non-cash information related to leases is as follows: Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 Cash paid for amounts included in the measurement of lease liabilities $ 2,907 $ 2,721 Right-of-use assets obtained in exchange for lease obligations $ 1,047 $ 297
Lessee Operating Lease Balance Sheet Amounts and Lines	As of September 30, 2021 and December 31, 2020, supplemental balance sheet information related to leases is as follows: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Assets Balance Sheet Classification Right-of-Use Assets Property, plant and equipment $ 12,833 $ 13,911 Liabilities Balance Sheet Classification Operating Leases Accrued and other liabilities $ 15,388 $ 16,634
Lessee Operating Leases Weighted Average Remaining Lease Term and Weighted Average Interest Rate	As of September 30, 2021 and December 31, 2020, the weighted-average remaining lease term and weighted-average interest rate associated with the Company’s operating leases are as follows: September 30, December 31, 2021 2020 Weighted-average remaining lease term (years) 7.0 7.6 Weighted-average discount rate 5.96 % 5.91 %
Lessee Operating Lease, Maturity	As of September 30, 2021, the maturities of the Company’s operating lease liabilities are as follows: (In thousands of U.S. Dollars) 2021 (three months remaining) $ 924 2022 3,360 2023 2,454 2024 2,230 2025 2,078 Thereafter 8,026 Total lease payments $ 19,072 Less: interest expense (3,684 ) Present value of operating lease liabilities $ 15,388

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Inventories	As of September 30, 2021 and December 31, 2020, Inventories consist of the following: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Raw materials $ 27,172 $ 30,096 Work-in-process 1,964 3,014 Finished goods 9,109 6,470 $ 38,245 $ 39,580

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Revolving Credit Facility Borrowings	As of September 30, 2021 and December 31, 2020, Revolving Credit Facility Borrowings consist of the following: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Credit Facility borrowings $ — $ 300,000 Working Capital Facility borrowings 10,974 7,643 Unamortized debt issuance costs (1,488 ) (1,967 ) Revolving Credit Facility Borrowings, net $ 9,486 $ 305,676
Summary of Convertible Notes	As of September 30, 2021 and December 31, 2020, Convertible Notes (as defined below) consist of the following: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Convertible Notes $ 230,000 $ — Unamortized discounts and debt issuance costs (6,735 ) — $ 223,265 $ —

Condensed Consolidated Statem_7

Condensed Consolidated Statements of Cash Flows Supplemental Information (Tables)	9 Months Ended
	Sep. 30, 2021
Supplemental Cash Flow Elements [Abstract]
Summary of Changes in Other Operating Assets and Liabilities	Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 (Increase) decrease in: Financing receivables $ (1,693 ) $ (3,212 ) Prepaid expenses (2,767 ) (1,332 ) Variable consideration receivables (1,243 ) (1,007 ) Other assets 664 (3,712 ) Decrease in: Accounts payable (5,135 ) (8,320 ) Accrued and other liabilities (1) (1,728 ) (6,526 ) $ (11,902 ) $ (24,109 ) (1) Includes a $9.5 million payment made in the second quarter of 2021 in connection with the settlement of the Giencourt matter, as discussed in Note 8(b)(ii).
Summary of Depreciation and Amortization	Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 Film assets $ 10,661 $ 6,159 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements 16,784 19,247 Other property, plant and equipment 7,176 8,478 Other intangible assets (1) 4,509 4,882 Other assets (2) 1,440 1,933 $ 40,570 $ 40,699 (1) Includes the amortization of licenses and intellectual property recorded in Research and Development on the Condensed Consolidated Statement of Operations of $1.0 million in the nine months ended September 30, 2021 ( 2020 $1.0 million). (2) Includes the amortization of lessee incentives provided by the Company to its customers under joint revenue sharing arrangements.
Write-downs	Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 Inventories (1) $ 468 $ 729 Property, plant and equipment: Equipment supporting joint revenue sharing arrangements (2) 328 1,050 Other property, plant and equipment — 66 Other intangible assets 63 132 Film assets (3) 19 10,211 Other assets (4) — 1,151 $ 878 $ 13,339 (1) In the nine months ended September 30, 2021, the Company recorded write-downs of $0.5 million (2020 — $0.7 million) in Costs and Expenses Applicable to Technology Sales related to excess and damaged inventory. (2) In the nine months ended September 30, 2021, the Company recorded charges of $0.3 million (2020 — $1.1 million) in Costs and Expenses Applicable to Technology Rentals mostly related to the write-down of leased xenon-based digital systems which were taken out of service in connection with customer upgrades to laser-based digital systems. (3) In the nine months ended September 30, 2020, the Company recorded impairment losses of $10.2 million in Costs and Expenses Applicable to Image Enhancement and Maintenance Services principally to write-down the carrying value of certain documentary and alternative film content due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments. To a much lesser extent, the impairment losses also relate to the write-down of DMR related film assets. ( 4 ) In the nine months ended September 30, 2020, the Company recorded a write-down of $1.2 million in Asset Impairments related to content-related assets which became impaired in the period.
Significant Non-cash Investing Activities	Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 Net (decrease) increase in accruals related to: Investment in equipment supporting joint revenue sharing arrangements $ 217 $ (1,897 ) Acquisition of other intangible assets (863 ) 69 Purchases of property, plant and equipment (8 ) 158 $ (654 ) $ (1,670 )

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Schedule of Effective Tax Rates	For the three months ended September 30, 2021, the Company recorded income tax expense of $4.4 million (2020 — income tax expense of $19.3 million). For the , t Three Months Ended Three Months Ended September 30, 2021 September 30, 2020 (In thousands of U.S. Dollars, except rates) Amount Rate Amount Rate Income tax benefit at combined statutory rates $ 509 26.2% $ 7,279 26.2% Adjustments resulting from: Unrealized investment gains not taxable — — 420 1.5% Increase of valuation allowance (4,270 ) (219.8%) (23,707 ) (85.3%) Changes to tax reserves (215 ) (11.1%) (181 ) (0.7%) Withholding taxes resulting from management's decision to no longer indefinitely reinvest the historical earnings of certain foreign subsidiaries — — (186 ) (0.7%) Reduction in tax benefits resulting from the vesting of share-based compensation (4 ) (0.2%) (38 ) (0.1%) Other non-deductible/non-taxable items (422 ) (21.7%) (2,936 ) (10.5%) Income tax expense $ (4,402 ) (226.6%) $ (19,349 ) (69.6%) For the nine months ended September 30, 2021, the Company recorded income tax expense of $9.4 million (2020 — $24.6 million). For the nine months ended September 30, 2021, the Company’s effective tax rate of (69.5)% varies from the Canadian statutory tax rate of 26.2% that was in effect during the period as follows: Nine Months Ended Nine Months Ended September 30, 2021 September 30, 2020 (In thousands of U.S. Dollars, except rates) Amount Rate Amount Rate Income tax benefit at combined statutory rates $ 3,548 26.2% $ 29,201 26.2% Adjustments resulting from: Realized and unrealized investment gains (losses) not taxable 1,367 10.1% (239 ) (0.2%) Increase of valuation allowance (14,248 ) (105.2%) (23,706 ) (21.3%) Changes to tax reserves 1,234 9.1% (4,978 ) (4.5%) Withholding taxes resulting from management's decision to no longer indefinitely reinvest the historical earnings of certain foreign subsidiaries (547 ) (4.0%) (18,661 ) (16.7%) Increase in tax benefits resulting from the vesting of share-based compensation 709 5.2% 33 — Other non-deductible/non-taxable items (1,479 ) (10.9%) (6,256 ) (5.6%) Income tax expense $ (9,416 ) (69.5%) $ (24,606 ) (22.1%)
Income Tax Expense in Other Comprehensive (Loss) Income	For the three and nine months ended September 30, 2021 and 2020, the income tax expense related to the following items in Other Comprehensive (Loss) Income are: Three Months Ended Nine Months Ended September 30, September 30, (In thousands of U.S. Dollars) 2021 2020 2021 2020 Unrealized change in cash flow hedging instruments $ 199 $ (160 ) $ 42 $ 235 Realized change in cash flow hedging instruments 82 (29 ) 358 (211 ) Reclassification of unrealized change in ineffective cash flow hedging instruments 7 — 83 — Defined benefit and postretirement benefit plans (12 ) — (37 ) 40 $ 276 $ (189 ) $ 446 $ 64

Capital Stock and Reserves (Tab

Capital Stock and Reserves (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stock Compensation	Three Months Ended Nine Months Ended September 30, September 30, (In Thousands of U.S. Dollars) 2021 2020 2021 2020 Cost and expenses applicable to revenues $ 314 $ 130 $ 920 $ 530 Selling, general and administrative expenses 5,706 5,151 17,046 15,325 Research and development 89 29 245 114 $ 6,109 $ 5,310 $ 18,211 $ 15,969
Stock-based Compensation by Plan Type	The following table summarizes the Company’s share-based compensation expense by each award type: Three Months Ended Nine Months Ended September 30, September 30, (In Thousands of U.S. Dollars) 2021 2020 2021 2020 Stock Options $ 253 $ 433 $ 808 $ 1,449 Restricted Share Units 3,900 3,430 11,524 10,866 Performance Stock Units 1,183 483 3,169 1,229 IMAX China Stock Options 41 600 143 701 IMAX China Long Term Incentive Plan Restricted Share Units 600 332 2,217 1,645 IMAX China Long Term Incentive Plan Performance Stock Units 132 32 350 79 $ 6,109 $ 5,310 $ 18,211 $ 15,969
Schedule of Share-based Compensation, Stock Options, Activity	The following table summarizes the activity under the Company’s Stock Option Plan (“SOP”) and the IMAX Corporation Second Amended and Restated Long-Term Incentive Plan (as may be amended, “IMAX LTIP”) for the nine months ended September 30, 2021 and 2020: Number of Shares Weighted Average Exercise Price Per Share 2021 2020 2021 2020 Stock options outstanding, beginning of period 4,892,962 5,732,209 $ 26.81 $ 26.82 Granted — — — — Exercised (41,613 ) — 21.23 — Forfeited (86,587 ) (23,633 ) 22.51 22.35 Expired (903,038 ) (772,665 ) 28.31 27.03 Cancelled (123,220 ) (18,483 ) 26.68 27.97 Stock options outstanding, end of period 3,738,504 4,917,428 26.61 26.80 Stock options exercisable, end of period 3,487,857 4,315,484 26.93 27.32
Restricted Stock Units Activity under the IMAX LTIP	The following table summarizes the activity in respect of RSUs issued under the IMAX LTIP for the nine months ended September 30, 2021 and 2020: Number of Awards Weighted Average Grant Date Fair Value Per Share 2021 2020 2021 2020 RSUs outstanding, beginning of period 1,564,838 1,065,347 $ 18.33 $ 23.17 Granted 831,123 1,050,385 21.03 15.35 Vested and settled (571,616 ) (386,451 ) 19.11 21.59 Forfeited (231,380 ) (54,933 ) 19.50 19.70 RSUs outstanding, end of period 1,592,965 1,674,348 19.29 18.75
Performance Stock Units Activity under the IMAX LTIP	The following table summarizes the activity in respect of PSUs issued under the IMAX LTIP for the nine months ended September 30, 2021 and 2020: Number of Awards Weighted Average Grant Date Fair Value Per Share 2021 2020 2021 2020 PSUs outstanding, beginning of period 361,844 — $ 15.68 $ — Granted 309,574 370,265 20.77 15.66 Forfeited (54,634 ) (2,526 ) 16.08 14.84 PSUs outstanding, end of period 616,784 367,739 18.20 15.67 As of September 30, 2021, the maximum number of shares of common stock that may be issued with respect to PSUs outstanding is 1,079,372, assuming full achievement of the EBITDA and TSR targets.
Basic and Diluted Per-share Computations	The following table reconciles the denominator of the basic and diluted weighted average share computations: Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (In thousands) Issued and outstanding, beginning of period 59,396 58,857 58,921 61,176 Weighted average number of shares (repurchased) issued, net (152 ) 2 286 (1,816 ) Weighted average number of shares outstanding - basic 59,244 58,859 59,207 59,360 Weighted average effect of potential common shares, if dilutive — — — — Weighted average number of shares outstanding - diluted 59,244 58,859 59,207 59,360

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue From Contract With Customer [Abstract]
Disaggregation of Revenue by Segment	The following tables summarize the Company’s revenues by type and reportable segment for the three and nine months ended September 30, 2021: Three Months Ended September 30, 2021 Revenue from Contracts with Customers Revenue from (In thousands of U.S. Dollars) Fixed Consideration Variable Consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems (1) $ 9,701 $ 802 $ 98 $ — $ 10,601 Joint Revenue Sharing Arrangements, fixed fees — — 1,036 — 1,036 Other Theater Business 363 — — — 363 Other sales (2) 1,154 6 — — 1,160 Sub-total 11,218 808 1,134 — 13,160 Image enhancement and maintenance services IMAX DMR — 15,701 — — 15,701 IMAX Maintenance 13,055 — — — 13,055 Film Post-Production 899 — — — 899 Film Distribution 203 496 — — 699 Other — 234 — — 234 Sub-total 14,157 16,431 — — 30,588 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 9,887 — 9,887 Other — — 332 — 332 Sub-total — — 10,219 — 10,219 Finance income IMAX Systems — — — 2,635 2,635 Total $ 25,375 $ 17,239 $ 11,353 $ 2,635 $ 56,602 Nine Months Ended September 30, 2021 Revenue from Contracts with Customers Revenue from (In thousands of U.S. Dollars) Fixed consideration Variable consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems (1) $ 20,143 $ 2,573 $ 4,220 $ — $ 26,936 Joint Revenue Sharing Arrangements, fixed fees — — 3,776 — 3,776 Other Theater Business 1,275 — — — 1,275 Other sales (2) 2,474 47 — — 2,521 Sub-total 23,892 2,620 7,996 — 34,508 Image enhancement and maintenance services IMAX DMR — 39,438 — — 39,438 IMAX Maintenance 33,196 — — — 33,196 Film Post-Production 2,886 — — — 2,886 Film Distribution 204 911 — — 1,115 Other — 279 — — 279 Sub-total 36,286 40,628 — — 76,914 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 26,108 — 26,108 Other — — 600 — 600 Sub-total — — 26,708 — 26,708 Finance income IMAX Systems — — — 8,181 8,181 Total $ 60,178 $ 43,248 $ 34,704 $ 8,181 $ 146,311 (1) Includes r evenues earned from sales or sales-type lease arrangements involving new and upgraded IMAX Theater Systems, as well as the impact on revenue of renewals and amendments to existing theater system arrangements. (2) Other sales include revenues associated with New Business Initiatives. The following tables summarize the Company’s revenues by type and reportable segment for the three and nine months ended September 30, 2020: Three Months Ended September 30, 2020 Revenue from Contracts with Customers Revenue from (In thousands of U.S. Dollars) Fixed Consideration Variable Consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems (1)(2) $ 12,356 $ 1,481 $ 1,159 $ — $ 14,996 Joint Revenue Sharing Arrangements, fixed fees — — 57 — 57 Other Theater Business 307 — — — 307 Other sales (3) 378 15 — — 393 Sub-total 13,041 1,496 1,216 — 15,753 Image enhancement and maintenance services IMAX DMR — 6,886 — — 6,886 IMAX Maintenance 5,855 — — — 5,855 Film Post-Production 739 — — — 739 Film Distribution 750 376 — — 1,126 Other — (17 ) — — (17 ) Sub-total 7,344 7,245 — — 14,589 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 4,473 — 4,473 Sub-total — — 4,473 — 4,473 Finance income IMAX Systems — — — 2,441 2,441 Total $ 20,385 $ 8,741 $ 5,689 $ 2,441 $ 37,256 Nine Months Ended September 30, 2020 Revenue from Contracts with Customers Revenue from (In thousands of U.S. Dollars) Fixed consideration Variable consideration Lease Arrangements Finance Income Total Technology sales IMAX Systems (1)(2) $ 14,711 $ 3,143 $ 2,325 $ — $ 20,179 Joint Revenue Sharing Arrangements, fixed fees — — 1,196 — 1,196 Other Theater Business 1,261 — — — 1,261 Other sales (3) 1,361 105 — — 1,466 Sub-total 17,333 3,248 3,521 — 24,102 Image enhancement and maintenance services IMAX DMR — 18,061 — — 18,061 IMAX Maintenance 13,225 — — — 13,225 Film Post-production 3,088 — — — 3,088 Film Distribution 3,000 1,453 — — 4,453 Other 282 — — 282 Sub-total 19,313 19,796 — — 39,109 Technology rentals Joint Revenue Sharing Arrangements, contingent rent — — 10,307 — 10,307 Sub-total — — 10,307 — 10,307 Finance income IMAX Systems — — — 7,495 7,495 Total $ 36,646 $ 23,044 $ 13,828 $ 7,495 $ 81,013 (1) Includes r evenues earned from sales or sales-type lease arrangements involving new and upgraded IMAX Theater Systems, as well as the impact on revenue of renewals and amendments to existing theater system arrangements. (2) Prior period comparatives have been revised to appropriately classify $1.1 million and $2.3 million, respectively, of fixed consideration under revenue from contracts with customers to revenue from lease arrangements for the three and nine months ended September 30, 2020. (3) Other sales include revenues associated with New Business Initiatives.

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Segment Reporting Information by Category and Reportable Segment	The following table presents the Company’s revenue and gross margin (margin loss) by category and reportable segment for the three months ended September 30, 2021 and 2020: Revenue (1) Gross Margin (Margin Loss) (4) (In thousands of U.S. Dollars) 2021 2020 2021 2020 IMAX Technology Network IMAX DMR $ 15,701 $ 6,886 $ 7,293 $ 3,079 Joint Revenue Sharing Arrangements, contingent rent 9,887 4,473 3,626 (2,491 ) 25,588 11,359 10,919 588 IMAX Technology Sales and Maintenance IMAX Systems (2) 13,236 17,437 8,086 8,671 Joint Revenue Sharing Arrangements, fixed fees 1,036 57 280 (117 ) IMAX Maintenance 13,055 5,855 6,462 794 Other Theater Business (3) 363 307 64 31 27,690 23,656 14,892 9,379 New Business Initiatives 1,238 378 1,189 372 Film Distribution and Post-Production Film Distribution (5) 699 1,126 (4 ) (5,597 ) Post-Production 899 739 420 (464 ) 1,598 1,865 416 (6,061 ) Sub-total 56,114 37,258 27,416 4,278 Other 488 (2 ) 71 (449 ) Total $ 56,602 $ 37,256 $ 27,487 $ 3,829 The following table presents the Company’s revenue and gross margin (margin loss) by category and reportable segment for the nine months ended September 30, 2021 and 2020: Revenue (1) Gross Margin (Margin Loss) (4) (In thousands of U.S. Dollars) 2021 2020 2021 2020 IMAX Technology Network IMAX DMR $ 39,438 $ 18,061 $ 22,405 $ 7,492 Joint Revenue Sharing Arrangements, contingent rent 26,108 10,307 7,299 (10,610 ) 65,546 28,368 29,704 (3,118 ) IMAX Technology Sales and Maintenance IMAX Systems (2) 35,117 27,674 21,646 14,497 Joint Revenue Sharing Arrangements, fixed fees 3,776 1,196 783 110 IMAX Maintenance 33,196 13,225 15,360 (355 ) Other Theater Business (3) 1,283 1,261 269 77 73,372 43,356 38,058 14,329 New Business Initiatives 2,554 1,488 2,281 1,245 Film Distribution and Post-Production Film Distribution (5) 1,115 4,453 (319 ) (9,296 ) Post-Production 2,886 3,088 1,316 (96 ) 4,001 7,541 997 (9,392 ) Sub-total 145,473 80,753 71,040 3,064 Other 838 260 (669 ) (1,837 ) Total $ 146,311 $ 81,013 $ 70,371 $ 1,227 (1) The Company’s largest customer represents 18.2% and 22.2%, respectively, of total Revenues for the three and nine months ended September 30, 2021 (2020 — 11.0% and 11.3%, respectively). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of September 30, 2021 and December 31, 2020. ( 2 ) The revenue from this segment includes the initial upfront payments and the present value of fixed minimum payments from sales and sales-type lease arrangements of IMAX Theater Systems, as well as the present value of estimated variable consideration from sales of IMAX Theater Systems. To a lesser extent, the revenue from this segment also includes finance income associated with these revenue streams. ( 3 ) The revenue from this segment principally includes after-market sales of IMAX projection system parts and 3D glasses. ( 4 ) IMAX DMR gross margin includes marketing costs of $3.2 million and $5.8 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.4 million and $2.8 million, respectively). JRSA gross margin includes advertising, marketing and commission expense of $0.8 million and $1.9 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.7 million and $1.3 million, respectively). IMAX Systems gross margin includes marketing and commission costs of $0.3 million and $0.9 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.6 million and $1.0 million, respectively). Film Distribution segment gross margin includes marketing expense of $nil and less than $0.1 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.2 million and $0.4 million, respectively). ( 5 ) During the three and nine months ended September 30, 2020, Film Distribution segment results include impairment losses of $5.4 million and $9.9 million, respectively, to write-down the carrying value of certain documentary and alternative content film assets . No such charges were incurred in the .
Geographic Information	Revenue by geographic area is based on the location of the customer. Revenue related to IMAX DMR is presented based upon the geographic location of the theaters that exhibit the remastered films. IMAX DMR revenue is generated through contractual relationships with studios and other third parties and these may not be in the same geographical location as the theater. Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Revenue Greater China $ 22,203 $ 19,346 $ 75,634 $ 26,008 United States 16,469 4,335 34,275 21,112 Western Europe 7,634 5,085 11,160 10,273 Asia (excluding Greater China) 4,925 4,935 12,837 12,663 Russia & the CIS 1,353 738 4,577 2,962 Latin America 1,181 1,616 1,579 3,251 Canada 1,083 384 620 1,327 Rest of the World 1,754 817 5,629 3,417 Total $ 56,602 $ 37,256 $ 146,311 $ 81,013

Employees Pension and Postret_2

Employees Pension and Postretirement Benefits (Tables)	9 Months Ended
	Sep. 30, 2021
SERP Benefits [Member]
Defined Benefit Plan Disclosure [Line Items]
Amounts Accrued	As of September 30, 2021 and December 31, 2020, the Company’s projected benefit obligation and unfunded status related to the SERP are as follows: September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Projected benefit obligation: Obligation, beginning of period $ 20,116 $ 18,840 Interest cost 54 379 Actuarial gain — 897 Obligation, end of period and unfunded status (1) $ 20,170 $ 20,116 (1) The accumulated benefit obligation for the SERP was $20.2 million at September 30, 2021 (December 31, 2020 — $20.1 million).

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Derivative Instruments Gain Loss [Line Items]
Fair Value of Financial Instruments	The carrying values of the Company’s Cash and Cash Equivalents, Accounts Receivable, Accounts Payable and Accrued Liabilities due within one year approximate their fair values due to the short-term maturity of these instruments. Including these instruments, the Company’s financial instruments consist of the following: As of September 30, 2021 As of December 31, 2020 (In thousands of U.S. Dollars) Carrying Amount Estimated Fair Value Carrying Amount Estimated Fair Value Level 1 Cash and cash equivalents (1) $ 193,008 $ 193,008 $ 317,379 $ 317,379 Equity securities (2) 1,089 1,089 13,633 13,633 Level 2 Net financed sales receivables (3) $ 113,200 $ 113,210 $ 112,396 $ 112,603 Net investment in sales-type leases (3) 22,002 21,850 19,414 19,373 Equity securities (1) 1,000 1,000 1,000 1,000 COLI (4) 3,244 3,244 3,155 3,155 Foreign exchange contracts — (3) (209 ) (209 ) 1,635 1,635 Foreign exchange contracts — (3) (61 ) (61 ) 344 344 Working Capital Facility borrowings (1) (10,974 ) (10,974 ) (7,643 ) (7,643 ) Credit Facility borrowings (1) — — (300,000 ) (300,000 ) Convertible Notes (5) (230,000 ) (224,574 ) — — (1) Recorded at cost, which approximates fair value. (2) Fair value is determined using quoted prices in active markets. ( 3 ) Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms. (4) Measured at cash surrender value, which approximates fair value. (5) Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data.
Notional Amount of Derivative	The following tabular disclosures reflect the impact that derivative instruments and hedging activities have on the Company’s Condensed Consolidated Financial Statements: Notional value of foreign exchange contracts September 30, December 31, (In thousands of U.S. Dollars) 2021 2020 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards $ 24,642 $ 26,358 Derivatives not designated as hedging instruments: Foreign exchange contracts — Forwards 1,123 5,552 $ 25,765 $ 31,910
Fair Value of Foreign Exchange Contracts	Fair value of derivatives in foreign exchange contracts September 30, December 31, (In thousands of U.S. Dollars) Balance Sheet Location 2021 2020 Derivatives designated as hedging instruments: Foreign exchange contracts — Forwards Other assets $ 128 $ 1,635 Accrued and other liabilities (337 ) — Derivatives not designated as hedging instruments: Foreign exchange contracts — Forwards Other assets — 344 Accrued and other liabilities (61 ) — $ (270 ) $ 1,979
Derivatives in Foreign Currency Hedging Relationships	Derivatives in foreign currency hedging relationships are as follows Three Months Ended September 30, Nine Months Ended September 30, (In thousands of U.S. Dollars) 2021 2020 2021 2020 Foreign exchange contracts Derivative (Loss) Gain — Forwards Recognized in OCI (Effective Portion) $ (759 ) $ 591 $ (159 ) $ (935 ) Location of Derivative Gain (Loss) Reclassified from AOCI Three Months Ended September 30, Nine months ended September 30, (In thousands of U.S. Dollars) (Effective Portion) 2021 2020 2021 2020 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ 312 $ (110 ) $ 1,367 (779 ) Inventory — — $ — (26 ) $ 312 $ (110 ) $ 1,367 $ (805 ) Three Months Ended September 30, Nine months ended September 30, (In thousands of U.S. Dollars) 2021 2020 2021 2020 Foreign exchange contracts Derivative Loss Recognized In — Forwards and Out of OCI (Effective Portion) $ — $ — $ — $ (55 )
Not Designated as Hedging Instrument [Member]
Derivative Instruments Gain Loss [Line Items]
Derivatives in Foreign Currency Hedging Relationships	Non-designated derivatives in foreign currency relationships are as follows Three Months Ended September 30, Nine months ended September 30, (In thousands of U.S. Dollars) 2021 2020 2021 2020 Foreign exchange contracts Derivative Gain Reclassified — Forwards From AOCI (Ineffective Portion) $ (25 ) $ — $ (318 ) $ — Three Months Ended September 30, Nine months ended September 30, (In thousands of U.S. Dollars) Location of Derivative (Loss) Gain 2021 2020 2021 2020 Foreign exchange contracts Selling, general and — Forwards administrative expenses $ (122 ) $ 75 $ 269 $ 102 $ (122 ) $ 75 $ 269 $ 102

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	9 Months Ended
	Sep. 30, 2021
Other Noncontrolling Interest [Member]
Redeemable Noncontrolling Interest [Line Items]
Summary of Movement of the Non-controlling Interest in Temporary Equity Related to Original Film Fund	The following table summarizes the movement of the non-controlling interest in temporary equity related to the Original Film Fund for the nine months ended September 30, 2021: Balance as of December 31, 2020 $ 759 Net income 1 Balance as of September 30, 2021 $ 760

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Variable Interest Entity [Line Items]
Number of variable interest entities		ten
COVID 19 [Member]
Variable Interest Entity [Line Items]
Allowance for current expected credit losses	$ 3.3	$ 4.9
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Number of variable interest entities primary beneficiary		five
Variable Interest Entity, Not Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Number of variable interest entities not a primary beneficiary		five

Basis of Presentation - VIEs To

Basis of Presentation - VIEs Total Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Variable Interest Entity [Line Items]
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	$ 871,161	$ 997,750
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	450,691	532,983
Variable Interest Entity, Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	1,575	1,543
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	$ 259	$ 230

Impact of COVID-19 Pandemic - A

Impact of COVID-19 Pandemic - Additional Information (Details) - Impact of COVID-19 Pandemic [Member] $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2021USD ($)Country
IMAX [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Percentage of global theater network open	93.00%	93.00%
Number of countries in which global theater network open | Country		70
IMAX [Member] | United States and Canada [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Percentage of global theater network open	100.00%	100.00%
IMAX [Member] | Greater China [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Percentage of global theater network open	93.00%	93.00%
IMAX [Member] | Rest of the World [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Percentage of global theater network open	87.00%	87.00%
IMAX DMR Films [Member]
Impact Of Coronavirus Nineteen Pandemic [Line Items]
Revenue generated from GBO receipts	$ 141.9	$ 360.7
Increase in revenue generated from GBO receipts	$ 71.7	$ 192.6
Percentage of increase in revenue generated from GBO receipts	102.00%	115.00%

Recently Issued Accounting St_2

Recently Issued Accounting Standards - Additional Information (Details)	9 Months Ended
	Sep. 30, 2021
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Credit facility maturity date	Jun. 28, 2023
ASU 2020-04
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]
Credit facility maturity date	Jun. 28, 2023

Current Expected Credit Losse_2

Current Expected Credit Losses - Summary of Allowance For Credit Losses Related to Accounts Receivable (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	$ 12,306	$ 12,610	$ 14,295	$ 5,137
Current period provision (reversal), net	(764)	1,829	(2,308)	9,506
Write-offs	(313)	(614)	(800)	(614)
Foreign exchange	(87)	308	(45)	104
Ending balance	11,142	14,133	11,142	14,133
Theatre Operators [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	8,597	6,317	8,368	3,302
Current period provision (reversal), net	(489)	1,623	(111)	4,718
Write-offs	(43)	(614)	(278)	(614)
Foreign exchange	(89)	133	(3)	53
Ending balance	7,976	7,459	7,976	7,459
Studios [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	2,517	5,455	4,481	893
Current period provision (reversal), net	(251)	(262)	(1,928)	4,424
Write-offs	(270)		(522)
Foreign exchange	2	184	(33)	60
Ending balance	1,998	5,377	1,998	5,377
Other [Member]
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	1,192	838	1,446	942
Current period provision (reversal), net	(24)	468	(269)	364
Foreign exchange		(9)	(9)	(9)
Ending balance	$ 1,168	$ 1,297	$ 1,168	$ 1,297

Current Expected Credit Losse_3

Current Expected Credit Losses - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Current Expected Credit Losses [Line Items]
Finance income related to net investment in leases with billed amounts past due			$ 0.1	$ 0.1
Finance income related to financed sale receivables with billed amounts past due	$ 1.3	$ 1.4	3.6	4.2
Maximum [Member]
Current Expected Credit Losses [Line Items]
Finance income related to net investment in leases with billed amounts past due	0.1
Theatre And Foreign Movie Studio [Member]
Current Expected Credit Losses [Line Items]
Increase (decrease) in allowance for current expected credit losses, accounts receivables	(1.2)	1.5	(3.2)	9
Theatre Operators [Member]
Current Expected Credit Losses [Line Items]
Increase (decrease) in allowance for current expected credit losses, variable consideration receivables	(0.9)	0.8	(0.8)	1.7
Theatre Operators [Member] | Variable Consideration Receivables [Member]
Current Expected Credit Losses [Line Items]
Increase (decrease) investment in leases and financed sale receivables provision for current expected credit losses	$ (1.6)	$ 1	$ (1.8)	$ 4.1

Current Expected Credit Losse_4

Current Expected Credit Losses - Schedule of Financing Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Net investment in leases
Gross minimum payments due under sales-type leases	$ 23,284	$ 20,830
Unearned finance income	(788)	(859)
Present value of minimum payments due under sales-type leases	22,496	19,971
Allowance for credit losses	(494)	(557)
Net investment in leases	22,002	19,414
Financed sales receivables
Gross minimum payments due under financed sales	150,964	150,917
Unearned finance income	(32,199)	(31,247)
Present value of minimum payments due under financed sales	118,765	119,670
Allowance for credit losses	(5,565)	(7,274)
Net financed sales receivables	113,200	112,396
Total financing receivables	135,202	131,810
Net financed sales receivables due within one year	32,154	34,937
Net financed sales receivables due after one year	81,046	77,459
Net financed sales receivables	$ 113,200	$ 112,396

Current Expected Credit Losse_5

Current Expected Credit Losses - Schedule of Weighted-average Remaining Lease Term and Weighted-average Interest Rate (Details)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Weighted-average remaining lease term (in years)
Sales-type lease arrangements	9 years	8 years 3 months 18 days
Weighted-average interest rate
Sales-type lease arrangements	6.55%	6.56%
Financed sales receivables	8.75%	8.92%

Current Expected Credit Losse_6

Current Expected Credit Losses - Schedule of Net Investment In Leases by Credit Quality Indicator (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Current fiscal year	$ 4,333	$ 4,148
Net investment leases, By Origination Year, Before latest fiscal year	3,998	8,468
Net investment leases, By Origination Year, Two years before latest fiscal year	7,895	2,730
Net investment leases, By Origination Year, Three years before latest fiscal year	2,533	988
Net investment leases, By Origination Year, Four years before latest fiscal year	881
Net investment leases, By Origination Year, Prior	2,856	3,637
Net Investment in Lease, Total	22,496	19,971
In Good Standing [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Current fiscal year	959	2,143
Net investment leases, By Origination Year, Before latest fiscal year	2,747	1,190
Net investment leases, By Origination Year, Two years before latest fiscal year	2,245	2,730
Net investment leases, By Origination Year, Prior	1,150	1,826
Net Investment in Lease, Total	7,101	7,889
Credit Watch [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Current fiscal year	3,374	2,005
Net investment leases, By Origination Year, Before latest fiscal year	1,251	7,278
Net investment leases, By Origination Year, Two years before latest fiscal year	5,650
Net investment leases, By Origination Year, Three years before latest fiscal year	2,533	988
Net investment leases, By Origination Year, Four years before latest fiscal year	881
Net investment leases, By Origination Year, Prior	863	1,047
Net Investment in Lease, Total	14,552	11,318
Transactions Suspended [Member]
Net Investment In Lease Credit Quality Indicator [Line Items]
Net investment leases, By Origination Year, Prior	843	764
Net Investment in Lease, Total	$ 843	$ 764

Current Expected Credit Losse_7

Current Expected Credit Losses - Schedule of Financed Sale Receivables by Credit Quality Indicator (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year	$ 8,222	$ 8,816
Financed sales receivables, By Origination Year, Before lastest fiscal year	8,522	11,981
Financed sales receivables, By Origination Year, Two year before latest fiscal year	11,779	14,903
Financed sales receivables, By Origination Year, Three year before latest fiscal year	13,987	17,247
Financed sales receivables, By Origination Year, Four year before latest fiscal year	16,358	17,859
Financed sales receivables, By Origination Year, Prior	59,897	48,864
Financed sales receivables, Total	141,261	139,641
Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	118,765	119,670
In Good Standing [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year	6,311	6,830
Financed sales receivables, By Origination Year, Before lastest fiscal year	4,414	5,480
Financed sales receivables, By Origination Year, Two year before latest fiscal year	5,733	3,547
Financed sales receivables, By Origination Year, Three year before latest fiscal year	3,831	3,740
Financed sales receivables, By Origination Year, Four year before latest fiscal year	5,890	5,072
Financed sales receivables, By Origination Year, Prior	17,830	12,660
In Good Standing [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	44,009	37,329
Credit Watch [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Current fiscal year	1,911	1,986
Financed sales receivables, By Origination Year, Before lastest fiscal year	4,108	6,501
Financed sales receivables, By Origination Year, Two year before latest fiscal year	6,046	11,356
Financed sales receivables, By Origination Year, Three year before latest fiscal year	9,847	12,520
Financed sales receivables, By Origination Year, Four year before latest fiscal year	7,733	11,446
Financed sales receivables, By Origination Year, Prior	35,739	34,351
Credit Watch [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	65,384	78,160
Pre-Approved Transactions [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Three year before latest fiscal year	309
Financed sales receivables, By Origination Year, Four year before latest fiscal year	1,420	613
Financed sales receivables, By Origination Year, Prior	2,285	755
Pre-Approved Transactions [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	4,014	1,368
Transactions Suspended [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, By Origination Year, Three year before latest fiscal year		987
Financed sales receivables, By Origination Year, Four year before latest fiscal year	1,315	728
Financed sales receivables, By Origination Year, Prior	4,043	1,098
Transactions Suspended [Member] | Financing Receivable [Member]
Financing Receivable Recorded Investment [Line Items]
Financed sales receivables, Total	$ 5,358	$ 2,813

Current Expected Credit Losse_8

Current Expected Credit Losses - Schedule of Aging Analysis for Net Investment in Leases and Financed Sale Receivables (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	$ 15,190		$ 17,116
Unbilled	126,071		122,525
Financed sales receivables, Total	141,261		139,641
Allowance for Credit Losses	(6,059)		(7,831)
Total financing receivables	135,202		131,810
Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,246		1,167
Unbilled	21,250		18,804
Financed sales receivables, Total	22,496		19,971
Allowance for Credit Losses	(494)	$ (579)	(557)	$ (504)	$ (459)	$ (155)
Total financing receivables	22,002		19,414
Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	13,944		15,949
Unbilled	104,821		103,721
Financed sales receivables, Total	118,765		119,670
Allowance for Credit Losses	(5,565)	$ (7,113)	(7,274)	$ (4,643)	$ (3,709)	$ (915)
Total financing receivables	113,200		112,396
Accrued and Current [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	2,210		3,605
Accrued and Current [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	221		298
Accrued and Current [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,989		3,307
30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,897		2,123
30 to 89 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	149		180
30 to 89 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	1,748		1,943
Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	11,083		11,388
Equal To Greater Than 90 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	876		689
Equal To Greater Than 90 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Current And Past Due [Line Items]
Billed	$ 10,207		$ 10,699

Current Expected Credit Losse_9

Current Expected Credit Losses - Schedule of Net Investment in Leases and Financed Sale Receivables with Billed Amounts Past Due Continues to Accrue Finance Income (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Jun. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	$ 15,190		$ 17,116
Unbilled	126,071		122,525
Allowance for Credit Losses	(6,059)		(7,831)
Total financing receivables	135,202		131,810
Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,246		1,167
Unbilled	21,250		18,804
Allowance for Credit Losses	(494)	$ (579)	(557)	$ (504)	$ (459)	$ (155)
Total financing receivables	22,002		19,414
Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	13,944		15,949
Unbilled	104,821		103,721
Allowance for Credit Losses	(5,565)	$ (7,113)	(7,274)	$ (4,643)	$ (3,709)	$ (915)
Total financing receivables	113,200		112,396
Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	2,210		3,605
Accrued and Current [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	221		298
Accrued and Current [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,989		3,307
30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,897		2,123
30 to 89 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	149		180
30 to 89 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,748		1,943
Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	11,083		11,388
Equal To Greater Than 90 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	876		689
Equal To Greater Than 90 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	10,207		10,699
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	11,303		14,578
Unbilled	65,526		76,514
Allowance for Credit Losses	(3,118)		(4,744)
Total financing receivables	73,711		86,348
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	782		752
Unbilled	13,770		13,912
Allowance for Credit Losses	(248)		(310)
Total financing receivables	14,304		14,354
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	10,521		13,826
Unbilled	51,756		62,602
Allowance for Credit Losses	(2,870)		(4,434)
Total financing receivables	59,407		71,994
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Accrued and Current [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,332		2,257
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Accrued and Current [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	180		231
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Accrued and Current [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,152		2,026
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | 30 to 89 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,227		1,713
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | 30 to 89 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	144		162
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | 30 to 89 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	1,083		1,551
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Equal To Greater Than 90 Days Past Due [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	8,744		10,608
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Equal To Greater Than 90 Days Past Due [Member] | Net Investment in Leases [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	458		359
Net Investment in Leases and Financed Sale Receivables Continue to Accrue Finance Income [Member] | Equal To Greater Than 90 Days Past Due [Member] | Net Financed Sales Receivables [Member]
Financing Receivable Recorded Investment Past Due [Line Items]
Billed	$ 8,286		$ 10,249

Current Expected Credit Loss_10

Current Expected Credit Losses - Schedule of Net Investment in Leases and Financed Sale Receivables on Nonaccrual Status (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	$ 7,001	$ 3,577
Allowance for Credit Losses	(1,292)	(1,500)
Net	5,709	2,077
Net Investment in Leases [Member]
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	843	764
Allowance for Credit Losses	(16)	(18)
Net	827	746
Net Financed Sales Receivables [Member]
Financing Receivable Nonaccrual Status [Line Items]
Recorded Receivable	6,158	2,813
Allowance for Credit Losses	(1,276)	(1,482)
Net	$ 4,882	$ 1,331

Current Expected Credit Loss_11

Current Expected Credit Losses - Summary of Allowance for Credit Losses Related to Net Investment in Leases and Financed Sale Receivables (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance			$ 7,831
Ending balance	$ 6,059		6,059
Net Investment in Leases [Member]
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	579	$ 459	557	$ 155
Current period (reversal) provision, net	(84)	105	(64)	409
Write-offs		(69)		(69)
Foreign exchange	(1)	9	1	9
Ending balance	494	504	494	504
Net Financed Sales Receivables [Member]
Financing Receivable Allowance For Credit Losses [Line Items]
Beginning balance	7,113	3,709	7,274	915
Current period (reversal) provision, net	(1,536)	1,201	(1,741)	4,014
Write-offs		(330)		(330)
Foreign exchange	(12)	63	32	44
Ending balance	$ 5,565	$ 4,643	$ 5,565	$ 4,643

Current Expected Credit Loss_12

Current Expected Credit Losses - Summary of Allowance For Credit Losses Related to Variable Consideration Receivables (Details) - Theatre Operators [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Accounts Receivable Allowance For Credit Loss [Line Items]
Beginning balance	$ 2,028	$ 863	$ 1,887
Current period (reversal) provision, net	(933)	790	(771)	$ 1,653
Foreign Exchange	(1)	6	(22)	6
Ending balance	$ 1,094	$ 1,659	$ 1,094	$ 1,659

Lease Arrangements - Additional

Lease Arrangements - Additional Information (Details)	9 Months Ended
	Sep. 30, 2021Lease
Leases [Line Items]
Lessee, operating lease description	The Company’s operating lease arrangements principally involve office and warehouse space. Office equipment is generally purchased outright. Leases with an initial term of less than 12 months are not recorded on the Condensed Consolidated Balance Sheets and the related lease expense is recognized on a straight-line basis over the lease term.
Lessee, operating lease, existence of option to extend term	true
Lessee, operating lease, existence of option to extend description	The Company has determined that it is reasonably certain that the renewal options on its warehouse leases will be exercised based on previous history, its current understanding of future business needs and its level of investment in leasehold improvements, among other factors.
Lessee, operating lease, assumptions for discount rate	The incremental borrowing rate used in the calculation of the Company’s lease liability is based on the location of each leased property.
Leases include options to purchase leased property	0
Lessee, operating lease, existence of residual value	false
Lessee, operating lease, sublease options	The Company rents or subleases certain office space to third parties, which have a remaining term of less than 12 months and are not expected to be renewed.
Lessor, sales-type lease description	The Company provides IMAX Theater Systems to customers through long-term lease arrangements that for accounting purposes are classified as sales-type leases. Under these arrangements, in exchange for providing the IMAX Theater System, the Company earns fixed upfront and ongoing consideration. Certain arrangements that are legal sales are also classified as sales-type leases as certain clauses within the arrangements limit transfer of title or provide the Company with conditional rights to the system.
Minimum [Member]
Leases [Line Items]
Lessee, operating lease, renewal term	1 year
Sales-type lease, lease term	10 years
Non-cancellable term of joint revenue sharing arrangements	10 years
Maximum [Member]
Leases [Line Items]
Lessee, operating lease, renewal term	5 years
Sales-type lease, lease term	20 years
Non-cancellable term of joint revenue sharing arrangements	or longer

Lease Arrangements - Components

Lease Arrangements - Components of Lease Expense (Details) - Selling, General and Administrative Expenses [Member] - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Leases [Line Items]
Operating lease cost	[1]	$ 163	$ 133	$ 546	$ 392
Amortization of lease assets		684	706	2,098	2,155
Interest on lease liabilities		242	258	715	765
Total lease cost		$ 1,089	$ 1,097	$ 3,359	$ 3,312
[1]	Includes short-term leases and variable lease costs, which are not significant for the three and nine months ended September 30, 2021 and 2020.

Lease Arrangements - Supplement

Lease Arrangements - Supplemental Cash and Non-Cash Flow Information Related to Leases (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities	$ 2,907	$ 2,721
Right-of-use assets obtained in exchange for lease obligations	$ 1,047	$ 297

Lease Arrangements - Lessee Ope

Lease Arrangements - Lessee Operating Lease Balance Sheet Amounts and Lines (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Leases [Line Items]
Operating Leases	$ 15,388
Property, plant and equipment [Member]
Leases [Line Items]
Right-of-Use Assets	12,833	$ 13,911
Accrued and other liabilities [Member]
Leases [Line Items]
Operating Leases	$ 15,388	$ 16,634

Lease Arrangements - Lessee O_2

Lease Arrangements - Lessee Operating Leases Weighted Average Remaining Lease Term and Weighted Average Interest Rate (Details)	Sep. 30, 2021	Dec. 31, 2020
Lease Cost [Abstract]
Weighted-average remaining lease term (years)	7 years	7 years 7 months 6 days
Weighted-average discount rate	5.96%	5.91%

Lease Arrangements - Lessee O_3

Lease Arrangements - Lessee Operating Lease, Maturity (Details) $ in Thousands	Sep. 30, 2021USD ($)
Operating Lease Liabilities Payments Due [Abstract]
2021 (three months remaining)	$ 924
2022	3,360
2023	2,454
2024	2,230
2025	2,078
Thereafter	8,026
Total lease payments	19,072
Less: interest expense	(3,684)
Present value of operating lease liabilities	$ 15,388

Inventories - Inventories (Deta

Inventories - Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventories
Raw materials	$ 27,172	$ 30,096
Work-in-process	1,964	3,014
Finished goods	9,109	6,470
Total	$ 38,245	$ 39,580

Inventories - Additional Inform

Inventories - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021		Sep. 30, 2020	[1]	Dec. 31, 2020
Inventories (Textuals) [Abstract]
Finished goods inventory with title passed to customer	$ 2,200		$ 2,200				$ 2,100
Write-downs for excess and obsolete inventory	$ 300	$ 600	$ 468	[1]	$ 729
[1]	In the nine months ended September 30, 2021, the Company recorded write-downs of $0.5 million (2020 — $0.7 million) in Costs and Expenses Applicable to Technology Sales related to excess and damaged inventory.

Debt - Revolving Credit Facilit

Debt - Revolving Credit Facility Borrowings (Details) $ in Thousands, ¥ in Millions	Sep. 30, 2021USD ($)	Sep. 30, 2021CNY (¥)	Dec. 31, 2020USD ($)	Dec. 31, 2020CNY (¥)
Bank indebtedness [Line Items]
Unamortized debt issuance costs	$ (1,488)		$ (1,967)
Revolving Credit Facility Borrowings, net	9,486		305,676
Credit Facility [Member]
Bank indebtedness [Line Items]
Borrowings			300,000
Working Capital Facility [Member]
Bank indebtedness [Line Items]
Borrowings	$ 10,974	¥ 71.2	$ 7,600	¥ 49.9

Debt - Additional Information (

Debt - Additional Information (Details) $ / shares in Units, ¥ in Millions	Jul. 28, 2021USD ($)	Jul. 27, 2021USD ($)	Mar. 19, 2021USD ($)	Mar. 15, 2021USD ($)	Sep. 30, 2021USD ($)$ / shares	Sep. 30, 2020	Mar. 31, 2020USD ($)	Jun. 30, 2021USD ($)	Sep. 30, 2021USD ($)$ / shares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)$ / shares	Sep. 30, 2021CNY (¥)	Jul. 01, 2021USD ($)	Jul. 01, 2021CNY (¥)	Dec. 31, 2020USD ($)	Dec. 31, 2020CNY (¥)	Oct. 28, 2019USD ($)
Borrowings (Textual) [Abstract]
Credit facility description									The Company has a credit agreement, the Fifth Amended and Restated Credit Agreement, with Wells Fargo Bank, National Association (“Wells Fargo”), as agent, and a syndicate of lenders party thereto (the “Credit Agreement”). The Company’s obligations under the Credit Agreement are guaranteed by certain of its subsidiaries (the “Guarantors”) and are secured by first-priority security interests in substantially all the assets of the Company and the Guarantors. The facility provided by the Credit Agreement (the “Credit Facility”) matures on June 28, 2023.
Credit facility maturity date									Jun. 28, 2023
Current borrowing capacity					$ 300,000,000				$ 300,000,000		$ 300,000,000
Repayment of outstanding indebtedness									$ 300,243,000
Line of credit facility covenant terms									The Credit Agreement contains a covenant that requires the Company to maintain a Senior Secured Net Leverage Ratio (as defined in the Credit Agreement), as of the last day of any Fiscal Quarter (as defined in the Credit Agreement) of no greater than 3.25:1.00.
Effective interest rate						2.70%			2.64%	2.24%
Letters of guarantee outstanding | ¥												¥ 0.3				¥ 0
Proceeds from issuance of convertible notes, net									$ 223,675,000
Debt issuance costs paid									$ 474,000	$ 1,026,000
Working Capital Facility [Member]
Borrowings (Textual) [Abstract]
Credit facility description									On July 1, 2021, IMAX (Shanghai) Multimedia Technology Co., Ltd. (“IMAX Shanghai”), one of the Company’s majority-owned subsidiaries in China, renewed its unsecured revolving facility for up to 200.0 million Chinese Renminbi (“RMB”) (approximately $30.8 million) to fund ongoing working capital requirements (the “Working Capital Facility”).
Current borrowing capacity													$ 30,800,000	¥ 200
Borrowings					$ 10,974,000				$ 10,974,000		10,974,000	71.2			$ 7,600,000	¥ 49.9
Effective interest rate					4.29%	4.35%			4.32%	4.35%
Line of credit facility expiration period									2022-07
Remaining borrowing capacity					$ 18,300,000				$ 18,300,000		18,300,000	¥ 118.8
Convertible Notes [Member]
Borrowings (Textual) [Abstract]
Borrowings					$ 230,000,000				$ 230,000,000		$ 230,000,000
Debt instrument, principal amount			$ 230,000,000
Debt instrument, annual interest rate			0.50%		0.50%				0.50%		0.50%	0.50%
Proceeds from issuance of convertible notes, net			$ 223,700,000
Debt issuance costs paid			$ 1,200,000
Debt instrument, frequency of periodic interest payment									semi-annually
Debt instrument, payment terms									The Convertible Notes are senior unsecured obligations of the Company and bear interest at a rate of 0.500% per annum on the principal thereof, payable semi-annually in arrears on April 1 and October 1 of each year, beginning on October 1, 2021.
Debt instrument, date of first required payment									Oct. 1, 2021
Debt instrument, maturity date									Apr. 1, 2026
Debt instrument, convertible, terms of conversion feature									Holders of the Convertible Notes have the right to convert their Convertible Notes in certain circumstances and during specified periods. Before January 1, 2026, holders of the Convertible Notes have the right to convert their Convertible Notes only upon the occurrence of certain events. From and after January 1, 2026, holders of the Convertible Notes may convert their Convertible Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Upon conversion, the Company will pay or deliver, as applicable, cash or a combination of cash (in an amount no less than the principal amount of the Convertible Notes being converted) and common shares, at its election, based on the applicable conversion rates. The initial conversion rate is 34.7766 common shares per $1,000 principal amount of Convertible Notes, which represents an initial conversion price of approximately $28.75 per common share, and is subject to adjustment upon the occurrence of certain events.
Debt instrument, initial conversion rate per $1,000 principal amount									34.7766
Convertible notes principal amount					$ 1,000				$ 1,000		$ 1,000
Debt instrument, initial conversion price | $ / shares					$ 28.75				$ 28.75		$ 28.75
Debt instrument, redemption, description									The Convertible Notes are redeemable, in whole or in part, at the Company’s option at any time, and from time to time, on or after April 6, 2024 and on or before the 40th scheduled trading day immediately before the maturity date, at a cash redemption price equal to the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company’s common stock exceeds 130% of the conversion price for a specified period of time. In addition, calling any Convertible Notes for redemption will constitute a “make-whole fundamental change” with respect to such notes, in which case the conversion rate applicable to the conversion of such notes will be increased in certain circumstances if such notes are converted after they are called for redemption.
Debt instrument, redemption start date									Apr. 6, 2024
Convertible Notes [Member] | Call Option [Member]
Borrowings (Textual) [Abstract]
Cap price of capped call transactions | $ / shares					37.2750				37.2750		37.2750
Percentage of premium of cap price over last reported sale price per common share on March 16, 2021									75.00%
Cost of capped call transactions									$ 19,100,000
Reduction to other equity									19,100,000
Credit Facility [Member]
Borrowings (Textual) [Abstract]
Current borrowing capacity															300,000,000
Borrowings					$ 0				0		$ 0
Amount drew down in available borrowing capacity							$ 280,000,000
Repayment of outstanding indebtedness								$ 300,000,000
Letters of credit or advance payment guarantees					0				$ 0		0				0
Line of credit facility covenant terms									On March 15, 2021, the Company entered into the Second Amendment to the Credit Agreement (as previously amended by the First Amendment to the Credit Agreement, dated as of June 10, 2020) (collectively, the “First and Secondment Amendments”). On July 28, 2021, the Company entered into the Third Amendment to the Credit Agreement (as previously amended by the First and Second Amendments) (collectively, the “Amendments”). The Amendments, among other things, (i) suspend the Senior Secured Net Leverage Ratio covenant through the first quarter of 2022, (ii) re-establish the Senior Secured Net Leverage Ratio covenant thereafter, provided that for subsequent quarters that such covenant is tested, as applicable, the Company will be permitted to use its quarterly EBITDA (as defined in the Credit Agreement) from the third and fourth quarters of 2019 in lieu of EBITDA for the corresponding quarters of 2021, (iii) add a $75.0 million minimum liquidity covenant measured at the end of each calendar month, (iv) restrict the Company’s ability to make certain restricted payments, dispositions and investments, create or assume liens and incur debt that would otherwise have been permitted by the Credit Agreement, (v) permit the issuance of the Convertible Notes (as discussed below) and related transactions, including the capped call transactions, or other unsecured debt, in an amount not to exceed $290.0 million, (vi) allow $30.0 million in permitted repurchases of the Company’s common shares, subject to a $300.0 million pro forma minimum liquidity covenant and (vii) increase permitted repurchases of the common shares of IMAX China Holding, Inc. from $5.0 million to $20.0 million, subject to pro forma compliance with the existing financial covenants set forth in the Credit Agreement. The modifications to the negative covenants, the minimum liquidity covenant, permitted share repurchases and modifications to certain other provisions in the Credit Agreement pursuant to the Amendments are effective until the earlier of the delivery of the compliance certificate for the fourth quarter of 2022 or the date on which the Company, in its sole discretion, elects to calculate its compliance with the Senior Secured Net Leverage Ratio by using either its actual EBITDA or annualized EBITDA (the “Designated Period”).
Compliance with covenants									As of September 30, 2021, the Company was in compliance with all of its requirements under the Credit Agreement, as amended.
Liquidity covenant minimum									$ 75,000,000
Debt instrument, permitted repurchase amount					30,000,000				30,000,000		30,000,000
Line of credit facility pro forma minimum liquidity covenant									$ 300,000,000
Line of credit facility Increase in permitted repurchases of pro forma compliance	$ 20,000,000	$ 5,000,000
Interest rate description									Borrowings under the Credit Facility bear interest, at the Company’s option, at (i) LIBOR plus a margin ranging from 1.00% to 1.75% per annum; or (ii) the U.S. base rate plus a margin ranging from 0.25% to 1.00% per annum, in each case depending on the Company’s Total Leverage Ratio (as defined in the Credit Agreement); provided, however, that from the effective date of the First Amendment to the Credit Agreement until the Company delivers a compliance certificate under the Credit Facility following the end of the Designated Period, the applicable margin for LIBOR borrowings will be 2.50% per annum and the applicable margin for U.S. base rate borrowings will be 1.75% per annum. The effective interest rate for the three and nine months ended September 30, 2021 was nil and 2.64%, respectively (2020 — 2.70% and 2.24%, respectively).
Standby fees percentage				0.50%
Fees incurred in connection with the amendments											1,600,000
Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Borrowings (Textual) [Abstract]
Interest rate margin percentage				2.50%
Credit Facility [Member] | Base Rate [Member]
Borrowings (Textual) [Abstract]
Interest rate margin percentage				1.75%
Letters of Guarantees [Member] | Working Capital Facility [Member]
Borrowings (Textual) [Abstract]
Remaining borrowing capacity					1,500,000				$ 1,500,000		1,500,000	¥ 9.7
Wells Fargo Foreign Exchange Facility [Member]
Borrowings (Textual) [Abstract]
Unrealized gain (loss) on outstanding foreign currency forward contracts					(300,000)				(300,000)		(300,000)				2,000,000
Notional Amount of arrangements entered into					25,800,000				25,800,000		25,800,000				31,900,000
NBC Facility [Member]
Borrowings (Textual) [Abstract]
Current borrowing capacity																	$ 5,000,000
Remaining borrowing capacity					0				$ 0		0				$ 0
Line of credit facility renewed date									Oct. 15, 2021
Minimum [Member]
Borrowings (Textual) [Abstract]
Borrowing capacity under uncommitted accordion feature					440,000,000				$ 440,000,000		440,000,000
Minimum [Member] | Convertible Notes [Member]
Borrowings (Textual) [Abstract]
Percentage of last reported sale price per common share against conversion price for specific period of time									130.00%
Minimum [Member] | Credit Facility [Member]
Borrowings (Textual) [Abstract]
Standby fees percentage									0.25%
Minimum [Member] | Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Borrowings (Textual) [Abstract]
Interest rate margin percentage									1.00%
Minimum [Member] | Credit Facility [Member] | Base Rate [Member]
Borrowings (Textual) [Abstract]
Interest rate margin percentage									0.25%
Maximum [Member]
Borrowings (Textual) [Abstract]
Letters of guarantee outstanding					$ 100,000				$ 100,000		$ 100,000
Maximum [Member] | Credit Facility [Member]
Borrowings (Textual) [Abstract]
Debt instrument net leverage ratio									3.25
Line of credit facility covenant capacity				$ 290,000,000
Standby fees percentage									0.38%
Maximum [Member] | Credit Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Borrowings (Textual) [Abstract]
Interest rate margin percentage									1.75%
Maximum [Member] | Credit Facility [Member] | Base Rate [Member]
Borrowings (Textual) [Abstract]
Interest rate margin percentage									1.00%

Debt - Summary of Convertible N

Debt - Summary of Convertible Notes (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Bank indebtedness [Line Items]
Unamortized discounts and debt issuance costs	$ (1,488)	$ (1,967)
Total	223,265
Convertible Notes [Member]
Bank indebtedness [Line Items]
Convertible Notes	230,000
Unamortized discounts and debt issuance costs	(6,735)
Total	$ 223,265

Commitments, Contingencies an_2

Commitments, Contingencies and Guarantees - Additional Information (Details) - USD ($)	Dec. 03, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Mar. 27, 2008	Dec. 02, 2011	Jun. 30, 2021	Jun. 23, 2021
Loss Contingencies [Line Items]
Final Award in favor of company							amount of $11.3 million, consisting of past and future rents owed to the Company, plus interest and costs, as well as an additional $2,512 each day in interest from October 1, 2007 until the date the award is paid	$30,000 to cover the costs of the application
Final Award amount issued							$ 11,300,000
Final Award additional interest							$ 2,512
Final Award settlement cost								$ 30,000
Award inclusive of interest				$ 24,200,000
Damages awarded	$ 11,300,000
Litigation liability related to Final Judgment						$ 11,300,000
Amounts collected in respect of theater systems not delivered						7,200,000
Legal judgement and arbitration awards		$ 0	$ 0	(1,770,000)	$ 0	4,100,000
Litigation liability paid									$ 9,500
Litigation settlement expense reversed										$ 1,800
Benefit of legal judgement and arbitration awards										$ 1,800
Product warranty accrual		0		0
Indemnification of its directors/officers		$ 0		0		0
Other Indemnification				$ 0		0
Maximum [Member]
Loss Contingencies [Line Items]
Product warranty accrual						$ 100,000

Condensed Consolidated Statem_8

Condensed Consolidated Statements of Operations Supplemental Information - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)exhibitorTheaterFilm	Sep. 30, 2020USD ($)exhibitorTheaterFilm	Sep. 30, 2021USD ($)exhibitorTheaterFilm	Sep. 30, 2020USD ($)exhibitorTheaterFilm	Dec. 31, 2020USD ($)
Selling Expenses
Film exploitation costs, including advertising and marketing included in costs and expenses applicable to revenues-services	$ 3,200	$ 500	$ 5,900	$ 3,100
Foreign Exchange
Foreign exchange translation gain (loss)	$ (600)	$ 200	$ 1,100	$ (800)
Collaborative Arrangements
Total number of exhibitors under traditional and hybrid joint revenue sharing agreements | exhibitor	42	41	42	41
Total number of theater systems under traditional and hybrid joint revenue sharing agreements | Theater	1,228	1,233	1,228	1,233
Total number of operating theaters under traditional and hybrid joint revenue sharing agreement | Theater	904	881	904	881
Average percentage of the box-office receipts of the film for recovering digital re-mastering cost	12.50%		12.50%
Number of films exhibited in the period | Film	24		53	20
Number of new films exhibited | Film	21	6	47	16
Number of carryover films exhibited | Film	3		6	4
Revenue attributable to transactions arising between the company and its customers under IMAX DMR arrangements	$ 15,700	$ 6,900	$ 39,400	$ 18,100
Number of significant co-produced film arrangements | Film	1		1
Number of other co-produced film arrangements | Film	3		3
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	$ 871,161		$ 871,161		$ 997,750
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	450,691		450,691		532,983
Variable Interest Entity, Primary Beneficiary [Member]
Collaborative Arrangements
Variable Interest Entity, Consolidated, Carrying Amount, Total Assets	1,575		1,575		1,543
Variable Interest Entity, Consolidated, Carrying Amount, Total Liabilities	259		259		$ 230
Retrospective adoption of ASC Topic 606, Revenue from Contracts with Customers [Member]
Collaborative Arrangements
Revenue attributable to transactions arising between the company and its customers under joint revenue sharing arrangements	10,900	4,500	$ 29,900	11,500
Minimum [Member]
Collaborative Arrangements
Non-cancellable term of joint revenue sharing arrangements			10 years
Maximum [Member]
Collaborative Arrangements
Non-cancellable term of joint revenue sharing arrangements			or longer
Amounts attributable to transactions between the company and other parties involved in the production of films included in cost and expense	200	500	$ 300	1,900
Technology Sales [Member]
Selling Expenses
Deferred direct selling costs and direct advertising and marketing included in costs and expenses applicable to revenues	200	300	600	400
Direct advertising and marketing costs included in costs and expenses applicable to revenues	100	300	300	600
Technology Rentals [Member]
Selling Expenses
Deferred direct selling costs and direct advertising and marketing included in costs and expenses applicable to revenues	100	300	400	500
Direct advertising and marketing costs included in costs and expenses applicable to revenues	$ 700	$ 400	$ 1,500	$ 800

Condensed Consolidated Statem_9

Condensed Consolidated Statements of Cash Flows Supplemental Information - Summary of Changes in Other Operating Assets and Liabilities (Details) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020
(Increase) decrease in:
Financing receivables		$ (1,693)	$ (3,212)
Prepaid expenses		(2,767)	(1,332)
Variable consideration receivables		(1,243)	(1,007)
Other assets		664	(3,712)
Decrease in:
Accounts payable		(5,135)	(8,320)
Accrued and other liabilities	[1]	(1,728)	(6,526)
Changes in other operating assets and liabilities		$ (11,902)	$ (24,109)
[1]	Includes a $9.5 million payment made in the second quarter of 2021 in connection with the settlement of the Giencourt matter, as discussed in Note 8(b)(ii)

Condensed Consolidated State_10

Condensed Consolidated Statements of Cash Flows Supplemental Information - Summary of Changes in Other Operating Assets and Liabilities (Parenthetical) (Details) $ in Millions	3 Months Ended
	Jun. 30, 2021USD ($)
Supplemental Cash Flow Elements [Abstract]
Payment for legal settlement	$ 9.5

Condensed Consolidated State_11

Condensed Consolidated Statements of Cash Flows Supplemental Information - Summary of Depreciation and Amortization (Details) - USD ($) $ in Thousands		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020
Summary of Depreciation and amortization
Film assets		$ 10,661	$ 6,159
Property, plant and equipment:
Equipment supporting joint revenue sharing arrangements		16,784	19,247
Other property, plant and equipment		7,176	8,478
Other intangible assets	[1]	4,509	4,882
Other assets	[2]	1,440	1,933
Depreciation and amortization		$ 40,570	$ 40,699
[1]	Includes the amortization of licenses and intellectual property recorded in Research and Development on the Condensed Consolidated Statement of Operations of $1.0 million in the nine months ended September 30, 2021 ( 2020 $1.0 million).
[2]	Includes the amortization of lessee incentives provided by the Company to its customers under joint revenue sharing arrangements.

Condensed Consolidated State_12

Condensed Consolidated Statements of Cash Flows Supplemental Information - Summary of Depreciation and Amortization (Parenthetical) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Amortization of intangible assets net in research and development	$ 1	$ 1

Condensed Consolidated State_13

Condensed Consolidated Statements of Cash Flows Supplemental Information - Write-downs (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021		Sep. 30, 2020
Write-downs
Inventories		$ 300	$ 600	$ 468	[1]	$ 729	[1]
Equipment supporting joint revenue sharing arrangements	[2]			328		1,050
Other property, plant and equipment				0		66
Other intangible assets				63		132
Film assets	[3]			19		10,211
Other assets	[4]			0		1,151
Write-downs				$ 878		$ 13,339
[1]	In the nine months ended September 30, 2021, the Company recorded write-downs of $0.5 million (2020 — $0.7 million) in Costs and Expenses Applicable to Technology Sales related to excess and damaged inventory.
[2]	In the nine months ended September 30, 2021, the Company recorded charges of $0.3 million (2020 — $1.1 million) in Costs and Expenses Applicable to Technology Rentals mostly related to the write-down of leased xenon-based digital systems which were taken out of service in connection with customer upgrades to laser-based digital systems.
[3]	In the nine months ended September 30, 2020, the Company recorded impairment losses of $10.2 million in Costs and Expenses Applicable to Image Enhancement and Maintenance Services principally to write-down the carrying value of certain documentary and alternative film content due to a decrease in projected box office totals and related revenues based on management’s regular quarterly recoverability assessments. To a much lesser extent, the impairment losses also relate to the write-down of DMR related film assets.
[4]	In the nine months ended September 30, 2020, the Company recorded a write-down of $1.2 million in Asset Impairments related to content-related assets which became impaired in the period.

Condensed Consolidated State_14

Condensed Consolidated Statements of Cash Flows Supplemental Information - Write-downs (Parenthetical) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021		Sep. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Theater system components written off in Costs and expenses			$ 300		$ 1,100
Write-downs for excess and obsolete inventory	$ 300	$ 600	$ 468	[1]	729	[1]
Film assets write downs on impairment loss					10,200
Other assets write down on impairment					$ 1,200
[1]	In the nine months ended September 30, 2021, the Company recorded write-downs of $0.5 million (2020 — $0.7 million) in Costs and Expenses Applicable to Technology Sales related to excess and damaged inventory.

Condensed Consolidated State_15

Condensed Consolidated Statements of Cash Flows Supplemental Information - Significant Non-cash Investing Activities - (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Net (decrease) increase in accruals related to:
Investment in equipment supporting joint revenue sharing arrangements	$ 217	$ (1,897)
Acquisition of other intangible assets	(863)	69
Purchases of property, plant and equipment	(8)	158
Net accruals	$ (654)	$ (1,670)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Income Tax Contingency [Line Items]
Income tax expense (benefit)	$ 4,402	$ 19,349	$ 9,416	$ 24,606
Effective income tax rate	(226.60%)	(69.60%)	(69.50%)	(22.10%)
Canadian statutory tax rate	26.20%		26.20%
Deferred tax asset, valuation allowance	$ 45,500		$ 45,500		$ 28,800
Deferred income tax asset after valuation allowance	18,700		18,700		$ 18,000
Deferred income tax asset, valuation allowance change			16,700
Deferred income tax (benefit) expense			(1,687)	$ 23,142
Payment of foreign withholding taxes			2,000
Foreign Country [Member] | China [Member]
Income Tax Contingency [Line Items]
Deferred income tax (benefit) expense	20,400		20,400
Shareholder's Equity [Member]
Income Tax Contingency [Line Items]
Deferred income tax asset, valuation allowance change			2,500
Income Tax Expense [Member]
Income Tax Contingency [Line Items]
Deferred income tax asset, valuation allowance change			14,200
Impact of COVID-19 Pandemic [Member]
Income Tax Contingency [Line Items]
Deferred tax asset, valuation allowance	$ 4,300		$ 4,300

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Tax Rates (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income tax benefit at combined statutory rates, Amount	$ 509	$ 7,279	$ 3,548	$ 29,201
Unrealized investment gains not taxable, Amount		420
Realized and unrealized investment gains (losses) not taxable, Amount			1,367	(239)
Increase of valuation allowance, Amount	(4,270)	(23,707)	(14,248)	(23,706)
Changes to tax reserves, Amount	(215)	(181)	1,234	(4,978)
Withholding taxes resulting from management's decision to no longer indefinitely reinvest the historical earnings of certain foreign subsidiaries, Amount		(186)	(547)	(18,661)
Reduction in tax benefits resulting from the vesting of share-based compensation	(4)	(38)	709	33
Other non-deductible/non-taxable items, Amount	(422)	(2,936)	(1,479)	(6,256)
Income tax expense	$ (4,402)	$ (19,349)	$ (9,416)	$ (24,606)
Income tax benefit at combined statutory rates, Rate	26.20%	26.20%	26.20%	26.20%
Unrealized investment gains not taxable, Rate		1.50%
Realized and unrealized investment gains (losses) not taxable, Rate			10.10%	(0.20%)
Increase of valuation allowance, Rate	(219.80%)	(85.30%)	(105.20%)	(21.30%)
Changes to tax reserves, Rate	(11.10%)	(0.70%)	9.10%	(4.50%)
Withholding taxes resulting from management's decision to no longer indefinitely reinvest the historical earnings of certain foreign subsidiaries, Rate		(0.70%)	(4.00%)	(16.70%)
Reduction in tax benefits resulting from the vesting of share-based compensation	(0.20%)	(0.10%)	5.20%
Other non-deductible/non-taxable items, Rate	(21.70%)	(10.50%)	(10.90%)	(5.60%)
Income tax expense	(226.60%)	(69.60%)	(69.50%)	(22.10%)

Income Taxes - Income Tax Expen

Income Taxes - Income Tax Expense in Other Comprehensive (Loss) Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Tax Disclosure [Abstract]
Unrealized change in cash flow hedging instruments	$ 199	$ (160)	$ 42	$ 235
Realized change in cash flow hedging instruments	82	(29)	358	(211)
Reclassification of unrealized change in ineffective cash flow hedging instruments	7		83
Defined benefit and postretirement benefit plans	(12)		(37)	40
Income tax effect on other comprehensive income (loss)	$ 276	$ (189)	$ 446	$ 64

Capital Stock and Reserves - Ad

Capital Stock and Reserves - Additional Information (Details) $ / shares in Units, ¥ in Millions	3 Months Ended				9 Months Ended				12 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2021CNY (¥)shares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)shares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2020$ / shares	Dec. 31, 2020USD ($)shares	Sep. 30, 2021CNY (¥)shares	Apr. 30, 2021USD ($)	Jun. 11, 2020shares	Jul. 01, 2017USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation costs recorded for the period	$ 6,100,000			$ 5,300,000	$ 18,200,000		$ 16,000,000
Stock-based compensation expense	$ 6,109,000			$ 5,310,000	$ 18,211,000		$ 15,969,000
Maximum number of shares of common stock may be issued for outstanding PSU | shares	59,082,275		59,082,275		59,082,275	59,082,275			58,921,731	59,082,275
Common shares purchased in open market by trustee in connection with RSUs | shares	0	0			0		200,000
Weighted average price of common shares purchased in open market by trustee in connection with RSUs | $ / shares							$ 15.43
Number of treasury shares held in trust for future settlement of share based awards | shares					276				723
Value of treasury shares held in trust for future settlement of RSUs and stock options	$ 4,000		$ 4,000		$ 4,000	$ 4,000			$ 11,000
Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units | shares	6,115,389	6,115,389		6,959,515	6,115,389		6,959,515
Percentage of statutory net profits to statutory surplus reserve to be appropriated.	10.00%		10.00%		10.00%	10.00%				10.00%
Discontinuation of contribution, Aggregate sum of statutory surplus reserve more than its registered capital,percent.	50.00%		50.00%		50.00%	50.00%				50.00%
Statutory surplus reserve appropriated	$ 5,600,000		$ 5,600,000		$ 5,600,000	$ 5,600,000				¥ 36.4
Dividends declared and paid	$ 20,400,000	¥ 131.6
Statutory surplus reserve to its subsidiaries registered capital percent	50.00%		50.00%		50.00%	50.00%				50.00%
IMAX China
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Details of the share repurchase program					In 2021, IMAX China announced that its shareholders granted its Board of Directors a general mandate authorizing the Board, subject to applicable laws, to repurchase of shares of IMAX China not to exceed 10% of the total number of issued shares as of May 6, 2021 (34,835,824 shares). This program will be valid until the 2022 Annual General Meeting of IMAX China. The repurchases may be made in the open market or through other means permitted by applicable laws. IMAX China has no obligation to repurchase its shares and the share repurchase program may be suspended or discontinued by IMAX China at any time.
Stock Repurchase Program Expiration Date					May 6, 2021
Repurchase of common shares | shares	3,569,000	3,569,000			3,569,000		906,400
Stock Acquired, Average Cost per Share | (per share)	$ 1.40		$ 10.90		$ 1.40	$ 10.90	$ 1.69	$ 13.13
Stock Repurchase Program, maximum percentage of shares to be repurchased												10.00%
Stock Repurchase Program, Authorized number of shares | shares												34,835,824
Parent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Details of the share repurchase program					In April 2021, the Company’s Board of Directors approved a 12-month extension to its share repurchase program through June 30, 2022. The extension authorized the Company to repurchase up to approximately $89.4 million worth of common shares, the remaining amount available of the original $200.0 million initially authorized under the share repurchase program when it commenced on July 1, 2017. The repurchases may be made either in the open market or through private transactions, including repurchases made pursuant a plan intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, subject to market conditions, applicable legal requirements, and other relevant factors. The Company has no obligation to repurchase shares and the share repurchase program may be suspended or discontinued by the Company at any time.
Stock Repurchase Program, Authorized Amount													$ 200,000,000
Stock Repurchase Program Expiration Date					Jun. 30, 2022
Repurchase of common shares | shares	316,812	316,812			316,812		2,484,123
Stock Acquired, Average Cost per Share | $ / shares	$ 14.53				$ 14.53		$ 14.72
Statutory surplus reserve appropriated	$ 3,900		$ 3,900		$ 3,900	$ 3,900
Non-controlling Interests [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Statutory surplus reserve appropriated	1,700		1,700		1,700	1,700
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Value of treasury shares held in trust for future settlement of RSUs and stock options	100,000		$ 100,000		100,000	$ 100,000			$ 100,000
Maximum [Member] | Parent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Repurchase Program, Authorized Amount											$ 89,400,000
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 3,900,000			$ 3,430,000	$ 11,524,000		$ 10,866,000
Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units | shares	1,592,965	1,592,965		1,674,348	1,592,965		1,674,348
Restricted Share Units [Member] | Minimum [Member] | Certain Advisor [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense							$ 100,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 253,000			$ 433,000	$ 808,000		$ 1,449,000
Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units | shares	3,738,504	3,738,504		4,917,428	3,738,504		4,917,428
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 1,183,000			$ 483,000	$ 3,169,000		$ 1,229,000
Antidilutive shares issuable upon exercise of stock options, restricted share units and performance stock units | shares	783,920	783,920		367,739	783,920		367,739
Performance Stock Units [Member] | Maximum [Member] | EBITDA
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares of common stock may be issued for outstanding PSU | shares	1,079,372		1,079,372		1,079,372	1,079,372				1,079,372

Capital Stock and Reserves - St

Capital Stock and Reserves - Stock Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 6,109	$ 5,310	$ 18,211	$ 15,969
Cost and Expenses Applicable to Revenues [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	314	130	920	530
Selling, General and Administrative Expenses [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	5,706	5,151	17,046	15,325
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 89	$ 29	$ 245	$ 114

Capital Stock and Reserves - _2

Capital Stock and Reserves - Stock-based Compensation by Plan Type (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	$ 6,109	$ 5,310	$ 18,211	$ 15,969
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	253	433	808	1,449
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	3,900	3,430	11,524	10,866
Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	1,183	483	3,169	1,229
IMAX China Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	41	600	143	701
IMAX China Long Term Incentive Plan Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	600	332	2,217	1,645
IMAX China Long Term Incentive Plan Performance Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense by plan type	$ 132	$ 32	$ 350	$ 79

Capital Stock and Reserves - Sc

Capital Stock and Reserves - Schedule of Share-based Compensation, Stock Options, Activity (Details) - Employee Stock Option [Member] - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options outstanding, beginning of period	4,892,962	5,732,209
Exercised	(41,613)
Forfeited	(86,587)	(23,633)
Expired	(903,038)	(772,665)
Cancelled	(123,220)	(18,483)
Stock options outstanding, end of period	3,738,504	4,917,428
Stock options exercisable, end of period	3,487,857	4,315,484
Stock options outstanding, weighted average exercise price per share	$ 26.81	$ 26.82
Exercised, weighted average exercise price per share	21.23
Forfeited, weighted average exercise price per share	22.51	22.35
Expired, weighted average exercise price per share	28.31	27.03
Cancelled, weighted average exercise price per share	26.68	27.97
Stock options outstanding, weighted average exercise price per share	26.61	26.80
Stock options exercisable, weighted average exercise price per share, end of period	$ 26.93	$ 27.32

Capital Stock and Reserves - Re

Capital Stock and Reserves - Restricted Stock Units Activity under the IMAX LTIP (Details) - Restricted Share Units [Member] - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards outstanding, beginning of period	1,564,838	1,065,347
Granted	831,123	1,050,385
Vested and settled	(571,616)	(386,451)
Forfeited	(231,380)	(54,933)
Number of awards outstanding,end of period	1,592,965	1,674,348
Weighted average grant date fair value per share, beginning of period	$ 18.33	$ 23.17
Granted, weighted average grant date fair value per share	21.03	15.35
Vested and settled, weighted average grant date fair value per share	19.11	21.59
Forfeited, weighted average grant date fair value per share	19.50	19.70
Weighted average grant date fair value per share, end of period	$ 19.29	$ 18.75

Capital Stock and Reserves - Pe

Capital Stock and Reserves - Performance Stock Units Activity under the IMAX LTIP (Details) - Performance Stock Units [Member] - $ / shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards outstanding, beginning of period	361,844
Granted	309,574	370,265
Forfeited	(54,634)	(2,526)
Number of awards outstanding,end of period	616,784	367,739
Weighted average grant date fair value per share, beginning of period	$ 15.68
Granted, weighted average grant date fair value per share	20.77	$ 15.66
Forfeited, weighted average grant date fair value per share	16.08	14.84
Weighted average grant date fair value per share, end of period	$ 18.20	$ 15.67

Capital Stock and Reserves - Ba

Capital Stock and Reserves - Basic and Diluted Per-share Computations (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Equity [Abstract]
Issued and outstanding, beginning of period	59,396	58,857	58,921	61,176
Weighted average number of shares (repurchased) issued, net	(152)	2	286	(1,816)
Weighted average number of shares outstanding - basic	59,244	58,859	59,207	59,360
Weighted average number of shares outstanding - diluted	59,244	58,859	59,207	59,360

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Disaggregation of Revenue by Segment (Details) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020		Sep. 30, 2021	Sep. 30, 2020
Revenue from Contracts with Customers [Line Items]
Revenues	[1]	$ 56,602	$ 37,256		$ 146,311	$ 81,013
Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		25,375	20,385		60,178	36,646
Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		17,239	8,741		43,248	23,044
Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		332			600
Other [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0			0
Other [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0			0
Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		11,353	5,689		34,704	13,828
Lease Arrangements [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		332			600
Finance Income [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		2,635	2,441		8,181	7,495
Finance Income [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0			0
Technology Sales [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		13,160	15,753		34,508	24,102
Technology Sales [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		11,218	13,041		23,892	17,333
Technology Sales [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		808	1,496		2,620	3,248
Technology Sales [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	10,601	14,996	[3]	26,936	20,179	[3]
Technology Sales [Member] | IMAX Systems [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	9,701	12,356	[3]	20,143	14,711	[3]
Technology Sales [Member] | IMAX Systems [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	802	1,481	[3]	2,573	3,143	[3]
Technology Sales [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		1,036	57		3,776	1,196
Technology Sales [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Technology Sales [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Technology Sales [Member] | Other Theater Business [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		363	307		1,275	1,261
Technology Sales [Member] | Other Theater Business [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		363	307		1,275	1,261
Technology Sales [Member] | Other Theater Business [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Technology Sales [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[4]	1,160	393		2,521	1,466
Technology Sales [Member] | Other [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[4]	1,154	378		2,474	1,361
Technology Sales [Member] | Other [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[4]	6	15		47	105
Technology Sales [Member] | Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		1,134	1,216		7,996	3,521
Technology Sales [Member] | Lease Arrangements [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	98	1,159	[3]	4,220	2,325	[3]
Technology Sales [Member] | Lease Arrangements [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		1,036	57		3,776	1,196
Technology Sales [Member] | Lease Arrangements [Member] | Other Theater Business [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Technology Sales [Member] | Lease Arrangements [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[4]	0	0		0	0
Technology Sales [Member] | Finance Income [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Technology Sales [Member] | Finance Income [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	0	0	[3]	0	0	[3]
Technology Sales [Member] | Finance Income [Member] | Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Technology Sales [Member] | Finance Income [Member] | Other Theater Business [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Technology Sales [Member] | Finance Income [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[4]	0	0		0	0
Image Enhancement and Maintenance Services [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		30,588	14,589		76,914	39,109
Image Enhancement and Maintenance Services [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		14,157	7,344		36,286	19,313
Image Enhancement and Maintenance Services [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		16,431	7,245		40,628	19,796
Image Enhancement and Maintenance Services [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		234	(17)		279	282
Image Enhancement and Maintenance Services [Member] | Other [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0
Image Enhancement and Maintenance Services [Member] | Other [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		234	(17)		279	282
Image Enhancement and Maintenance Services [Member] | IMAX DMR [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		15,701	6,886		39,438	18,061
Image Enhancement and Maintenance Services [Member] | IMAX DMR [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | IMAX DMR [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		15,701	6,886		39,438	18,061
Image Enhancement and Maintenance Services [Member] | IMAX Maintenance Segment [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		13,055	5,855		33,196	13,225
Image Enhancement and Maintenance Services [Member] | IMAX Maintenance Segment [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		13,055	5,855		33,196	13,225
Image Enhancement and Maintenance Services [Member] | IMAX Maintenance Segment [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | Film Post-Production [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		899	739		2,886	3,088
Image Enhancement and Maintenance Services [Member] | Film Post-Production [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		899	739		2,886	3,088
Image Enhancement and Maintenance Services [Member] | Film Post-Production [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | Film Distribution [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		699	1,126		1,115	4,453
Image Enhancement and Maintenance Services [Member] | Film Distribution [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		203	750		204	3,000
Image Enhancement and Maintenance Services [Member] | Film Distribution [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		496	376		911	1,453
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | IMAX DMR [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | IMAX Maintenance Segment [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | Film Post-Production [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | Lease Arrangements [Member] | Film Distribution [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | Other [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | IMAX DMR [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | IMAX Maintenance Segment [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | Film Post-Production [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Image Enhancement and Maintenance Services [Member] | Finance Income [Member] | Film Distribution [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Technology Rentals [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		10,219	4,473		26,708	10,307
Technology Rentals [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Technology Rentals [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Technology Rentals [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		9,887	4,473		26,108	10,307
Technology Rentals [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Technology Rentals [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Technology Rentals [Member] | Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		10,219	4,473		26,708	10,307
Technology Rentals [Member] | Lease Arrangements [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		9,887	4,473		26,108	10,307
Technology Rentals [Member] | Finance Income [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Technology Rentals [Member] | Finance Income [Member] | Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Finance Income [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		2,635	2,441		8,181	7,495
Finance Income [Member] | IMAX Systems [Member] | Fixed Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Finance Income [Member] | IMAX Systems [Member] | Variable Consideration [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Finance Income [Member] | Lease Arrangements [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		0	0		0	0
Finance Income [Member] | Finance Income [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		$ 2,635	$ 2,441		$ 8,181	$ 7,495
[1]	The Company’s largest customer represents 18.2% and 22.2%, respectively, of total Revenues for the three and nine months ended September 30, 2021 (2020 — 11.0% and 11.3%, respectively). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of September 30, 2021 and December 31, 2020.
[2]	Includes r evenues earned from sales or sales-type lease arrangements involving new and upgraded IMAX Theater Systems, as well as the impact on revenue of renewals and amendments to existing theater system arrangements.
[3]	Prior period comparatives have been revised to appropriately classify $1.1 million and $2.3 million, respectively, of fixed consideration under revenue from contracts with customers to revenue from lease arrangements for the three and nine months ended September 30, 2020.
[4]	Other sales include revenues associated with New Business Initiatives.

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Disaggregation of Revenue by Segment (Parenthetical) (Details) - USD ($) $ in Thousands		3 Months Ended			9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020		Sep. 30, 2021	Sep. 30, 2020
Revenue from Contracts with Customers [Line Items]
Revenues	[1]	$ 56,602	$ 37,256		$ 146,311	$ 81,013
Technology Sales [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		13,160	15,753		34,508	24,102
Technology Sales [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	10,601	14,996	[3]	26,936	20,179	[3]
Lease Arrangements [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		11,353	5,689		34,704	13,828
Lease Arrangements [Member] | Technology Sales [Member]
Revenue from Contracts with Customers [Line Items]
Revenues		1,134	1,216		7,996	3,521
Lease Arrangements [Member] | Technology Sales [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues	[2]	$ 98	1,159	[3]	$ 4,220	2,325	[3]
Lease Arrangements [Member] | Maximum [Member] | Technology Sales [Member] | IMAX Systems [Member]
Revenue from Contracts with Customers [Line Items]
Revenues			$ 1,100			$ 2,300
[1]	The Company’s largest customer represents 18.2% and 22.2%, respectively, of total Revenues for the three and nine months ended September 30, 2021 (2020 — 11.0% and 11.3%, respectively). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of September 30, 2021 and December 31, 2020.
[2]	Includes r evenues earned from sales or sales-type lease arrangements involving new and upgraded IMAX Theater Systems, as well as the impact on revenue of renewals and amendments to existing theater system arrangements.
[3]	Prior period comparatives have been revised to appropriately classify $1.1 million and $2.3 million, respectively, of fixed consideration under revenue from contracts with customers to revenue from lease arrangements for the three and nine months ended September 30, 2020.

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Additional Information (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Revenue From Contract With Customer [Abstract]
Revenue Remaining Performance Obligation	$ 20.3	$ 21.6

Segment Reporting - Additional

Segment Reporting - Additional Information (Details)	9 Months Ended
	Sep. 30, 2021
Segment Reporting (Textual) [Abstract]
Description of products and services from which each reportable segment derives its revenues	The Company has the following reportable segments: (i) IMAX DMR; (ii) Joint Revenue Sharing Arrangements; (iii) IMAX Systems, (iv) IMAX Maintenance; (v) Other Theater Business; (vi) New Business Initiatives; (vii) Film Distribution; and (viii) Film Post-Production.
Disclosure on geographic areas, description of revenue from external customers	No single country in the Rest of the World, Western Europe, Latin America and Asia (excluding Greater China) comprises more than 10% of the Company’s total revenue in the three and nine months ended September 30, 2021.

Segment Reporting - Segment Rep

Segment Reporting - Segment Reporting Information by Category and Reportable Segment (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues
Revenue	[1]	$ 56,602	$ 37,256	$ 146,311	$ 81,013
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	27,487	3,829	70,371	1,227
IMAX DMR [Member]
Revenues
Revenue	[1]	15,701	6,886	39,438	18,061
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	7,293	3,079	22,405	7,492
Joint Revenue Sharing Arrangements, Contingent Rent [Member]
Revenues
Revenue	[1]	9,887	4,473	26,108	10,307
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	3,626	(2,491)	7,299	(10,610)
IMAX Technology Network [Member]
Revenues
Revenue	[1]	25,588	11,359	65,546	28,368
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	10,919	588	29,704	(3,118)
IMAX Systems [Member]
Revenues
Revenue	[1],[3]	13,236	17,437	35,117	27,674
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2],[3]	8,086	8,671	21,646	14,497
Joint Revenue Sharing Arrangements, Fixed Fees [Member]
Revenues
Revenue	[1]	1,036	57	3,776	1,196
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	280	(117)	783	110
IMAX Maintenance Segment [Member]
Revenues
Revenue	[1]	13,055	5,855	33,196	13,225
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	6,462	794	15,360	(355)
Other Theater Business [Member]
Revenues
Revenue	[1],[4]	363	307	1,283	1,261
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2],[4]	64	31	269	77
IMAX Technology Sales and Maintenance [Member]
Revenues
Revenue	[1]	27,690	23,656	73,372	43,356
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	14,892	9,379	38,058	14,329
New Business Initiatives [Member]
Revenues
Revenue	[1]	1,238	378	2,554	1,488
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	1,189	372	2,281	1,245
Post-production [Member]
Revenues
Revenue	[1]	899	739	2,886	3,088
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	420	(464)	1,316	(96)
Film Distribution [Member]
Revenues
Revenue	[1],[5]	699	1,126	1,115	4,453
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2],[5]	(4)	(5,597)	(319)	(9,296)
Film Distribution and Post-Production [Member]
Revenues
Revenue	[1]	1,598	1,865	4,001	7,541
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	416	(6,061)	997	(9,392)
Reportable Segments [Member]
Revenues
Revenue	[1]	56,114	37,258	145,473	80,753
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	27,416	4,278	71,040	3,064
Other [Member]
Revenues
Revenue	[1]	488	(2)	838	260
Gross Margin (Margin Loss)
Gross Margin (Margin Loss)	[2]	$ 71	$ (449)	$ (669)	$ (1,837)
[1]	The Company’s largest customer represents 18.2% and 22.2%, respectively, of total Revenues for the three and nine months ended September 30, 2021 (2020 — 11.0% and 11.3%, respectively). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of September 30, 2021 and December 31, 2020.
[2]	IMAX DMR gross margin includes marketing costs of $3.2 million and $5.8 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.4 million and $2.8 million, respectively). JRSA gross margin includes advertising, marketing and commission expense of $0.8 million and $1.9 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.7 million and $1.3 million, respectively). IMAX Systems gross margin includes marketing and commission costs of $0.3 million and $0.9 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.6 million and $1.0 million, respectively). Film Distribution segment gross margin includes marketing expense of $nil and less than $0.1 million, respectively, for the three and nine months ended September 30, 2021 (2020 — $0.2 million and $0.4 million, respectively).
[3]	The revenue from this segment includes the initial upfront payments and the present value of fixed minimum payments from sales and sales-type lease arrangements of IMAX Theater Systems, as well as the present value of estimated variable consideration from sales of IMAX Theater Systems. To a lesser extent, the revenue from this segment also includes finance income associated with these revenue streams.
[4]	principally includes after-market sales of IMAX projection system parts and 3D glasses.
[5]	During the three and nine months ended September 30, 2020, Film Distribution segment results include impairment losses of $5.4 million and $9.9 million, respectively, to write-down the carrying value of certain documentary and alternative content film assets . No such charges were incurred in the .

Segment Reporting - Segment R_2

Segment Reporting - Segment Reporting Information by Category and Reportable Segment (Parenthetical) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Percentage of total revenues represented by largest customer	18.20%	11.00%	22.20%	11.30%
IMAX DMR [Member]
Segment Reporting (Textual) [Abstract]
Marketing costs and expense	$ 3.2	$ 0.4	$ 5.8	$ 2.8
Joint revenue sharing arrangements [Member]
Segment Reporting (Textual) [Abstract]
Advertising, marketing and commission costs	0.8	0.7	1.9	1.3
IMAX systems [Member]
Segment Reporting (Textual) [Abstract]
Advertising, marketing and commission costs	$ 0.3	0.6	0.9	1
Film Distribution [Member]
Segment Reporting (Textual) [Abstract]
Marketing costs and expense		0.2	$ 0.1	0.4
Impairment loss		$ 5.4		$ 9.9

Segment Reporting - Geographic

Segment Reporting - Geographic Information (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total	[1]	$ 56,602	$ 37,256	$ 146,311	$ 81,013
Greater China [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		22,203	19,346	75,634	26,008
United States [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		16,469	4,335	34,275	21,112
Western Europe [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		7,634	5,085	11,160	10,273
Asia (excluding China) [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		4,925	4,935	12,837	12,663
Russia & the CIS [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		1,353	738	4,577	2,962
Latin America [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		1,181	1,616	1,579	3,251
Canada [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		1,083	384	620	1,327
Rest of the World [Member]
Revenues From External Customers And Long Lived Assets [Line Items]
Revenues, total		$ 1,754	$ 817	$ 5,629	$ 3,417
[1]	The Company’s largest customer represents 18.2% and 22.2%, respectively, of total Revenues for the three and nine months ended September 30, 2021 (2020 — 11.0% and 11.3%, respectively). No single customer comprises more than 10% of the Company’s total Accounts Receivable as of September 30, 2021 and December 31, 2020.

Employees Pension and Postret_3

Employees Pension and Postretirement Benefits - Additional Information (Details) - USD ($)	Nov. 01, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Deferred Compensation Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Deferred compensation plan description				The Company maintained a nonqualified deferred compensation benefit plan (the “Retirement Plan”) covering the former CEO of IMAX Entertainment and Senior Executive Vice President of the Company. Under the terms of the Retirement Plan, the benefits were due to vest in full if the executive incurred a separation from service from the Company (as defined therein).
Deferred Compensation Plan [Member] | Accrued and Other Liabilities [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit obligation recorded		$ 3,800,000		$ 3,800,000		$ 3,700,000
Deferred Compensation Plan [Member] | Prepaid Expenses [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Company-owned life insurance		3,200,000		$ 3,200,000		3,200,000
Richard L. Gelfond [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit payable	$ 20,300,000
SERP Benefits [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Defined benefit pension plan				The Company has an unfunded defined benefit pension plan, the Supplemental Executive Retirement Plan (the “SERP”), covering its CEO, Richard L.
Benefit Obligation		20,170,000		$ 20,170,000		20,116,000	$ 18,840,000
Interest costs			$ 100,000	54,000	$ 300,000	379,000
Companies contribution and expenses during the remainder of 2021		0		0
SERP Benefits [Member] | Maximum [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Interest costs		100,000
Expected interest costs in the remainder of the year		100,000		$ 100,000
Defined Contribution Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Defined contribution pension plans for employees				The Company also maintains defined contribution plans for its employees, including its executive officers. The Company makes contributions to these plans on behalf of employees in an amount up to 5% of their base salary subject to certain prescribed maximums.
Maximum percentage of base salary contributed to Defined Contribution Pension Plan by Company				5.00%
Canadian Plan [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Contribution and recorded expense		300,000	300,000	$ 800,000	800,000
Us Internal Revenue Code [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Contribution and recorded expense		100,000	100,000	400,000	500,000
Postretirement Benefits Executives [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit Obligation		700,000		700,000		700,000
Postretirement Benefits Executives [Member] | Maximum [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Maximum amount of Postretirement benefit recorded expense		100,000	100,000	100,000	100,000
Postretirement Benefits Canadian Employees [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Benefit Obligation		1,800,000		1,800,000		$ 1,900,000
Postretirement Benefits Canadian Employees [Member] | Maximum [Member]
Pension and Other Postretirement Benefit Expense (Textual) [Abstract]
Maximum amount of Postretirement benefit recorded expense		$ 100,000	$ 100,000	$ 100,000	$ 100,000

Employee's Pension and Postreti

Employee's Pension and Postretirement Benefits - Amounts Accrued and Unfunded Status (Details) - Pension Plans, Defined Benefit [Member] - USD ($) $ in Thousands	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Amounts Accrued
Obligation, beginning of period		$ 20,116	$ 18,840	$ 18,840
Interest cost	$ 100	54	$ 300	379
Actuarial gain		0		897
Obligation, end of period and unfunded status		$ 20,170		$ 20,116

Financial Instruments - Additio

Financial Instruments - Additional Information (Details) $ in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Feb. 28, 2021USD ($)shares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)Country	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Financial Instruments (Textual) [Abstract]
Cash and cash equivalents			$ 193,008		$ 317,379
Cash held outside of Canada			$ 101,000		89,900
Number of countries that generate box office | Country			85
Foreign Exchange contract settlement date range			settlement dates throughout 2022
Estimated loss to be reclassified to earnings within the next twelve months			$ 200
Investment in equity securities			1,089		13,633
Investment in equity securities - cost			$ 15,200
Equity securities restrictions			lock-up period of six months
Fixed Income Securities [Member]
Financial Instruments (Textual) [Abstract]
Equity Investment, Debt Securities			$ 1,100		1,100
Preferred Stock [Member] | Other Assets [Member]
Financial Instruments (Textual) [Abstract]
Investment in equity securities			$ 1,000		1,000
Maoyan [Member]
Financial Instruments (Textual) [Abstract]
Investment in equity securities					12,600
Gain (loss) in fair value of equity securities		$ 1,600		$ (900)
Number of shares sold | shares	7,949,000
Gross proceeds from sale of investment	$ 17,800
Gain relating to acquisition cost	2,600
Realized gain on fair value of investment	$ 5,200
Maximum [Member]
Financial Instruments (Textual) [Abstract]
Equity securities percentage ownership			1.00%
Republic of China [Member]
Financial Instruments (Textual) [Abstract]
Cash held/undistributed earnings			$ 70,300		$ 77,200

Financial Instruments - Fair Va

Financial Instruments - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands		Sep. 30, 2021	Dec. 31, 2020
Other Financial Instrument
Cash and cash equivalents		$ 193,008	$ 317,379
Net investment in sales-type leases		22,002	19,414
Equity securities		1,089	13,633
Foreign exchange contracts — forwards		(270)	1,979
Credit Facility borrowings		(9,486)	(305,676)
Carrying Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	[1]	193,008	317,379
Equity securities	[2]	1,089	13,633
Carrying Amount, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Net financed sales receivables	[3]	113,200	112,396
Net investment in sales-type leases	[3]	22,002	19,414
Equity securities	[1]	1,000	1,000
COLI	[4]	3,244	3,155
Working Capital Facility borrowings	[1]	(10,974)	(7,643)
Credit Facility borrowings	[1]	0	(300,000)
Convertible notes	[5]	(230,000)	0
Carrying Amount, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts — forwards	[3]	(209)	1,635
Carrying Amount, Fair Value Disclosure [Member] | Not Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts — forwards	[3]	(61)	344
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 1 [Member]
Other Financial Instrument
Cash and cash equivalents	[1]	193,008	317,379
Equity securities	[2]	1,089	13,633
Estimate of Fair Value, Fair Value Disclosure [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Net financed sales receivables	[3]	113,210	112,603
Net investment in sales-type leases	[3]	21,850	19,373
Equity securities	[1]	1,000	1,000
COLI	[4]	3,244	3,155
Working Capital Facility borrowings	[1]	(10,974)	(7,643)
Credit Facility borrowings	[1]	0	(300,000)
Convertible notes	[5]	(224,574)	0
Estimate of Fair Value, Fair Value Disclosure [Member] | Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts — forwards	[3]	(209)	1,635
Estimate of Fair Value, Fair Value Disclosure [Member] | Not Designated as Hedging Instrument [Member] | Fair Value, Inputs, Level 2 [Member]
Other Financial Instrument
Foreign exchange contracts — forwards	[3]	$ (61)	$ 344
[1]	Recorded at cost, which approximates fair value.
[2]	Fair value is determined using quoted prices in active markets
[3]	Fair value is estimated based on discounting future cash flows at currently available interest rates with comparable terms
[4]	Measured at cash surrender value, which approximates fair value
[5]	Fair value is determined using quoted market prices that are observable in the market or that could be derived from observable market data

Financial Instruments - Notiona

Financial Instruments - Notional Amount of Derivative (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Derivatives Fair Value [Line Items]
Foreign exchange contracts — Forwards	$ 25,765	$ 31,910
Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Foreign exchange contracts — Forwards	24,642	26,358
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Foreign exchange contracts — Forwards	$ 1,123	$ 5,552

Financial Instruments - Fair _2

Financial Instruments - Fair Value of Foreign Exchange Contracts (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Derivatives Fair Value [Line Items]
Foreign exchange contracts - designated forwards	$ (270)	$ 1,979
Other Assets [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Derivative Asset, Fair Value	128	1,635
Other Assets [Member] | Not Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Derivative Asset, Fair Value		$ 344
Accrued and other liabilities [Member] | Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Derivative Liability, Fair Value	(337)
Accrued and other liabilities [Member] | Not Designated as Hedging Instrument [Member]
Derivatives Fair Value [Line Items]
Derivative Liability, Fair Value	$ (61)

Financial Instruments - Derivat

Financial Instruments - Derivatives in Foreign Currency Hedging Relationships (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Derivative Instruments Gain Loss [Line Items]
Derivative (Loss) Gain Recognized in OCI (Effective Portion)	$ (759)	$ 591	$ (159)	$ (935)
Location of Derivative Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	312	(110)	1,367	(805)
Derivative Loss Recognized In and Out of OCI (Effective Portion)				(55)
Fair Value Hedging [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative (Loss) Gain Recognized in OCI (Effective Portion)	(759)	591	(159)	(935)
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Location of Derivative Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	$ 312	$ (110)	$ 1,367	(779)
Inventory [Member]
Derivative Instruments Gain Loss [Line Items]
Location of Derivative Gain (Loss) Reclassified from AOCI into Income (Effective Portion)				$ (26)

Financial Instruments - Non Des

Financial Instruments - Non Designated Derivatives in Foreign Currency Relationships (Details) - Not Designated as Hedging Instrument [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Derivative Instruments Gain Loss [Line Items]
Location of Derivative (Loss) Gain	$ (122)	$ 75	$ 269	$ 102
Foreign Exchange Contracts - Forwards [Member]
Derivative Instruments Gain Loss [Line Items]
Derivative Gain Reclassified From AOCI (Ineffective portion)	(25)		(318)
Foreign Exchange Contracts - Forwards [Member] | Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Location of Derivative (Loss) Gain	$ (122)	$ 75	$ 269	$ 102

Non-Controlling Interests - Add

Non-Controlling Interests - Additional Information (Details) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended	93 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Dec. 31, 2014USD ($)Film	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Non-controlling Interests
Non-controlling interest	$ 82,804		$ 82,804			$ 82,804	$ 78,519
Net income (loss) attributable to non-controlling interest	$ 2,034	$ (1,275)	9,473	$ (15,412)
Investment in film assets			$ 10,035	6,177
IMAX China Noncontrolling Interest [Member]
Non-controlling Interests
Minority Interest Ownership Percentage By Company	69.83%		69.83%			69.83%
IMAX China
Non-controlling Interests
Non-controlling interest	$ 82,800		$ 82,800			$ 82,800
Net income (loss) attributable to non-controlling interest	$ 2,000	$ 2,200	9,500	$ (10,300)
Other Noncontrolling Interest [Member]
Non-controlling Interests
Net income (loss) attributable to non-controlling interest			$ 1
Non-controlling interest description			The Company’s Original Film Fund was established in 2014 to co-finance a portfolio of 10 original large-format films. The initial investment in the Original Film Fund was committed by a third party in the amount of $25.0 million, with the possibility of contributing additional funds. The Company has contributed $9.0 million to the Original Film Fund since 2014 and has reached its maximum contribution.
Number of expected original films | Film					10
Investment in film assets						22,300
Other Noncontrolling Interest [Member] | Third Party [Member]
Non-controlling Interests
Expected contribution to film fund by third party					$ 25,000
Other Noncontrolling Interest [Member] | IMAX [Member]
Non-controlling Interests
Film fund contributions paid						$ 9,000

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary of Movement of the Non-controlling Interest in Temporary Equity Related to Original Film Fund (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Non-controlling Interests
Net income	$ 2,034	$ (1,275)	$ 9,473	$ (15,412)
Other Noncontrolling Interest [Member]
Non-controlling Interests
Balance as of December 31, 2020			759
Net income			1
Balance as of September 30, 2021	$ 760		$ 760